WO2002030895A1 - SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-η BINDING AGENTS - Google Patents

SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-η BINDING AGENTS Download PDF

Info

Publication number
WO2002030895A1
WO2002030895A1 PCT/US2001/042644 US0142644W WO0230895A1 WO 2002030895 A1 WO2002030895 A1 WO 2002030895A1 US 0142644 W US0142644 W US 0142644W WO 0230895 A1 WO0230895 A1 WO 0230895A1
Authority
WO
WIPO (PCT)
Prior art keywords
carbon atoms
heteroatoms selected
alkyl
cycloalkyl
heterocycloalkyl
Prior art date
Application number
PCT/US2001/042644
Other languages
French (fr)
Inventor
Andreas Stolle
Jacques P. Dumas
William Carley
Phillip D. G. Coish
Steven R. Magnuson
Yamin Wang
Dhanapalan Nagarathnam
Derek B. Lowe
Ning Su
William H. Bullock
Ann-Marie Campbell
Ning Qi
Jeremy L. Baryza
James H. Cook
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to AU2002211901A priority Critical patent/AU2002211901A1/en
Priority to KR10-2003-7005093A priority patent/KR20030036917A/en
Priority to HU0302477A priority patent/HUP0302477A2/en
Priority to CA002427499A priority patent/CA2427499A1/en
Priority to IL15498101A priority patent/IL154981A0/en
Priority to EP01979996A priority patent/EP1341761A1/en
Priority to JP2002534281A priority patent/JP2004529855A/en
Priority to MXPA03003174A priority patent/MXPA03003174A/en
Publication of WO2002030895A1 publication Critical patent/WO2002030895A1/en
Priority to NO20031619A priority patent/NO20031619L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Definitions

  • the invention relates to substituted indoles, pharmaceutical compositions containing such indoles, and their use in treating or preventing diseases or conditions mediated by the Peroxisome Proliferator Activated Receptor- ⁇ (PPAR- ⁇ ).
  • PPAR- ⁇ Peroxisome Proliferator Activated Receptor- ⁇
  • PPARs Peroxisome Proliferator Activated Receptors
  • PPAR- ⁇ Peroxisome Proliferator Activated Receptors
  • PPARs regulate expression of target genes by binding to DNA response elements as heterodimers with the retinoid X receptor. These DNA response elements have been identified in the regulatory regions of a number of genes encoding proteins involved in lipid metabolism and energy balance. The biological role of the PPARs in the regulation of lipid metabolism and storage has been recently reviewed. Spiegelman, Diabetes. (1998), Vol. 47, pp. 507-514; Schoonjans, et al, Curr. Opin. LipidoL. (1997), Vol. 8, pp 159-166; Brun, et al, Curr. Opin. LipidoL. (1991). Vol. 8, pp 212-218.
  • Molecules that interact with PPAR- ⁇ may be useful in modulating PPAR- ⁇ mediated processes for the treatment or prevention of various diseases and conditions.
  • essential dietary fatty acids and certain of their eicosanoid metabolites are naturally occurring hormonal ligands for the PPAR- ⁇ receptor, which can promote adipogenesis through activation of the PPAR- ⁇ receptor. Kliewer, et al, Proc. Natl. Acad. Sci. USA, (1997), Vol. 94, pp 4318-4323; Kliewer, et al, Cell, (1995), Vol. 83, pp 813- 819.
  • molecules that inhibit the adipogenic effects of endogenous PPAR- ⁇ hormones may be useful in the treatment of diseases caused by increased fat accumulation or lipid storage, such as osteoporosis, obesity and acne.
  • diseases caused by increased fat accumulation or lipid storage such as osteoporosis, obesity and acne.
  • the thiazolidinedione (TZD) class of PPAR- ⁇ ligands promotes adipogenesis in bone marrow and inhibits expression of markers of the osteoblast phenotype, such as alkaline phosphatase. Paulik, et al, Cell Tissue Res.. (1997), Nol. 290, pp 79-87.
  • TZDs can promote lipid accumulation in sebocytes. Rosenfield, et al, ⁇ . Dermatology, (1998), Nol. 196, pp 43-46. These effects may lead to sebocyte differentiation and acne formation. Thus, molecules that block adipogenesis in adipocytes, pre-adipocytes, bone marrow, or sebocytes may have beneficial effects in the treatment of obesity, osteoporosis, or acne.
  • the PPAR- ⁇ receptor has been found in tissues other than adipose, and it is believed that synthetic PPAR- ⁇ ligands and natural PPAR- ⁇ hormones (natural ligands) may have beneficial effects in many other diseases including cardiovascular disease, inflammation, and cancer. Schoonjans, supra; Ricote, et al, Nature, (1998), Vol. 391, pp 79-82; Mueller, et al, Mol. Cell. (1998), Vol. 1, pp 465-470.
  • TZD PPAR- ⁇ ligands enhance the actions of insulin in man and reduce circulating glucose levels in rodent models of diabetes.
  • the PPAR- ⁇ receptor is expressed in adipose tissue and plays a pivotal role in the regulation of adipocyte differentiation in vitro.
  • TZD such as rosiglitazone induce adipocyte differentiation in vitro through activation of the PPAR- ⁇ receptor.
  • PPAR- ⁇ ligands Although there are clearly therapeutic uses for PPAR- ⁇ ligands in the treatment of diseases of lipid metabolism and energy balance, it is possible that there will be side effects of these drugs. For example, PPAR- ⁇ ligands that promote adipocyte differentiation in vivo could lead to increased fat accumulation and weight gain. This side effect might offset the beneficial effects of a PPAR- ⁇ ligand in the treatment of diabetes or other diseases where obesity is a risk factor. Spiegelman, supra; Bran, supra.
  • the invention provides compounds that modulate PPAR- ⁇ mediated processes, particularly substituted indole compounds, which can act as agonists or antagonists of PPAR- ⁇ and thereby modulate PPAR- ⁇ mediated processes.
  • the invention further provides pharmaceutical compositions containing such compounds.
  • the invention provides for methods of treating or preventing a PPAR- ⁇ mediated diseases or condition in a mammal by administering a compound of the invention.
  • the invention relates to compounds of the Formula I:
  • n 0-8;
  • cycloalkyl of 3-8 carbon atoms is selected from phenyl, cycloalkyl of 3-8 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O,
  • R may be substituted with alkoxy of 1-8 carbon atoms, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, halogen, alkyl of 1-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or Q-(CH 2 ) n R 10 ;
  • NR 33 is selected from NR 33 , NH, S and O;
  • cycloalkyl of 3-9 carbon atoms is selected from cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O;
  • alkyl of 1-8 carbon atoms is selected from alkyl of 1-8 carbon atoms, alkenyl of 1-8 carbon atoms and alkynyl of 1-8 carbon atoms;
  • NR 33 is selected from NR 33 , NH, O, and S;
  • R 11 is selected from aryl of 5-14 carbon atoms and heteroaryl of 3-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, with the proviso that R is not isoxazole,
  • R may be substituted with alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, alkoxy of 1-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or halogen;
  • cycloalkyl of 3-7 carbon atoms is selected from cycloalkyl of 3-7 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O,
  • R may be substituted with alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, alkoxy of 1-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or halogen; or
  • heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O;
  • R 14 is selected from cycloalkyl of 3-7 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, aryl of 5-14 carbon atoms and heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O;
  • R 15 which combines with R 5 to form a radical of the formula -Y-(CH 2 )r Y-
  • Y is selected from NR » NH, S and O;
  • R is selected from alkyl of 1-8 carbon atoms, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and Z-R 17 >
  • Z is selected from (CH 2 ) n , NH, NR , O and S,
  • R is selected from cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, aryl of 5-14 carbon atoms and heteroaryl of 3-11 carbon atoms and 1-2 heteroatoms selected from N, S and
  • R is selected from hydrogen, halogen, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8
  • R is selected from aryl of 5-14 carbon atoms and heteroaryl of 3- 11 carbon atoms and 1-2 heteroatoms selected from N, S and O, and
  • R is selected from hydrogen, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, aryl of 5-14 carbon atoms and heteroaryl of 3-11 carbon atoms and 1-2 heteroatoms selected from N, S and O;
  • R when R is furyl, benzofuranyl, benzothienyl, benzoxazolidmyl, benzoxazolyl, benzothiazolydinyl, benzothiazolyl, benzoisothiazolyl, benzopyrazolyl, bbeennzzooiimmiiddaazzoollyyll, 1 benzoimidazolidinyl, benzoisooxazolyl, or benzoxadiazolyl R may be unsubstituted, and
  • R is other than hydrogen and R is other than alkyl or alkenyl
  • R is substituted with Q(CH 2 ) n R »
  • R is other than hydrogen, or R is other than hydrogen
  • E is selected from NR 33 > NH, S and O;
  • R 34 is selected from alkyl of 1-8 carbon atoms, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O;
  • R is selected from hydrogen, halogen, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O; and
  • R 33 has the meaning given above;
  • (1) is selected from:
  • R is selected from alkyl of 1-8 carbon atoms, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, aryl of 5-14 carbon atoms and heteroaryl of 3-11 carbon atoms and 1-2 heteroatoms selected from N, S and O;
  • heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O;
  • D is selected from NR 33 , NH, S and O, and
  • - m is 0-4, with the proviso that when R 3 is phenyl or napthyl, Z is O, R 18 is alkyl and R 19 is hydrogen, halogen, haloalkyl or alkyl, m is 1-4,
  • R 28 is selected from hydrogen, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, aryl of 5-14 carbon atoms and heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O,
  • R is selected from cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, aryl of 5-14 carbon atoms, and heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, and
  • R 30 is selected from hydrogen, halogen, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, alkoxy of 1-
  • R 5 combines with R to form a radical of formula -Y-(CH 2 ) t -Y-,
  • T is selected from NR 33 , NH, S and O and R 18 > R 19 and R 33 are as defined above; R 7
  • alkyl of 1-7 carbon atoms is selected from alkyl of 1-7 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of
  • aryl of 5-14 carbon atoms is selected from aryl of 5-14 carbon atoms, heteroaryl of 3-11 carbon atoms and 1- 2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O,
  • R may be substituted with alkyl of 1-7 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, alkoxy of 1-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or halogen;
  • the invention further relates to pharmaceutical compositions containing any of the above-described compounds of Formula I and a pharmaceutically acceptable carrier.
  • the invention also provides methods for treating or preventing a PPAR- ⁇ mediated disease or condition in a mammal.
  • the PPAR- ⁇ mediated disease or condition may be osteopororsis, osteopenia, PPAR- ⁇ mediated cancer, including breast, prostate, colon and lung cancer, inflammation, including atherosclerosis, inflammatory bowel disease, Alzheimer's disease and rheumatoid arthritis, hypertension, hyperglycemia, type 1 diabetes, type 2 diabetes, syndrome X, insulin resistance, obesity, dyslipidemia, hypertriglyceridemia, diabetic dyslipidemia, hyperhpidemia, hypercholesteremia, and skin disorders, such as acne, psoriasis, dermatitis, eczema, keratosis and inflammatory skin conditions caused by lupus erythematosus.
  • the methods of the invention provide for the administration of a compound of Formula I or a compound of Formula Ila:
  • (1) is selected from hydrogen and R > 8 -R r>9 , or
  • R 9 is selected from aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected fromN, S and O; wherein R 9 may be substitituted with alkoxy of 1-8 carbon atoms, haloalkoxy of 1- 8 carbon atoms and a number of halogen atoms up to the perhalo level, halogen, alkyl of 1-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or X-(CH 2 ) n CH 3 R 10
  • R 10 is selected from cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O;
  • X and X' are each independently selected from NH, NR 33 , (CH 2 ) discipline, O and S; n is a number from 0-8;
  • alkyl of 1-8 carbon atoms is selected from alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms and alkynyl of 2-8 carbon atoms;
  • R 11 is selected from aryl of 5-14 carbon atoms and heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, wherein R 11 may be substituted with alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, alkoxy of 1-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, alkoxy of 1-8 carbon atoms, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or halogen;
  • R 3 is selected from:
  • R 13 is selected from aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and
  • R 13 may be substituted with alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, alkoxy of 1-8 carbon atoms, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or halogen;
  • R is selected from aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O,
  • R 15 which combines with R 5 to form a radical of the formula — Y- (CH 2 ) n -Y-, wherein Y and n are as defined above;
  • R 16 is selected from alkyl of 1-8 carbon atoms and X-R 17 - wherein R 17 is selected from aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and wherein X is as defined above;
  • X-R 18 -R 19 - R 18 is selected from alkyl of 1-8 carbon atoms, aryl of 5-
  • R 19 is selected from hydrogen, halogen, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, R 20 -R 21 and X- R 21 , - X is as defined above,
  • R 20 is aryl of 5-14 carbon atoms or heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, and
  • R 21 is selected from aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O,
  • R 4 is selected from hydrogen and X-R 18 -R 19 , wherein X, R 18 and R 19 have the meanings given above; R 5
  • (1) is selected from: (a) hydrogen;
  • R 22 is selected from alkyl of 1-8 carbon atoms, aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O,
  • alkyl of 1-8 carbon atoms alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O,
  • R 25 is alkyl of 1-8 carbon atoms
  • R 26 is selected from aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, - R 24 is selected from cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3- 8 carbon atoms and 1 -2 heteroatoms selected from N, S and O, heterocycloalkenyl of 3-8 carbon atoms and 1-2
  • R is alkyl of 1-8 carbon atoms
  • R is selected from hydrogen, aryl of 5-14 carbon 10 atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and 15 heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, all of which, with the exception of hydrogen, may be fused with aryl of 5- 14 carbon atoms or heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected N, S and O,
  • R 29 is selected from aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2
  • heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and
  • R 30 is selected from hydrogen, halogen, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the
  • alkyl of 1-8 carbon atoms alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, alkoxy of 1- 8 carbon atoms, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, aryl of 5-14 carbon atoms and heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O;
  • R 6 combines with R 6 to form a radical of the formula -Y-(CH 2 ) n -Y-, wherein Y and n have the meanings given above;
  • R 6 is selected from hydrogen, OH and X-R 18 -R 19 , wherein X, R 18 and R 19 have the meanings give above
  • the present invention therefore provides compounds, pharmaceutical compositions containing such compounds, and methods for the treatment or prevention of PPAR- ⁇ mediated diseases and conditions.
  • Compounds, compositions and methods of the present invention therefore are useful in treatment of PPAR- ⁇ mediated diseases and conditions without the concommitant undesired side-effects of natural hormones.
  • the invention provides novel, substituted indoles of Formula I, pharmaceutical compositions containing such indoles, and their use in the treatment or prevention of PPAR- ⁇ mediated diseases or conditions in a mammal.
  • the invention further provides methods of treating or preventing PPAR- ⁇ mediated diseases or conditions in a mammal, such as a human, by administration of a compound of Formula Ila.
  • the compounds of Formula I and Formula Ila have both been broadly described above.
  • R 8 is alkyl
  • R 9 is phenyl, which may or may not be substituted; X is O;
  • R is hydrogen
  • R 3 is aryl, particularly phenyl, or heteroaryl, either of which may or may not be substituted.
  • aryl includes aromatic ring structures that are substituents on another atom. These aryls may also be substituted with substituents, such as halogen, haloalkyl, alkoxy, haloalkoxy, etc. Non-limiting examples of aryls include phenyl, napthyl, etc.
  • heteroaryl as used herein includes aromatic ring structures containing between one and two heteroatoms, such as O, N and S, that are substituents on another atom. These heteroaryls may also be substituted with substituents, such as alkyl, alkenyl, alkoxy, haloalkoxy, halogen, haloalkyl, etc. Non-limiting examples of heteroaryls include pyridyl, furyl, quinolyl, etc.
  • alkyl includes straight-chain or branched alkyls of between 1 and 8 carbon atoms.
  • alkenyl includes straight-chain or branched alkenyls of between 2 and 8 carbon atoms.
  • alkynyl includes straight-chain or branched alkynyls of between 2 and 8 carbon atoms. Such alkyls, alkenyls and alkynyls may be terminal or may be linkers between other portions of a molecule.
  • R is a heteroaryl
  • R is phenyl
  • R is R -R , where R is cycloalkyl, heterocycloalkyl, cycloalkenyl or heterocycloalkenyl.
  • R 3 is R 12 -R 13 include, but are not limited to:
  • R 3 is a cycloalkyl, heterocylcoalkyl, cycloalkenyl or heterocycloalkenyl, which may be substituted or may be fused with a spiro ring of 3-9 carbon atoms.
  • Examples of compounds of the invention where R 3 is a cycloalkyl, heterocylcoalkyl, cycloalkenyl or heterocycloalkenyl include, but are not limited to:
  • R 4 , R 5 , R 6 and or R 7 may be other than hydrogen.
  • examples of compounds of the invention where R 4 , R 5 , R 6 and/or R 7 are other than hydrogen include, but are not limited to:
  • Compounds of Formulas I and Ila may be useful in the treatment or prevention of PPAR- ⁇ mediated diseases or conditions.
  • An agent which binds to PPAR- ⁇ may be employed for a wide variety of indications, including, but not limited to:
  • osteoporosis and osteopenia see, Nuttall, et al, Bone 27 (2), (2000), 177-184; Gimble, et al, Bone 19 (5), (1996), 421- 428;
  • cancer particularly PPAR- ⁇ mediated cancers, such as breast and prostate cancers (see, Gelman, et al, Cell, and Mol. Life Sci-, 55 (6-7), (1999), 935-943; Kersten, et al, Nature, 405 (6785), May 25, 2000, 421-424), colon cancer (see, Saez, et al, Nat. Med., 4 (9) Sept. 1998, 1058-1061; Lefebvre, et al, Nat. Med.. 4 (9), Sept. 1998, 1053-1057; Demetri, et al, Proc. Nat'L Acad. Sci. USA, 96 (7), Mar. 30, 1999, 3951- 3956) liposarcoma (Demetri, et al., Proc. Nat'L Acad. Sci USA, 96 (7), Mar. 30, 1999, 3951-3956) and lung cancer (see, Chang, etal, Cancer Res., 60, 2000, 1129-1138);
  • inflammation particularly inflammatory bowel disease (see Cell, and Mol. Life Sci.. 55 (6-7), (1999), 935-943), Alzheimer's disease (see, Combs, et al, J. Neurosci. 20 (2),
  • cardiovascular disease particularly hypertension, (see Cell. and Mol. Life Sci.. 55 (6-7), (1999), 935-943 review);
  • dyslipidemia hypertriglyceridemia, diabetic dyslipidemia, hyperlipidemia and hypercholesteremia (see Hulin, et al, Curr. Pharm. Design. 2 (1996), 85-102); and
  • Compounds of Formulas I and Ila are preferably used in the treatment or prevention of osteopenia, osteoporosis, and PPAR- ⁇ mediated cancers, including breast, prostate and colon cancer.
  • the present invention also includes pharmaceutically acceptable salts of the compounds of Formulas I and Ila.
  • Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluoromethanesulfonic acid, sulphonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid.
  • pharmaceutically acceptable salts include acid salts of inorganic bases, such as salts containing alkaline cations (e.g., Li + Na + or K + ), alkaline earth cations (e.g., Mg +2 , Ca +2 or Ba +2 ), the ammonium cation, as well as acid salts of organic bases, including aliphatic and aromatic substituted ammonium, and quaternary ammonium cations such as those arising from protonation or peralkylation of triethylamine, N,N-diethylamine, N,N-dicyclohexylamine, pyridine, N,N- dimethylaminopyridine (DMAP), l,4-diazabicyclo[2.2.2]octane (DABCO), 1,5- diazabicyclo[4.3.0]non-5-ene (DB ⁇ ) and l,8-diazabicyclo[5.4.0]undec-7-ene (DBU).
  • a number of the compounds of Formulas I and Ila possess asymmetric carbons and can therefore exist in racemic and optically active forms. Methods of separation of enantiomeric and diastereomeric mixtures are well known to the skilled in the art.
  • the present invention encompasses any racemic or optically active forms of compounds described in Formula I or Formula Ila which possess PPAR- ⁇ modulating activity or the use of any racemic or optically active forms of the compounds described in Formulas I and Ila for the treatment or prevention of PPAR- ⁇ mediated diseases or conditions.
  • the therapeutic agents of the invention may be employed alone or concurrently with other therapies.
  • the compounds of the invention when employed as a treatment for osteoporosis or osteopenia, may be used in combination with a calcium source, vitamin D or analogues of vitamin D, and/or antiresorptive therapies such as estrogen replacement therapy, treatment with a fluoride source, treatment with calcitonin or a calcitonin analogue, or treatment with a bisphosphonate such as alendronate.
  • the method of the invention is intended to be employed for treatment of PPAR- ⁇ mediated diseases or conditions in both humans and other mammals.
  • the compounds may be administered orally, dermally, parenterally, by injection, by inhalation or spray, or sublingually, rectally or vaginally in dosage unit formulations.
  • administered by injection includes intravenous, intraarticular, intramuscular, subcutaneous and parenteral injections, as well as use of infusion techniques.
  • Dermal administration may include topical application or transdermal administration.
  • One or more compounds may be present in association with one or more non-toxic pharmaceutically acceptable carriers and, if desired, other active ingredients.
  • compositions intended for oral use may be prepared according to any suitable method known to the art for the manufacture of pharmaceutical compositions.
  • Such compositions may contain one or more agents selected from the group consisting of diluents, sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide palatable preparations.
  • Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, com starch, or alginic acid; and binding agents, for example magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
  • These compounds may also be prepared in solid, rapidly released form.
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • water or an oil medium for example peanut oil, liquid paraffin or olive oil.
  • Aqueous suspensions containing the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions may also be used.
  • excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl-methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbit
  • the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, /J-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
  • preservatives for example ethyl, or n-propyl, /J-hydroxybenzoate
  • coloring agents for example ethyl, or n-propyl, /J-hydroxybenzoate
  • flavoring agents for example ethyl, or n-propyl, /J-hydroxybenzoate
  • sweetening agents such as sucrose or saccharin.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
  • a dispersing or wetting agent e.g., talc, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol,
  • the compounds may also be in the form of non-aqueous liquid formulations, e.g., oily suspensions which may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or peanut oil, or in a mineral oil such as liquid paraffin.
  • oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • compositions of the invention may also be in the form of oil-in- water emulsions.
  • the oil phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
  • Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening and flavoring agents.
  • Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
  • sweetening agents for example glycerol, propylene glycol, sorbitol or sucrose.
  • Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
  • the compounds may also be administered in the form of suppositories for rectal or vaginal administration of the drug.
  • suppositories for rectal or vaginal administration of the drug.
  • These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal or vaginal temperature and will therefore melt in the rectum or vagina to release the drug.
  • suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal or vaginal temperature and will therefore melt in the rectum or vagina to release the drug.
  • Such materials include cocoa butter and polyethylene glycols.
  • Compounds of the invention may also be administered transdermally using methods known to those skilled in the art (see, e.g., Chien; "Transdermal Controlled
  • a solution or suspension of a compound of Formula I or Ila in a suitable volatile solvent optionally containing penetration enhancing agents can be combined with additional additives known to those skilled in the art, such as matrix materials and bacteriocides. After sterilization, the resulting mixture can be formulated following known procedures into dosage forms.
  • a solution or suspension of a compound of Formula I or Ila may be formulated into a lotion or salve.
  • Suitable solvents for processing transdermal delivery systems are known to those skilled in the art, and include lower alcohols such as ethanol or isopropyl alcohol, lower ketones such as acetone, lower carboxylic acid esters such as ethyl acetate, polar ethers such as tetrahydrofuran, lower hydrocarbons such as hexane, cyclohexane or benzene, or halogenated hydrocarbons such as dichloromethane, chloroform, trichlorotrifluoroethane, or trichlorofluoroethane.
  • Suitable solvents may also include mixtures one or more materials selected from lower alcohols, lower ketones, lower carboxylic acid esters, polar ethers, lower hydrocarbons, halogenated hydrocarbons.
  • Suitable penetration enhancing materials for transdermal delivery systems include, for example, monohydroxy or polyhydroxy alcohols such as ethanol, propylene glycol or benzyl alcohol, saturated or unsaturated C 8 - Cis fatty alcohols such as lauryl alcohol or cetyl alcohol, saturated or unsaturated C 8 -C ⁇ 8 fatty acids such as stearic acid, saturated or unsaturated fatty esters with up to 24 carbons such as methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl isobutyl tert-butyl or monoglycerin esters of acetic acid, capronic acid, lauric acid, myristinic acid, stearic acid, or palmitic acid, or diesters of saturated or unsaturated dicarboxylic acids with a total of up to 24 carbons such as diisopropyl adipate, diisobutyl adipate, diiso
  • Additional penetration enhancing materials include phosphatidyl derivatives such as lecithin or cephalin, terpenes, amides, ketones, ureas and their derivatives, and ethers such as dimethyl isosorbid and diethyleneglycol monoethyl ether.
  • Suitable penetration enhancing formulations may also include mixtures one or more materials selected from monohydroxy or polyhydroxy alcohols, saturated or unsaturated C 8 -C 18 fatty alcohols, saturated or unsaturated C 8 -C 18 fatty acids, saturated or unsaturated fatty esters with up to 24 carbons, diesters of saturated or unsaturated dicarboxylic acids with a total of up to 24 carbons, phosphatidyl derivatives, terpenes, amides, ketones, ureas and their derivatives, and ethers.
  • Suitable binding materials for transdermal delivery systems include polyacrylates, silicones, polyurethanes, block polymers, styrene-butadiene coploymers, and natural and synthetic rubbers.
  • Cellulose ethers, derivatized polyethylenes, and silicates may also be used as matrix components. Additional additives, such as viscous resins or oils may be added to increase the viscosity of the matrix.
  • the daily oral dosage regimen will preferably be from 0.01 to 200 mg/Kg of total body weight.
  • the daily dosage for administration by injection including intravenous, intramuscular, subcutaneous and parenteral injections, and use of infusion techniques will preferably be from 0.01 to 200 mg/Kg of total body weight.
  • the daily rectal dosage regimen will preferably be from 0.01 to 200 mg/Kg of total body weight.
  • the daily vaginal dosage regimen will preferably be from 0.01 to 200 mg/Kg of total body weight.
  • the daily topical dosage regimen will preferably be from 0J to 200 mg administered between one to four times daily.
  • the transdermal concentration will preferably be that required to maintain a daily dose of from 0.01 to 200 mg/Kg.
  • the daily inhalation dosage regimen will preferably be from 0.01 to 10 mg/Kg of total body weight.
  • the particular method of administration will depend on a variety of factors, all of which are considered routinely when administering therapeutics. It will also be understood, however, that the specific dose level for any given patient will depend upon a variety of factors, including, but not limited to the activity of the specific compound employed, the age of the patient, the body weight of the patient, the general health of the patient, the gender of the patient, the diet of the patient, time of administration, route of administration, rate of excretion, drug combinations, and the severity of the condition undergoing therapy.
  • the optimal course of treatment i.e., the mode of treatment and the daily number of doses of a compound of Formula I or Ila or a pharmaceutically acceptable salt thereof given for a defined number of days, can be ascertained by those skilled in the art using conventional treatment tests.
  • the compounds of Formulas I and Ila may be prepared by use of known chemical reactions and procedures, from known compounds (or from starting materials which, in turn, are producible from known compounds) through the preparative methods shown below, as well as by other reactions and procedures known to the skilled in the art.
  • Such reactions and procedures include, but are not limited to, esterification, hydrolysis, alkylation, acylation neutralization, coupling, oxidation, reduction, condensation, elimination and substitution reactions.
  • the following general preparative methods are presented to aid practitioners in synthesizing the compounds of the invention, with more detailed particular examples being presented in the experimental section. The examples are for illustrative purposes only and are not intended, nor should they be construed, to limit the invention in any way.
  • substituents may appear on reagents or intermediates which may act as protecting groups or other non-participating groups. Utilizing methods well known to those skilled in the art, such groups are introduced and/or removed during the course of the synthetic schemes to provide the compounds of the present invention. All variable groups not defined below are as described hereinabove.
  • compounds of Formula I or Ila may be prepared from the appropriately substituted indoles, by esterification, hydrolysis, sulfonylation or neutralization reactions as shown in Flow Diagram I:
  • Preparation of certain Formula I compounds with a variety of R substituents may be prepared by a sequence involving conversion of VI to a boronic acid intermediate, followed by a palladium-facilitated coupling reaction with an organohalide and base, such as triethylamine, potassium carbonate or Huenig's base, as shown in Flow Diagram II.
  • an organohalide and base such as triethylamine, potassium carbonate or Huenig's base
  • R' lower alkyl
  • halogen Br, CI, I
  • Certain aryl substituents on the R 3 aryl ring may be further transformed to other substituents by standard means. An illustration of this is shown in Flow Diagram IN, in which a nitro group is reduced and acylated to provide amido substituents.
  • R" alkyl, cycloalkyl, aryl, or heteroaryl
  • Compounds of Formula I which bear certain R 3 substituents may be prepared by Friedel-Crafts acylation of the corresponding unsubstituted indole, followed by reduction of the carbonyl group to a methylene, as shown in Flow Diagram N.
  • O-Alkylation reactions may be utilized to prepare Formula I compounds bearing substituents on R 4 , R 5 , R 6 or R 7 positions.
  • alkylation of the corresponding hydroxy intermediates provides ethers containing an R 18 or R 23 group, depending upon position, as shown in Flow Diagram NHL
  • Other compounds of Formula I may also be obtained from a hydroxy intermediate.
  • the hydroxy group may be converted to a trifluoromethylsulfonate which reacts with an alkyl stannane to give alkyl-substituted indoles, as exemplified in Flow Diagram X for the R 5 position.
  • Nitration of indoles that are unsubstituted at positions 5 and/or 7 provides nitro- substituted intermediates which may be reduced and either acylated or alkylated to give a variety of Formula I compounds as shown in Flow Diagram XI.
  • Indole intermediates which are useful in the preparation of compounds in the present invention are either commercially available or may be prepared by standard methods. These transformations are summarized in Flow Diagram XII for intermediates of Formula NI, IN and N. For example, an appropriately substituted 2-bromonitrobenzene may be converted to a 2-mtrocinnamic acid derivative which cyclizes to an indole upon reduction. The resulting indole intermediate may then be brominated at the 3 position, and the desired R 1 substituent introduced by ⁇ -alkylation giving the intermediate compounds of Formula NI.
  • Compounds of Formula IN may be prepared from NI in a stepwise sequence involving halogen-metal exchange, addition to formaldehyde, and oxidation of the resulting carbinol to a 3-carboxylic acid. It is understood that the presence of certain R 4 -R 7 substituents may require additional steps of protection and deprotection during this process in order to avoid undesired side reactions.
  • HPLC - electrospray mass spectra were obtained using a Hewlett-Packard 1100 HPLC equipped with a quaternary pump, a variable wavelength detector, a YMC Pro C18 2.0 mm x 23 mm column, and a Finnigan LCQ ion trap mass spectrometer with electrospray ionization. Gradient elution from 90% A to 95% B over 4 minutes was used on the HPLC. Buffer A was 98% water, 2% Acetonitrile and 0.02% TFA. Buffer B was 98% Acetonitrile, 2% water and 0.018% TFA. Spectra were scanned from 140-1200 amu using a variable ion time according to the number of ions in the source.
  • Butyl lithium (2.5 M in hexane, 14.4 mL, 36 mmol) was added dropwise (5 min) to a cooled (-78 °C) and stirred solution of 4-(cyclopropylmethoxy)iodobenzene 1 (9.00 g, 32.8 mmol) in tetrahydrofuran (100 mL). After 20 min, trimethyl borate (11.3 mL, 10.4 g, 100 mmol) was added dropwise (10 mL). The reaction was stirred for an additional 20 min, and was then allowed to warm to rt. The reaction was quenched with 1 M hydrochloric acid (300 mL) and stirring was continued for 30 min.
  • Indole-2-carboxylic acid was converted to 3-bromoindole-2-carboxylic acid using the method described for Example 13.
  • N,N-dimethylformamide di-tert-butyl acetal 35 mL was added dropwise to a stirring mixture of indole-3-bromo-2-carboxylic acid (14.9 g, 62 mmol) suspended in toluene (100 mL).
  • the reaction was heated at 90 °C for 8 h.
  • the reaction mixture was then cooled to room temperature and washed with cold water (2 100 mL).
  • the organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to yield the crude tert-butyl 3-bromoindole-2-carboxylate, assume quantitative yield.
  • the crude product was used in the next step without purification.
  • Example 5 (2.30 g, 12.0 mmol) and 2 M aqueous sodium carbonate (20 mL) were added to a stirred solution of ethyl 5-(benzyloxy)-3-bromo-l-(3-methoxybenzyl)-lH- indole-2-carboxylate (4.03 g, 8J5 mmol) in EtOH (30 mL) and toluene (30 mL). Argon was bubbled through the mixture for 15 min and then tetrakis(triphenylphosphine)palladium(0) (1J5 g, 1.00 mmol) was added. The reaction was heated (85 °C) for 16 h and then cooled.
  • Example 61 The mixture was diluted with 1 M hydrochloric acid (200 mL) and then extracted with ethyl acetate (3x100 mL). The combined organic extracts were washed with water and brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo. Flash chromatography of the residue over silica gel using 60% dichloromethane/hexane gave 3.41 g (75%) of Example 61.
  • Example 33 A mixture of Example 33 (300 mg, 0.70 mmol), benzothiophene-2-boronic acid (195 mg, IJ mmol), 2N Na 2 CO 3 (0.7 mL) and N,N-dimethylformamide (7 mL) was flushed with argon. Pd(OAc) 2 (16 mg, 0.07 mmol) and P(o-tolyl) 3 (43 mg, 0J4 mmol) were added and the mixture was heated at 100°C for ⁇ 15 h. The mixture was cooled and filtered through a short column of silica gel and sodium bicarbonate (elution with ethyl acetate).
  • Example 62 As a white solid.
  • Rf 0.51 (7/1 hexane/ethyl acetate); LRMS (+esi) obs'd: 480.0; calc'd 479.1.
  • Example 33 A mixture of Example 33 (300 mg, 0.70 mmol), 2-(tributylstannyl)furan (0.22 mL, 0.7 mmol), lithium chloride (30 mg, 0.7 mmol) and N,N-dimethylformamide (7 mL) was flushed with argon. Tetrakis(triphenylphosphine) palladium (80 mg, 0.07 mmol) was added and the mixture was heated at 100°C for -15 h. The mixture was cooled and filtered through a short column of silica gel (elution with ethyl acetate).
  • Example 63 as a white solid.
  • Rf 0.45 (7/1 hexane/ethyl acetate); LRMS (+esi) obs'd: 414J; calc'd 413J.
  • Example 33 A suspension/solution of Example 33 (500 mg, 1J7 mmol), phenyl acetylene (600 mg, 5.86mmol), triethyl amine (5.5 mL) in dry N,N-dimethylformamide (12 mL) was flushed with argon. Copper iodide (73 mg, 0.38 mmol) and Pd(dppf) Cl 2 - dichloromethane (96 mg, 0J2 mmol) was added and again the system was flushed with Ar. The mixture was then heated at 79°C for 70 min. The suspension was filtered through Celite® (elution with ether) and the filtrate was washed water (3x 20 mL) and brine (20 mL).
  • Example 65 Ethyl 7-(4-tert-butylphenyl)-5H-ri.31dioxolor4 ⁇ 51-findole-6-carboxyIate
  • the reaction was stirred with heating (85 °C) for 16 h and then cooled.
  • the mixture was diluted with 1 M hydrochloric acid (200 mL) and then extracted with ethyl acetate (3x100 mL).
  • the combined organic extracts were washed with water and brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo.
  • the residue was dissolved in tetrahydrofuran (100 mL) and tetrabutylammonium fluoride (1.0 M in tetrahydrofuran, 20 mL, 20 mmol) was added.
  • the reaction was stirred for 1 h and then diluted with ethyl acetate (300 mL).
  • the product had: 1H NMR (300 MHz, acetone-D 6 ) ⁇ 7.85 (s, 1 H), 7.28-7.37 (m, 3 H), 7J2 (dd, 1 H), 6.84-7.00 (m, 4 H), 6.61-6.74 (m, 3 H), 5.73 (s, 2 H), 4.09 (q, 2 H), 3.86 (d, 2 H), 3.67 (s, 3 H), 1.20-1.32 (m, 1 H), 0.84 (t, 3 H), 0.52-0.63 (m, 2 H), 0.31-0.41 (m, 2 H).
  • Example 106 150 mg, 0.36 mmol
  • Example 4 68 mg, 0.28 mmol
  • toluene 0.7 L
  • ethanol 0.7 mL
  • Tetrakis(triphenylphosphine)- palladium 34 mg, 0.029 mmol
  • Example 109 was purified by flash chromatography (silica gel, 7:1 hexane:ethyl acetate) to afford 100 mg (66%) of Example 109 as a yellow solid.
  • Rf 0.61 (7/1 hexane/ethyl acetate); LRMS (+esi) obs'd: 536.8; calc'd 536.0.
  • Example 108 A mixture of Example 108 (300 mg, 0.56 mmol), Pd(PPh 3 ) 4 (70 mg, 0.06 mmol) and lithium chloride (80 mg, 1.68 mmol) in tetrahydrofuran (2 mL) and toluene (2 mL) was flushed with argon.
  • 1-Ethoxyvinyl tri-77-butylstannane 224 mg, 0.62 mmol
  • a second portion of stannane 107 mg, 0.30 mmol was added and heating was continued for 1 h.
  • the mixture was cooled to rt. and 10% hydrochloric acid (2 mL) was added.
  • Cyclopropyl boronic acid A solution of t-butyllithium in hexane (17.0 mL, 25.4 mmol) was added to a -78°C solution of cyclopropyl bromide (1.51 gm, 12.4 mmol) in dry tetrahydrofuran (20 mL). After stirring for 15 min., trimethoxy borate (1.23 gm, 11.8 mmol) was added and the resulting mixture was warmed to rt. over Hi. 2N HC1 (15 mL) was added and the aq. phase was extracted with ethyl acetate. The extracts were dried over anhydrous sodium sulfate and concentrated to give the cyclopropyl boronic which was used in the coupling step without further purification.
  • Triflic anhydride (0.84 mL, 1.4 g, 5.0 mmol) and dimethylaminopyridine (25 mg, 0.20 mmol) were added to a cooled (0 °C) and stirred solution of ethyl 3-[3- (cyclopropylmethoxy)phenyl]-5-hydroxy-l-(3-methoxybenzyl)-lH-indole-2-carboxylate (Example 66, 1.00 g, 2J 2 mmol) in dichloromethane (10 mL) and pyridine (2 mL). The reaction was warmed to rt and then stirred an additional 2 h.
  • the product had: X ⁇ ⁇ MR (300 MHz, acetone-D 6 ) ⁇ 7.49- 7.56 (m, 3 H), 7.37-7.43 (m, 3 H), 7J 7-7.23 (m, 2 H), 6.68-6.92 (m, 3 H), 4.09 (q, 3 H), 3.92-4.01 (m, 1 H), 3.75 (s, 3 H), 2.31-2.50 (m, 3 H), 1.62-1.77 (m, 1 H), 1.39 (s, 9 H), 0.98 (t, 3 H).
  • Lithium chloride (297 mg, 7.0 mmol) and tributylvinyl tin (0.43 mL, 467 mg, 1.5 mmol) were added to a stirred solution of ethyl 3-(4-tert-butylphenyl)-l-(3- methoxybenzyl)-5- ⁇ [(trifluoromethyl)sulfonyl]oxy ⁇ -lH-indole-2-carboxylate (Example 125, 570 mg, 0.995 mmol) in tetrahydrofuran (10 mL).
  • Acetic acid (63 ⁇ L, 66 mg, 1.1 mmol) was added slowly to a cooled (0 °C) and stirred slurry of sodium borohydride (41.6 mg, 1J0 mmol) in tetrahydrofuran (2 mL). The mixture was stirred for 1 h and then a solution of ethyl 3-(4-tert-butylphenyl)-l-(3- methoxybenzyl)-5 -vinyl- lH-indole-2-carboxylate (Example 129, 430 mg, 0.920 mmol) in tetrahydrofuran (5 + 2 mL rinse) was added. The reaction was stirred overnight and then cooled (0 °C).
  • the product had: 1H NMR (300 MHz, acetone- D 6 ) ⁇ 7.34-7.46 (m, 3 H), 7J6 (dd, 1 H), 6.93-7.02 (m, 4 H), 6.65-6.81 (m, 3 H), 5.78 (s, 2 H), 3.82-4.23 (m, 9 H), 3.69 (s, 3 H), 1.24-1.34 (m, 1 H), 1.02 (t, 3 H), 0.60-0.70 (m, 2 H), 0.34-0.44 (m, 2 H).
  • Ethyl 3 -(4-tert-butylphenyl)- 1 -(3-methoxybenzyl)-5-vinyl- 1 H-indole-2- carboxylate (Example 129, 2.28 g, 4.9 mmol) was dissolved in anhydrous tetrahydrofuran (25 mL), and osmium tetroxide (2.5 weight % solution in 2-methyl-2-propanol, 1.5 mL, 0J5 mmol) was added. After ten minutes, the reaction mixture was cooled with an ice bath. Sodium periodate (2J0 g, 9.8 mmol) was added followed by a minimum volume of water to dissolve the solids.
  • the reaction was allowed to return to room temperature, and after 30 minutes, the reaction was partitioned between water and diethyl ether. The organic layer was separated, dried over anhydrous magnesium sulfate, and concenfrated. The resulting crude oil was passed through a pad of silica gel with 20% > ethyl acetate/hexane. The filtrate was concentrated in vacuo without heat to provide the title compound as a brown oil (1.70g, 75%).
  • the product had: 1H ⁇ MR (300 MHz, acetone-D 6 ) ⁇ 7.42 (d, 1 H), 7.29-7.36 (m, 2 H), 7J4 (dd, 1 H), 6.94-7.02 (m, 4 H), 6.63-6.79 (m, 3 H), 5.78 (s, 2 H), 3.99-4J2 (m, 4 H), 3.86 (d, 2 H), 3.64-3.71 (m, 5 H), 3.48 (q, 2 H), 1.24-1.34 (m, 1 H), IJ 1 (t, 3 H), 0.98 (t, 3 H), 0.54-0.64 (m, 2 H), 0.32- 0.42 (m, 2 H).
  • a reaction mixture of ethyl 5-(2-chloroethoxy)-l-(3-methoxybenzyl)-3-(4- methoxyphenyl)-lH-indole-2-carboxylate (Example 152, 290mg, O.588mmol) and methylamine in tetrahydrofuran (2 M, 40ml) was sealed in a stainless steel vessel (100ml, bomb) at 0°C. Then it was heated and stirred at 120°C for 3days in a oil bath. Oil bath was removed and the bomb was allowed to cooled to room temperature before opened. The reaction solution was transferred to an round-bottomed flask and solvent was concentrated in vacuo.
  • Tin (II) chloride (8.5 g, 45 mmol) was added to a stirred solution of ethyl 3-(4-tert- butylphenyl)-l-(3-methoxybenzyl)-5-nifro-lH-indole-2-carboxylate (Example 28, 4.5 g, 9.3 mmol) in EtO ⁇ (24 mL). The mixture was heated (50 °C) until there was a homogenous solution and then concentrated hydrochloric acid (16 mL) was added. The reaction was stirred at 60 °C for 2 h and then cooled.
  • Cyclopropanecarboxaldehyde (168 mg, 2.4 mmol) was added to a stirred mixture of ethyl 5-amino-3-(4-tert-butylphenyl)- 1 -(3-methoxybenzyl)- lH-indole-2-carboxylate (Example 160, 530 mg, 1.2 mmol) in toluene (12 mL) and molecular sieves (2 g). The reaction was stirred for 16 h and then filtered using toluene to rinse. The filtrate was concentrated in vacuo and the residue was dissolved in methanol (12 mL).
  • Triethylamine (0J2 mL, 91 mg, 0.90 mmol), dimethylaminopyridine (20 mg, 0J6 mmol), and cyclopropanecarbonyl chloride (82 ⁇ L, 94 mg, 0.90 mmol) were added successively to a cooled (0 °C) and stirred solution of methyl 5-amino-3-(4-tert- butylphenyl)-l -(3-methoxybenzyl)- lH-indole-2-carboxylate (Example 160, 140 mg, 0.31 mmol) in dichloromethane (10 mL). The reaction was warmed to rt and stirred for 16 h.
  • Example 160 500 mg, IJ mmol
  • dichloromethane (10 mL) 500 mg, IJ mmol
  • the reaction was warmed to rt and stirred for 3 h.
  • the solution was concentrated in vacuo leaving crude Example 172.
  • a portion (260 mg, 0.54 mmol) of the intermediate was dissolved in dichloromethane (10 mL) and then (cyclopropylmethyl)amine (0J3 mL, 108 mg, 1.5 mmol) was added.
  • the product had: 1H NMR (300 MHz, acetone- ⁇ ) ⁇ 7.78 (d, 1 H), 7.56-7.45 (m, 4 H), 7.34-7.32 (m, 1 H), 7.28-7.26 (m, 1 H), 7J6-7J3 (m, 1 H), 5.93 (s, 2 H), 4.32 (q, 2 H), 3.08 (d, 2 H), 1.31 (t, 3 H), 1J3-1J5 (m, 1 H), 0.42-0.38 (m, 2 H), 0.29-0.26 (m, 2 H).
  • Example 187 100 mg, 0.25 mmol was taken up in dichloromethane (10 mL) with a catalytic amount of DMF, and the mixture was cooled (0 °C.) Oxalyl chloride (0.044 mL, 2 eq.) was added, and the reaction was stirred for 1 hour. The mixture was concentrated in vacuo and used directly with no further purification.
  • Example 191 100 mg, 0.25 mmol was taken up in dichloromethane (10 mL) with a catalytic amount of DMF, and the mixture was cooled (0 °C.) Oxalyl chloride (0.044 mL, 2 eq.) was added, and the reaction was stirred for 1 hour. The mixture was concentrated in vacuo and used directly with no further purification.
  • Example 191 100 mg, 0.25 mmol was taken up in dichloromethane (10 mL) with a catalytic amount of DMF, and the mixture was cooled (0 °C.) Oxalyl chloride (0.0
  • Example 189 (Example 189, 0J6 g, 0.4 mmol) was taken up in excess morpholine (0.3 mL) at room temperature. The reaction was stirred for 72 hours, quenched with water, and extracted with diethyl ether (2 x 25 mL.) The combined organic extracts were dried over sodium sulfate and purified by flash chromatography to yield 0.268 mg (91%) of the desired product.
  • Ethyl-l-(3-trifluoromethylbenzyl)-lH-indole-2-carboxylate-3-carbonyl chloride (Example 189) was prepared as above from the corresponding acid (600 mg, 1.53 mmol.) The crude material was taken up in dichloromethane (50 mL) and cooled to 0 °C. Triethylamine (0.85 mL, 4 eq.) was added, followed by 2-aminophenol (0.5 g, 3 eq.), and the reaction mixture was allowed to warm to room temperature. The mixture was quenched with 1 N HC1, and the organic layers were separated and concentrated in vacuo.
  • Ethyl-3-benzthiazol-2-yl-l-(3-cyclopropylmethoxybenzyl)-lH-indole-2- carboxaldehyde (Example 41, 0.42 g, IJ mmol) was taken up in EtOH (30 mL) at room temperature. 2-arninothiophenol (0J5 g, 1.05 eq.) was added, followed by cone. HCl (0.5 mL), and the reaction mixture was heated to reflux for 24 hours.
  • Example 189 To a 0°C solution of Example 189 (545 mg, 1.28 mmol) in dichloromethane (8 mL) was added 2-hydroxy-l,l-dimethyl-ethylamine (285 mg, 3.2 mmol). Triethyl amine (0.7 mL, 5J2 mmol) was added in one portion. The mixture was stirred for 15 min. and then allowed to warm to r.t. over 20 min. The reaction was quenched with IN HCl and the resulting mixture was washed with IN HCl (2X). The organic layer was dried over anhydrous sodium sulfate, concentrated, and filtered through a short plug of silica gel (elution with 8:92 methanol: dichloromethane). Concentration of the filtrate provide 440 mg (74 %) of Example 196. LRMS (+esi) obs'd: 463 J; calc'd 462.2.
  • Example 189 (434 mg, 1.02 mmol) in dichloromethane (7 mL) was added cycloleucinol (295 mg, 2.55 mmol). Triethyl amine (0.57 mL, 4.08 mmol) was added in one portion. The mixture was stirred for lh and was then allowed to warm to r.t. over 40 min. The reaction was diluted with water and the organic layer was washed with IN HCl, dried over anhydrous sodium sulfate and concentrated to afford 498 mg of Example 198 which was used without further purification. LRMS (+esi) obs'd: 489J; calc'd 488.2.
  • Example 204 Ethyl 3-(cyclobutylcarbonyl)indole-2-carboxylate
  • the concentrated residue was used without further purification. It was mixed with triethyl phosphite (920 mg, 5.50 mmol) and heated to 170 °C for 3 hours before it was cooled to rt and diluted with ethyl acetate. The mixture was washed with water, brine and dried over anhydrous sodium sulfate.
  • the reaction was then quenched with 15mL of 3N HCl then extracted with 3x50 mL of ethyl acetate and dried over Na 2 SO 4 then concenfrated in vacuo.
  • the crude material was purified via column chromatography to yield 4.7g (70.1% yield) of a white solid.
  • the product had a Rf of 0.33 20% ethyl acetate/hexane; 1H NMR (300 MHz, Acetone-D 6 ); 8.22 Hz, (d, 2H), 8.11 Hz, (m, 3H), 7.73 Hz, (m, 3H), 7.62 Hz, (t, 4H), 7.34 Hz, (s, IH), 7.29 Hz, (dd, IH).
  • the reaction was extracted with 3x50 mL of ethyl acetate then dried over Na 2 SO 4 and concenfrated in vacuo.
  • the crude material was purified via column chromatography to yield 3.28g (99.0% yield) of an off white solid.
  • the product had a Rf of 0.42 20% ethyl acetate/hexane; 1H NMR (300 MHz, Acetone-D 6 ); 8.80 Hz, (s, IH), 8.02 Hz, (dd, IH), 7.95 Hz, (dd, IH), 7.68 Hz, (dd, IH), 7.58 Hz, (m, 2H), 7.46 Hz, (d, 2H), 7.21 Hz, (d, IH), 6.87 Hz, (dd, IH), 4.31 Hz (q, 2H), 1.31 Hz (t, 3H).
  • Example 42 1.0 M Aqueous sodium hydroxide (4 mL), methanol (2 mL), and potassium hydroxide (5 pellets) were added to a stirred solution of Example 42 (181 mg, 0.499 mmol) in tetrahydrofuran (4 mL). The resulting mixture was heated to reflux for 18 h, cooled to RT, and acidified with 1.0 M hydrochloric aced. The resulting mixture was extracted with ethyl acetate and the combined organic extracts were dried over anhydrous magnesium sulfate and concentrated in vacuo to give 122 mg (72%) of a white solid.
  • the compound was prepared from ethyl 3-(cyclopropylidenemethyl)-l-[3-
  • Example 121 21 mg, 0.05 mmol
  • bromomethylcyclopropane 14 mg, 0J0 mmol
  • potassium carbonate 21 mg, 0J5 mmol
  • potassium iodide catalytic amount
  • Sodium hydride (60% dispersion in mineral oil, 64 mg, 1.60 mmol) was added in portions to a cooled (0 °C) and stirred solution of ethyl 3-(4-ethoxyphenyl)-l-(4- fluorobenzyl)-5-(hydroxymethyl)-lH-indole-2-carboxylate (Example 141, 480 mg, 1.073 mmol) in tetrahydrofuran (10 mL). The mixture was allowed to warm to room temperature over a period of 1 hour. Cyclopropylmethylbromide (216 mg, 1.60 mmol) was added, and the mixture was stirred for 18 hours. The reaction was partitioned between water and ethyl acetate.
  • the aqueous layer was extracted with ethyl acetate (2x).
  • the combined organic extracts were washed with brine, dried over anhydrous magnesium sulfate, and concenfrated in vacuo.
  • the resulting crude oil was purified by flash chromatography on silica gel eluted on a gradient from 100% hexane to 50% ethyl acetate/hexane.
  • Benzenesulfonamide (155 mg, 1.0 mmol), l-(3-dimethylaminopropyl)-3-ethyl- carbodiimide hydrochloride (96 mg, 0.50 mmol), and 4-(dimethylamino)pyridine (20 mg, 0J6 mmol) were added to a stirred solution of 3 -(4-methoxyphenyl)- 1- ⁇ [3- (trifluoromethyl)phenyl]methyl ⁇ indole-2-carboxylic acid (Lit: WO94/14434, 213 mg, 0.50 mmol in dichloromethane (5 mL).
  • Dess-Martin reagent 39 mg, 0.09 mmol was added to a stirred solution of 2,2,2- trifluoro-l-(3-(4-methoxyphenyl)-l- ⁇ [3-(trifluoromethyl)phenyl]methyl ⁇ indol-2-yl)ethan- l-ol (Example 219, 40 mg, 0.08 mmol) in dichloromethane (2 mL). The resulting solution was stirred for 2 hours, more oxidant was added, and then the mixture was left stirring for 18 h.
  • reaction was quenched with a mixed aqueous solution of saturated sodium bicarbonate and saturated sodium thiosulfate (l.J, 10 mL), and the mixture was extracted with ethyl acetate (2 x 10 mL).
  • ethyl acetate 2 x 10 mL.
  • the combined organic exfracts were washed with water, and brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo.
  • the activity of a given compound in binding to PPAR- ⁇ can be assayed routinely according to procedures known in the art. See, e.g., Nichols, et al, Anal. Biochem., 257 (2), (1998), 112-119, 114; Brown, et al, Chem. & Bio.. 4 (12), (1997) 909-918.
  • the PPAR- ⁇ binding assay described below was used to determine the PPAR- ⁇ binding activities of the compounds of the invention. Compounds were tested for their ability to bind to PPAR ⁇ using a spin plate assay (gel filtration binding assay).
  • the PPAR ⁇ ligand binding domain (amino acids 195-475) was expressed in Escherichia coli as polyHis-tagged fusion proteins and purified by means of an epitope tag.
  • the LBD (210 ng per well) was then incubated in 96-well microtiter plates for two hours at room temperature with a constant concentration of radioligand (8nM per well) ([ 3 H]BRL 49653) and four concentrations (1 nM, 10 nM, lOOnM and 1 ⁇ M) of test compound. Each compound was tested in triplicate.
  • the compounds of the invention were found to inhibit [ 3 H]BRL 49653 binding at PPAR- ⁇ with an IC50 of 10 ⁇ M or less.
  • IC 50 ranges of compounds of the present invention in the PPAR- ⁇ Binding Assay are given in the table below.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Disclosed are substituted indoles, pharmaceutical compositions containing such indoles, and their use in treating or preventing PPAR-η mediated diseases or conditions, such as osteopenia, osteoporosis, cancer, diabetes and atherosclerosis.

Description

SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-γ BINDING AGENTS
Field of the Invention
The invention relates to substituted indoles, pharmaceutical compositions containing such indoles, and their use in treating or preventing diseases or conditions mediated by the Peroxisome Proliferator Activated Receptor-γ (PPAR-γ).
Background
Peroxisome Proliferator Activated Receptors (PPARs) belong to the steroid/retinoid receptor superfamily of ligand-activated transcription factors. Willson, et al, Curr. Opin. Chem. Biol.. (1997), Vol. 1, pp 235-241. To date, three mammalian PPARs have been identified, namely PPAR-α, PPAR-γ, and PPAR-δ.
PPARs regulate expression of target genes by binding to DNA response elements as heterodimers with the retinoid X receptor. These DNA response elements have been identified in the regulatory regions of a number of genes encoding proteins involved in lipid metabolism and energy balance. The biological role of the PPARs in the regulation of lipid metabolism and storage has been recently reviewed. Spiegelman, Diabetes. (1998), Vol. 47, pp. 507-514; Schoonjans, et al, Curr. Opin. LipidoL. (1997), Vol. 8, pp 159-166; Brun, et al, Curr. Opin. LipidoL. (1991). Vol. 8, pp 212-218.
Molecules that interact with PPAR-γ may be useful in modulating PPAR-γ mediated processes for the treatment or prevention of various diseases and conditions. For example, essential dietary fatty acids and certain of their eicosanoid metabolites are naturally occurring hormonal ligands for the PPAR-γ receptor, which can promote adipogenesis through activation of the PPAR-γ receptor. Kliewer, et al, Proc. Natl. Acad. Sci. USA, (1997), Vol. 94, pp 4318-4323; Kliewer, et al, Cell, (1995), Vol. 83, pp 813- 819. Therefore, molecules that inhibit the adipogenic effects of endogenous PPAR-γ hormones may be useful in the treatment of diseases caused by increased fat accumulation or lipid storage, such as osteoporosis, obesity and acne. Tontonoz, et al, Curr. Opin. Genet. Dev.. (1995), Vol. 5, pp 571-576. For example, it has been noted that the thiazolidinedione (TZD) class of PPAR-γ ligands promotes adipogenesis in bone marrow and inhibits expression of markers of the osteoblast phenotype, such as alkaline phosphatase. Paulik, et al, Cell Tissue Res.. (1997), Nol. 290, pp 79-87. These effects may lead to low bone mineral density and osteoporosis. Similarly, it is known that TZDs can promote lipid accumulation in sebocytes. Rosenfield, et al, Ν. Dermatology, (1998), Nol. 196, pp 43-46. These effects may lead to sebocyte differentiation and acne formation. Thus, molecules that block adipogenesis in adipocytes, pre-adipocytes, bone marrow, or sebocytes may have beneficial effects in the treatment of obesity, osteoporosis, or acne.
The PPAR-γ receptor has been found in tissues other than adipose, and it is believed that synthetic PPAR-γ ligands and natural PPAR-γ hormones (natural ligands) may have beneficial effects in many other diseases including cardiovascular disease, inflammation, and cancer. Schoonjans, supra; Ricote, et al, Nature, (1998), Vol. 391, pp 79-82; Mueller, et al, Mol. Cell. (1998), Vol. 1, pp 465-470.
TZD PPAR-γ ligands enhance the actions of insulin in man and reduce circulating glucose levels in rodent models of diabetes. The PPAR-γ receptor is expressed in adipose tissue and plays a pivotal role in the regulation of adipocyte differentiation in vitro. TZD such as rosiglitazone induce adipocyte differentiation in vitro through activation of the PPAR-γ receptor.
Although there are clearly therapeutic uses for PPAR-γ ligands in the treatment of diseases of lipid metabolism and energy balance, it is possible that there will be side effects of these drugs. For example, PPAR-γ ligands that promote adipocyte differentiation in vivo could lead to increased fat accumulation and weight gain. This side effect might offset the beneficial effects of a PPAR-γ ligand in the treatment of diabetes or other diseases where obesity is a risk factor. Spiegelman, supra; Bran, supra.
There is precedent among other member of the steroid/retinoid receptor superfamily that synthetic ligands can be identified which mimic many of the beneficial effects but inhibit some of the detrimental side effects of the natural hormones. McDonnell, Biochem. Soc. Trans., (1998), Vol. 26, pp 54-60. These synthetic ligands have been given various labels, including antagonists, anti-hormones, partial agonists, selective receptor modulators, tissue selective ligands, and others. Katzenellenbogen, et al, Mol. EndocinoL. (1996), Nol. 10, pp 119-131. Compounds are needed that will modulate PPAR-γ mediated processes for the treatment or prevention of diseases such as osteoporosis, cancer, etc. without the concommitant side-effects of natural hormones.
Summary of the Invention
The invention provides compounds that modulate PPAR-γ mediated processes, particularly substituted indole compounds, which can act as agonists or antagonists of PPAR-γ and thereby modulate PPAR-γ mediated processes. The invention further provides pharmaceutical compositions containing such compounds. Finally, the invention provides for methods of treating or preventing a PPAR-γ mediated diseases or condition in a mammal by administering a compound of the invention.
The invention relates to compounds of the Formula I:
Figure imgf000004_0001
wherein
R1
is R°-Ry
Rδ
is selected from alkyl of 1-7 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, (CH2)tS(=O)2, and (CH2)nC(=O);
t
is 1-7;
n is 0-8;
9
R
is selected from phenyl, cycloalkyl of 3-8 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O,
wherein R may be substituted with alkoxy of 1-8 carbon atoms, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, halogen, alkyl of 1-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or Q-(CH2)nR10;
is selected from NR33, NH, S and O;
R 10
is selected from cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O;
R 33
is selected from alkyl of 1-8 carbon atoms, alkenyl of 1-8 carbon atoms and alkynyl of 1-8 carbon atoms;
X
is selected from NR33, NH, O, and S;
Rz
is selected from hydrogen, alkyl of 1-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, and (CH2)nS(=O) R1 ;
R11 is selected from aryl of 5-14 carbon atoms and heteroaryl of 3-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, with the proviso that R is not isoxazole,
wherein R may be substituted with alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, alkoxy of 1-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or halogen;
3
R
is selected from:
(a) R12-R13, wherein
R12
is selected from alkyl of 1-7 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, and C(=O), and
R13
is selected from cycloalkyl of 3-7 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O,
13 wherein R may be substituted with alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, alkoxy of 1-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or halogen; or
(b) cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, all of which may be substituted with alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, heterocycloalkenyl of 3-8 carbon atoms and 1- 2 heteroatoms selected from N, S and O, aryl of 5-14 carbon atoms and heteroaryl of 4-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, or may be spiro fused with cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and
1-2 heteroatoms selected from N, S and O, cycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, aryl of 5-14 carbon atoms and heteroaryl of 4-8 carbon atoms and 1-2 heteroatoms selected
Figure imgf000007_0001
(c) aryl of 5-14 carbon atoms or heteroaryl of 3-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, which are substituted with 1-3 of the following:
(i) Si(CH3)3;
(ii) cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and
1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O;
Figure imgf000007_0002
wherein R14 is selected from cycloalkyl of 3-7 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, aryl of 5-14 carbon atoms and heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O;
(iv) R15, which combines with R5 to form a radical of the formula -Y-(CH2)r Y-
wherein Y is selected from NR » NH, S and O;
(v) C(=O)R16>
~ wherein R is selected from alkyl of 1-8 carbon atoms, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and Z-R 17 >
33
- wherein Z is selected from (CH2)n, NH, NR , O and S,
17 - wherein R is selected from cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, aryl of 5-14 carbon atoms and heteroaryl of 3-11 carbon atoms and 1-2 heteroatoms selected from N, S and
O;
(vi) Z-R18-R19, wherein:
18
- R is selected from alkyl of 1-8 carbon atoms, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, aryl of 5-14 carbon atoms, heteroaryl of 3-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, and (CH2)nC(=O), and
R is selected from hydrogen, halogen, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8
90 carbon atoms and 1-2 heteroatoms selected from N, S and O, R - R and Z-R , and
- Z is as defined above, and
90
- R is selected from aryl of 5-14 carbon atoms and heteroaryl of 3- 11 carbon atoms and 1-2 heteroatoms selected from N, S and O, and
91
- R is selected from hydrogen, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, aryl of 5-14 carbon atoms and heteroaryl of 3-11 carbon atoms and 1-2 heteroatoms selected from N, S and O;
with the proviso that when R is furyl, benzofuranyl, benzothienyl, benzoxazolidmyl, benzoxazolyl, benzothiazolydinyl, benzothiazolyl, benzoisothiazolyl, benzopyrazolyl, bbeennzzooiimmiiddaazzoollyyll,, 1 benzoimidazolidinyl, benzoisooxazolyl, or benzoxadiazolyl R may be unsubstituted, and
3 1 o with the further proviso that, (1) when R is aryl or heteroaryl, Z is O or (CH2)n, R is (CH2)nC(=O), alkyl, aryl or heteroaryl, and R19 is hydrogen, halogen, haloalkyl or alkyl, or (2) when R is phenyl or napthyl and R is alkyl, one of the following applies:
5 23
R is other than hydrogen and R is other than alkyl or alkenyl,
X is NH and R2 is (CH2)nS(=O)2R11>
- R8 is (CH2)nC(=O), (CH2)tS(=O)2, alkenyl or alkynyl,
Q 10
R is substituted with Q(CH2)nR »
7
R is other than hydrogen, or R is other than hydrogen; and
(d) furyl, benzofuranyl, benzothienyl, benzoxazolidinyl, benzoxazolyl, benzothiazolydinyl, benzothiazolyl, benzoisothiazolyl, benzopyrazolyl, benzoimidazolyl, benzoimidazolidinyl, benzoisooxazolyl, or benzoxadiazolyl, which may be substituted with alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, alkoxy of 1-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or halogen; or
R*
is selected from hydrogen and E-R -R , wherein
E is selected from NR33> NH, S and O;
R34 is selected from alkyl of 1-8 carbon atoms, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O;
R is selected from hydrogen, halogen, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O; and
R 33 has the meaning given above;
R 5
(1) is selected from:
(a) hydrogen; (b) (CH2)qCOOH
where q is 1-4
(c) C(=O)R22>
22 wherein R is selected from alkyl of 1-8 carbon atoms, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, aryl of 5-14 carbon atoms and heteroaryl of 3-11 carbon atoms and 1-2 heteroatoms selected from N, S and O;
(d) cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and
1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O;
(e) -(CH2)n-D-R23> wherein:
(i) D is selected from NR33, NH, S and O, and
(iϊ) R23 is selected from alkyl of 1-8 carbon atoms, alkenyl of 2- 8 carbon atoms, alkynyl of 2-8 carbon atoms, C(=O)R24, and (CH2)mR24, wherein
- m is 0-4, with the proviso that when R3 is phenyl or napthyl, Z is O, R18 is alkyl and R19 is hydrogen, halogen, haloalkyl or alkyl, m is 1-4,
R24 is selected from cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, C(=O)OH, NHR 7_R28, NR27_R28, (CH2)„OR27-R28, NH- R29-R30and R29-R30, - R27 is alkyl of 1-8 carbon atoms,
- R28 is selected from hydrogen, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, aryl of 5-14 carbon atoms and heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O,
- R is selected from cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, aryl of 5-14 carbon atoms, and heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, and
- R30 is selected from hydrogen, halogen, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, alkoxy of 1-
8 carbon atoms, aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, and C(=O)OH, or
(2) R 5 combines with R to form a radical of formula -Y-(CH2)t-Y-,
wherein Y is as defined above;
R6
is selected from hydrogen, OH, and T-R18-R19>
wherein T is selected from NR33, NH, S and O and R18> R19 and R33 are as defined above; R7
is selected from hydrogen, C( =O)R22> (CH2)n-D-R23> and R31-R32>
97 wherein D, R and R are as defined above, and
R31
is selected from alkyl of 1-7 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of
2-8 carbon atoms, and C(=O), and
R32
is selected from aryl of 5-14 carbon atoms, heteroaryl of 3-11 carbon atoms and 1- 2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O,
32 wherein R may be substituted with alkyl of 1-7 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, alkoxy of 1-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or halogen;
and pharmaceutically acceptable salts thereof.
The invention further relates to pharmaceutical compositions containing any of the above-described compounds of Formula I and a pharmaceutically acceptable carrier.
The invention also provides methods for treating or preventing a PPAR-γ mediated disease or condition in a mammal. The PPAR-γ mediated disease or condition may be osteopororsis, osteopenia, PPAR-γ mediated cancer, including breast, prostate, colon and lung cancer, inflammation, including atherosclerosis, inflammatory bowel disease, Alzheimer's disease and rheumatoid arthritis, hypertension, hyperglycemia, type 1 diabetes, type 2 diabetes, syndrome X, insulin resistance, obesity, dyslipidemia, hypertriglyceridemia, diabetic dyslipidemia, hyperhpidemia, hypercholesteremia, and skin disorders, such as acne, psoriasis, dermatitis, eczema, keratosis and inflammatory skin conditions caused by lupus erythematosus. The methods of the invention provide for the administration of a compound of Formula I or a compound of Formula Ila:
Figure imgf000014_0001
wherein R1
(1) is selected from hydrogen and R > 8 -R r>9 , or
(2) combines with R7 to form a radical of the formula
Figure imgf000014_0002
Rs is selected from alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, (CH2)nS(=O)2 and (CH2)nC(=O);
R9 is selected from aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected fromN, S and O; wherein R9 may be substitituted with alkoxy of 1-8 carbon atoms, haloalkoxy of 1- 8 carbon atoms and a number of halogen atoms up to the perhalo level, halogen, alkyl of 1-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or X-(CH2)nCH3R 10
R 10 is selected from cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O;
X and X' are each independently selected from NH, NR33, (CH2)„, O and S; n is a number from 0-8;
R33
is selected from alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms and alkynyl of 2-8 carbon atoms;
R2 is selected from hydrogen, alkyl of 1-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, NHS(=O)2Rπ, and (CH2)nS(= )2Ru;
R11 is selected from aryl of 5-14 carbon atoms and heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, wherein R11 may be substituted with alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, alkoxy of 1-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, alkoxy of 1-8 carbon atoms, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or halogen;
R3 is selected from:
(a) hydrogen, (b) R12-R13, wherein
R 12
is selected from alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, and (CH2)nC(=O),
R 13 is selected from aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and
1-2 heteroatoms selected from N, S and O, wherein R13 may be substituted with alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, alkoxy of 1-8 carbon atoms, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or halogen;
(c) cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected fromN, S and O, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, all of which maybe:
(i) substituted with aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and C(=O)(CH2)nCH3, or
(ii) fused with a spiro ring of 1 -6 carbon atoms, or
(iii) fused with an aryl of 5-14 carbon atoms or a heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, either of which may be substituted with alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, alkoxy of 1-8 carbon atoms, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or halogen;
(d) aryl of 5-14 carbon atoms or heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, either of which may be substituted with: (i) -Si(CH3)3;
(ii) S(=O)2R14, wherein R is selected from aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O,
(iii) R15, which combines with R5 to form a radical of the formula — Y- (CH2)n-Y-, wherein Y and n are as defined above;
(iv) C(=O)R16,
- wherein R16 is selected from alkyl of 1-8 carbon atoms and X-R17 - wherein R17 is selected from aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and wherein X is as defined above;
(v) X-R18-R19 - R18 is selected from alkyl of 1-8 carbon atoms, aryl of 5-
14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1- 2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O,
- R19 is selected from hydrogen, halogen, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, R20-R21 and X- R21, - X is as defined above,
- R20 is aryl of 5-14 carbon atoms or heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, and
- R21 is selected from aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O,
R4 is selected from hydrogen and X-R18-R19, wherein X, R18 and R19 have the meanings given above; R5
(1) is selected from: (a) hydrogen;
(b) R12-R13, wherein R and R are as defined above,
(c) C(=O)R22, wherein R22 is selected from alkyl of 1-8 carbon atoms, aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O,
(d) alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O,
(e) -(CH2)n-Y-R23, wherein:
(i) Y and n are as defined above,
(ii) R23 is selected from alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, C(=O)R24, (CH2)nR24, and R25-R26, wherein
- R25 is alkyl of 1-8 carbon atoms,
R26 is selected from aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, - R24 is selected from cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3- 8 carbon atoms and 1 -2 heteroatoms selected from N, S and O, heterocycloalkenyl of 3-8 carbon atoms and 1-2
5 heteroatoms selected from N, S and O, C(=O)OH,
NHR 7-R28, NR27-R28, NR33R27-R28, (CH2)nR27-R28, and R29-R30,
97
- R is alkyl of 1-8 carbon atoms,
- R is selected from hydrogen, aryl of 5-14 carbon 10 atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and 15 heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, all of which, with the exception of hydrogen, may be fused with aryl of 5- 14 carbon atoms or heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected N, S and O,
20 - R29 is selected from aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2
25 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and
- R30 is selected from hydrogen, halogen, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the
30 perhalo level, alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, alkoxy of 1- 8 carbon atoms, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, aryl of 5-14 carbon atoms and heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O;
(2) combines with R6 to form a radical of the formula -Y-(CH2)n-Y-, wherein Y and n have the meanings given above; R6 is selected from hydrogen, OH and X-R18-R19, wherein X, R18 and R19 have the meanings give above
R7 is selected from hydrogen, C(=O)R22, (CH2)n-Y-R23, and R1 -R13,
OO Tϊ 1 0 1 " wherein R , R , R , R , Y and n have the meanings give above; and pharmaceutically acceptable salts thereof.
The present invention therefore provides compounds, pharmaceutical compositions containing such compounds, and methods for the treatment or prevention of PPAR-γ mediated diseases and conditions. Compounds, compositions and methods of the present invention therefore are useful in treatment of PPAR-γ mediated diseases and conditions without the concommitant undesired side-effects of natural hormones. These and other aspects of the invention will be more apparent from the following description and claims.
Detailed Description of the Invention
The invention provides novel, substituted indoles of Formula I, pharmaceutical compositions containing such indoles, and their use in the treatment or prevention of PPAR-γ mediated diseases or conditions in a mammal. The invention further provides methods of treating or preventing PPAR-γ mediated diseases or conditions in a mammal, such as a human, by administration of a compound of Formula Ila. The compounds of Formula I and Formula Ila have both been broadly described above.
h one embodiment of the compounds of Formula I:
R8 is alkyl
R9 is phenyl, which may or may not be substituted; X is O;
R is hydrogen; and
R3 is aryl, particularly phenyl, or heteroaryl, either of which may or may not be substituted.
As used herein, the term "aryl" includes aromatic ring structures that are substituents on another atom. These aryls may also be substituted with substituents, such as halogen, haloalkyl, alkoxy, haloalkoxy, etc. Non-limiting examples of aryls include phenyl, napthyl, etc. Likewise, the term "heteroaryl" as used herein includes aromatic ring structures containing between one and two heteroatoms, such as O, N and S, that are substituents on another atom. These heteroaryls may also be substituted with substituents, such as alkyl, alkenyl, alkoxy, haloalkoxy, halogen, haloalkyl, etc. Non-limiting examples of heteroaryls include pyridyl, furyl, quinolyl, etc.
As used herein the term "alkyl" includes straight-chain or branched alkyls of between 1 and 8 carbon atoms. The term "alkenyl" includes straight-chain or branched alkenyls of between 2 and 8 carbon atoms. As used herein the term "alkynyl" includes straight-chain or branched alkynyls of between 2 and 8 carbon atoms. Such alkyls, alkenyls and alkynyls may be terminal or may be linkers between other portions of a molecule.
Examples of compounds of the invention where R is a heteroaryl include, but are not limited to:
Figure imgf000022_0001
Figure imgf000023_0001
Figure imgf000024_0001
Examples of compounds of the invention where R is phenyl include, but are not limited to:
Figure imgf000024_0002
Figure imgf000025_0001
24
Figure imgf000026_0001
25
Figure imgf000027_0001
Figure imgf000028_0001
In another embodiment of the invention, R is R -R , where R is cycloalkyl, heterocycloalkyl, cycloalkenyl or heterocycloalkenyl. Examples of compounds of the invention where R3 is R12-R13 include, but are not limited to:
Figure imgf000028_0002
In other embodiments of the invention, R3 is a cycloalkyl, heterocylcoalkyl, cycloalkenyl or heterocycloalkenyl, which may be substituted or may be fused with a spiro ring of 3-9 carbon atoms. Examples of compounds of the invention where R3 is a cycloalkyl, heterocylcoalkyl, cycloalkenyl or heterocycloalkenyl include, but are not limited to:
Figure imgf000029_0001
In still other embodiments of the invention, R4, R5, R6 and or R7 may be other than hydrogen. Examples of compounds of the invention where R4, R5, R6 and/or R7 are other than hydrogen include, but are not limited to:
Figure imgf000029_0002
Figure imgf000030_0001
Figure imgf000031_0001
30
Figure imgf000032_0001
Compounds of Formulas I and Ila may be useful in the treatment or prevention of PPAR-γ mediated diseases or conditions. An agent which binds to PPAR-γ may be employed for a wide variety of indications, including, but not limited to:
(1) osteoporosis and osteopenia, see, Nuttall, et al, Bone 27 (2), (2000), 177-184; Gimble, et al, Bone 19 (5), (1996), 421- 428;
(2) cancer, particularly PPAR-γ mediated cancers, such as breast and prostate cancers (see, Gelman, et al, Cell, and Mol. Life Sci-, 55 (6-7), (1999), 935-943; Kersten, et al, Nature, 405 (6785), May 25, 2000, 421-424), colon cancer (see, Saez, et al, Nat. Med., 4 (9) Sept. 1998, 1058-1061; Lefebvre, et al, Nat. Med.. 4 (9), Sept. 1998, 1053-1057; Demetri, et al, Proc. Nat'L Acad. Sci. USA, 96 (7), Mar. 30, 1999, 3951- 3956) liposarcoma (Demetri, et al., Proc. Nat'L Acad. Sci USA, 96 (7), Mar. 30, 1999, 3951-3956) and lung cancer (see, Chang, etal, Cancer Res., 60, 2000, 1129-1138);
(3) hyperglycemia, type 1 diabetes, type 2 diabetes, syndrome X, and insulin resistance, (see Lehmann, et al, J. Bio. Chem., 270 (22) (1995), 12953-12956; Spiegelman, Diabetes. 47 (4), (1998), 507-514); (4) obesity, (see Zhou, et al, Proc. Nat'L Ac. Sci. USA. 96 (5), (1999), 2391-2395; U.S. Patent No. 6,033,656);
(5) inflammation, particularly inflammatory bowel disease (see Cell, and Mol. Life Sci.. 55 (6-7), (1999), 935-943), Alzheimer's disease (see, Combs, et al, J. Neurosci. 20 (2),
2000, 558-567), rheumatoid arthritis (see, Jiang, et al, Nature 391 (6662), 1998, 82-86), and atherosclerosis (see Pasceri, et al, Circulation. 101 (3), 2000, 235-238);
(6) cardiovascular disease, particularly hypertension, (see Cell. and Mol. Life Sci.. 55 (6-7), (1999), 935-943 review);
(7) dyslipidemia, hypertriglyceridemia, diabetic dyslipidemia, hyperlipidemia and hypercholesteremia (see Hulin, et al, Curr. Pharm. Design. 2 (1996), 85-102); and
(8) skin disorders, particularly inflammatory skin disorders caused by lupus erythematosus, and acne, psoriasis, dermatitis, eczema and keratosis (see, WO 99/34783; U.S. Patent No. 5,981,586).
Compounds of Formulas I and Ila are preferably used in the treatment or prevention of osteopenia, osteoporosis, and PPAR-γ mediated cancers, including breast, prostate and colon cancer.
The present invention also includes pharmaceutically acceptable salts of the compounds of Formulas I and Ila. Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluoromethanesulfonic acid, sulphonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid. In addition, pharmaceutically acceptable salts include acid salts of inorganic bases, such as salts containing alkaline cations (e.g., Li+ Na+ or K+), alkaline earth cations (e.g., Mg+2, Ca+2 or Ba+2), the ammonium cation, as well as acid salts of organic bases, including aliphatic and aromatic substituted ammonium, and quaternary ammonium cations such as those arising from protonation or peralkylation of triethylamine, N,N-diethylamine, N,N-dicyclohexylamine, pyridine, N,N- dimethylaminopyridine (DMAP), l,4-diazabicyclo[2.2.2]octane (DABCO), 1,5- diazabicyclo[4.3.0]non-5-ene (DBΝ) and l,8-diazabicyclo[5.4.0]undec-7-ene (DBU).
A number of the compounds of Formulas I and Ila possess asymmetric carbons and can therefore exist in racemic and optically active forms. Methods of separation of enantiomeric and diastereomeric mixtures are well known to the skilled in the art. The present invention encompasses any racemic or optically active forms of compounds described in Formula I or Formula Ila which possess PPAR-γ modulating activity or the use of any racemic or optically active forms of the compounds described in Formulas I and Ila for the treatment or prevention of PPAR-γ mediated diseases or conditions.
The therapeutic agents of the invention may be employed alone or concurrently with other therapies. For example, when employed as a treatment for osteoporosis or osteopenia, the compounds of the invention may be used in combination with a calcium source, vitamin D or analogues of vitamin D, and/or antiresorptive therapies such as estrogen replacement therapy, treatment with a fluoride source, treatment with calcitonin or a calcitonin analogue, or treatment with a bisphosphonate such as alendronate. The method of the invention is intended to be employed for treatment of PPAR-γ mediated diseases or conditions in both humans and other mammals.
The compounds may be administered orally, dermally, parenterally, by injection, by inhalation or spray, or sublingually, rectally or vaginally in dosage unit formulations. The term "administered by injection" includes intravenous, intraarticular, intramuscular, subcutaneous and parenteral injections, as well as use of infusion techniques. Dermal administration may include topical application or transdermal administration. One or more compounds may be present in association with one or more non-toxic pharmaceutically acceptable carriers and, if desired, other active ingredients.
Compositions intended for oral use may be prepared according to any suitable method known to the art for the manufacture of pharmaceutical compositions. Such compositions may contain one or more agents selected from the group consisting of diluents, sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, com starch, or alginic acid; and binding agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. These compounds may also be prepared in solid, rapidly released form.
Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
Aqueous suspensions containing the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions may also be used. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl-methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, /J-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example, sweetening, flavoring and coloring agents, may also be present.
The compounds may also be in the form of non-aqueous liquid formulations, e.g., oily suspensions which may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or peanut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
Pharmaceutical compositions of the invention may also be in the form of oil-in- water emulsions. The oil phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.
Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
The compounds may also be administered in the form of suppositories for rectal or vaginal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal or vaginal temperature and will therefore melt in the rectum or vagina to release the drug. Such materials include cocoa butter and polyethylene glycols.
Compounds of the invention may also be administered transdermally using methods known to those skilled in the art (see, e.g., Chien; "Transdermal Controlled
Systemic Medications"; Marcel Dekker, Inc.; 1987. Lipp et al. WO 94/04157 3Mar94). For example, a solution or suspension of a compound of Formula I or Ila in a suitable volatile solvent optionally containing penetration enhancing agents can be combined with additional additives known to those skilled in the art, such as matrix materials and bacteriocides. After sterilization, the resulting mixture can be formulated following known procedures into dosage forms. In addition, on treatment with emulsifying agents and water, a solution or suspension of a compound of Formula I or Ila may be formulated into a lotion or salve.
Suitable solvents for processing transdermal delivery systems are known to those skilled in the art, and include lower alcohols such as ethanol or isopropyl alcohol, lower ketones such as acetone, lower carboxylic acid esters such as ethyl acetate, polar ethers such as tetrahydrofuran, lower hydrocarbons such as hexane, cyclohexane or benzene, or halogenated hydrocarbons such as dichloromethane, chloroform, trichlorotrifluoroethane, or trichlorofluoroethane. Suitable solvents may also include mixtures one or more materials selected from lower alcohols, lower ketones, lower carboxylic acid esters, polar ethers, lower hydrocarbons, halogenated hydrocarbons.
Suitable penetration enhancing materials for transdermal delivery systems are known to those skilled in the art, and include, for example, monohydroxy or polyhydroxy alcohols such as ethanol, propylene glycol or benzyl alcohol, saturated or unsaturated C8- Cis fatty alcohols such as lauryl alcohol or cetyl alcohol, saturated or unsaturated C8-Cι8 fatty acids such as stearic acid, saturated or unsaturated fatty esters with up to 24 carbons such as methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl isobutyl tert-butyl or monoglycerin esters of acetic acid, capronic acid, lauric acid, myristinic acid, stearic acid, or palmitic acid, or diesters of saturated or unsaturated dicarboxylic acids with a total of up to 24 carbons such as diisopropyl adipate, diisobutyl adipate, diisopropyl sebacate, diisopropyl maleate, or diisopropyl fumarate. Additional penetration enhancing materials include phosphatidyl derivatives such as lecithin or cephalin, terpenes, amides, ketones, ureas and their derivatives, and ethers such as dimethyl isosorbid and diethyleneglycol monoethyl ether. Suitable penetration enhancing formulations may also include mixtures one or more materials selected from monohydroxy or polyhydroxy alcohols, saturated or unsaturated C8-C18 fatty alcohols, saturated or unsaturated C8-C18 fatty acids, saturated or unsaturated fatty esters with up to 24 carbons, diesters of saturated or unsaturated dicarboxylic acids with a total of up to 24 carbons, phosphatidyl derivatives, terpenes, amides, ketones, ureas and their derivatives, and ethers.
Suitable binding materials for transdermal delivery systems are known to those skilled in the art and include polyacrylates, silicones, polyurethanes, block polymers, styrene-butadiene coploymers, and natural and synthetic rubbers. Cellulose ethers, derivatized polyethylenes, and silicates may also be used as matrix components. Additional additives, such as viscous resins or oils may be added to increase the viscosity of the matrix.
For all regimens of use disclosed herein for compounds of Formulas I and Ila, the daily oral dosage regimen will preferably be from 0.01 to 200 mg/Kg of total body weight. The daily dosage for administration by injection, including intravenous, intramuscular, subcutaneous and parenteral injections, and use of infusion techniques will preferably be from 0.01 to 200 mg/Kg of total body weight. The daily rectal dosage regimen will preferably be from 0.01 to 200 mg/Kg of total body weight. The daily vaginal dosage regimen will preferably be from 0.01 to 200 mg/Kg of total body weight. The daily topical dosage regimen will preferably be from 0J to 200 mg administered between one to four times daily. The transdermal concentration will preferably be that required to maintain a daily dose of from 0.01 to 200 mg/Kg. The daily inhalation dosage regimen will preferably be from 0.01 to 10 mg/Kg of total body weight.
It will be appreciated by those skilled in the art that the particular method of administration will depend on a variety of factors, all of which are considered routinely when administering therapeutics. It will also be understood, however, that the specific dose level for any given patient will depend upon a variety of factors, including, but not limited to the activity of the specific compound employed, the age of the patient, the body weight of the patient, the general health of the patient, the gender of the patient, the diet of the patient, time of administration, route of administration, rate of excretion, drug combinations, and the severity of the condition undergoing therapy. It will be further appreciated by one skilled in the art that the optimal course of treatment, i.e., the mode of treatment and the daily number of doses of a compound of Formula I or Ila or a pharmaceutically acceptable salt thereof given for a defined number of days, can be ascertained by those skilled in the art using conventional treatment tests.
The compounds of Formulas I and Ila may be prepared by use of known chemical reactions and procedures, from known compounds (or from starting materials which, in turn, are producible from known compounds) through the preparative methods shown below, as well as by other reactions and procedures known to the skilled in the art. Such reactions and procedures include, but are not limited to, esterification, hydrolysis, alkylation, acylation neutralization, coupling, oxidation, reduction, condensation, elimination and substitution reactions. Nevertheless, the following general preparative methods are presented to aid practitioners in synthesizing the compounds of the invention, with more detailed particular examples being presented in the experimental section. The examples are for illustrative purposes only and are not intended, nor should they be construed, to limit the invention in any way.
Within the scope of each method, optional substituents may appear on reagents or intermediates which may act as protecting groups or other non-participating groups. Utilizing methods well known to those skilled in the art, such groups are introduced and/or removed during the course of the synthetic schemes to provide the compounds of the present invention. All variable groups not defined below are as described hereinabove.
In general, compounds of Formula I or Ila may be prepared from the appropriately substituted indoles, by esterification, hydrolysis, sulfonylation or neutralization reactions as shown in Flow Diagram I:
Flow Diagram I
Figure imgf000039_0001
Figure imgf000039_0002
Preparation of certain Formula I compounds with a variety of R substituents may be prepared by a sequence involving conversion of VI to a boronic acid intermediate, followed by a palladium-facilitated coupling reaction with an organohalide and base, such as triethylamine, potassium carbonate or Huenig's base, as shown in Flow Diagram II. Alternatively, either a boronic acid or organotin intermediate may be coupled with NI under similar conditions.
Flow Diagram II
Figure imgf000040_0001
R -halogen Pd(PPh3)4,
R3-B(OH)2 base, H20 or R3Sn(R')3
base, Pd catalyst
R' = lower alkyl; halogen = Br, CI, I
Figure imgf000040_0002
Other compounds with heterocycloakenyl or heteroaryl substituents at the R3 position may prepared by condensation of 3-carboxy-substiruted indoles with 2- aminoethanols, 2-aminophenols or 2-aminothiols as illustrated in Flow Diagram III.
Flow Diagram III
Figure imgf000041_0001
Certain aryl substituents on the R3 aryl ring may be further transformed to other substituents by standard means. An illustration of this is shown in Flow Diagram IN, in which a nitro group is reduced and acylated to provide amido substituents.
Flow Diagram IN
Figure imgf000041_0002
R" = alkyl, cycloalkyl, aryl, or heteroaryl
Figure imgf000041_0003
Compounds of Formula I which bear certain R3 substituents may be prepared by Friedel-Crafts acylation of the corresponding unsubstituted indole, followed by reduction of the carbonyl group to a methylene, as shown in Flow Diagram N.
Flow Diagram V
Figure imgf000042_0001
Compounds of Formula I with similar substituents at either R5 or R7 may be likewise prepared, either individually (Flow Diagram NI) or as mixtures (Flow Diagram Nil) by an analogous sequence of acylation and reduction reactions. In the latter scheme, where R5 and R7 are hydrogen in the starting materials, individual compounds may be obtained by chromato graphic separation of products (Ig and Ii) after the initial step.
Flow Diagram VI
(R5, R7≠ H)
Figure imgf000043_0001
TFA, Et3SiH TFA, Et3SiH
Figure imgf000043_0002
Flow Diagram VII
Figure imgf000044_0001
R22COCI Lewis Acid
Figure imgf000044_0002
TFA, Et3SiH TFA, Et3SiH
Figure imgf000044_0003
O-Alkylation reactions may be utilized to prepare Formula I compounds bearing substituents on R4, R5, R6 or R7 positions. For example, alkylation of the corresponding hydroxy intermediates provides ethers containing an R18 or R23 group, depending upon position, as shown in Flow Diagram NHL
Flow Diagram VIII
Figure imgf000044_0004
A more detailed example of this process is shown for compounds bearing R5 the group in Flow Diagram IX. Flow Diagram IX
Figure imgf000045_0001
CL NaH OTs Toluene
Figure imgf000045_0002
Other compounds of Formula I may also be obtained from a hydroxy intermediate. For example, the hydroxy group may be converted to a trifluoromethylsulfonate which reacts with an alkyl stannane to give alkyl-substituted indoles, as exemplified in Flow Diagram X for the R5 position.
Flow Diagram X
Figure imgf000046_0001
Nitration of indoles that are unsubstituted at positions 5 and/or 7 provides nitro- substituted intermediates which may be reduced and either acylated or alkylated to give a variety of Formula I compounds as shown in Flow Diagram XI.
Flow Diagram XI
Figure imgf000046_0002
Indole intermediates which are useful in the preparation of compounds in the present invention are either commercially available or may be prepared by standard methods. These transformations are summarized in Flow Diagram XII for intermediates of Formula NI, IN and N. For example, an appropriately substituted 2-bromonitrobenzene may be converted to a 2-mtrocinnamic acid derivative which cyclizes to an indole upon reduction. The resulting indole intermediate may then be brominated at the 3 position, and the desired R1 substituent introduced by Ν-alkylation giving the intermediate compounds of Formula NI. Compounds of Formula IN may be prepared from NI in a stepwise sequence involving halogen-metal exchange, addition to formaldehyde, and oxidation of the resulting carbinol to a 3-carboxylic acid. It is understood that the presence of certain R4-R7 substituents may require additional steps of protection and deprotection during this process in order to avoid undesired side reactions.
Flow Diagram XII
Figure imgf000047_0001
Figure imgf000047_0002
Figure imgf000047_0003
1. Vilsmeier formylation
R1 -halogen 2. oxidation base i ' 3. RPhalogen
Figure imgf000047_0004
(VI) (IV)
The introduction of the carboxyl functionality at position 2 of other indole compounds may be accomplished by a sequence shown in Flow Diagram XIII. The nitrogen of the unsubstituted indole is first protected as a sulfonamide, then subjected to acylation conditions catalyzed by Lewis acid. Protection may be then be removed and the desired R1 attached as described above. Flow Diagram XIII
Figure imgf000048_0001
1. LDA
2. R2XCO-halogen or R2XCOXR2
Figure imgf000048_0002
Preparative Examples
Examples of preparations of both intermediates and compounds of the invention are provided in the following detailed synthetic procedures. In the tables of compounds to follow, the synthesis of each compound is referenced back to these exemplary preparative steps. All temperatures are reported uncorrected in degrees Celsius (°C). Unless otherwise indicated, all parts and percentages are by volume.
All reactions were performed under a positive pressure of dry argon, and were stirred magnetically unless otherwise indicated. Sensitive liquids and solutions were transferred via syringe or cannula, and introduced into reaction vessels through rubber septa. Commercial grade reagents and solvents were used without further purification. Thin-layer chromatography (TLC) was performed on Whatman® pre-coated, glass-backed silica gel 60A F-254 250 μm plates. Column chromatography (flash chromatography) was performed using 230-400 mesh EM Science® silica gel. Melting points (mp) were determined using a Thomas-Hoover melting point apparatus, an Electrothermal melting point apparatus, or a Mettler FP66 automated melting point apparatus and are uncorrected.
1H-NMR spectra were recorded with a Narian Mercury (300 MHz,) or a Bruker Avance 500 (500 MHz) spectrometer with either Me Si (5 0.00) or residual protonated solvent (CDC13 δ 7.26; CD3OD δ 3.30; DMSO-D6 δ 2.49; Acetone-D6 δ 2.04; or CD3CN δ 1.94).
HPLC - electrospray mass spectra (HPLC ES-MS) were obtained using a Hewlett-Packard 1100 HPLC equipped with a quaternary pump, a variable wavelength detector, a YMC Pro C18 2.0 mm x 23 mm column, and a Finnigan LCQ ion trap mass spectrometer with electrospray ionization. Gradient elution from 90% A to 95% B over 4 minutes was used on the HPLC. Buffer A was 98% water, 2% Acetonitrile and 0.02% TFA. Buffer B was 98% Acetonitrile, 2% water and 0.018% TFA. Spectra were scanned from 140-1200 amu using a variable ion time according to the number of ions in the source.
Fourier transform infrared spectra were obtained using a Mattson 4020 Galaxy Series spectrophotometer.
Elemental analyses were conducted by Robertson Microlit Labs, Madison NJ. NMR mass and infrared spectra, and elemental analyses of the compounds were consistent with the assigned structures.
List of Abbreviations and Acronyms
As employed herein, the following terms have the indicated meanings.
Figure imgf000049_0001
Figure imgf000050_0001
Example 1 4-(Cyclopropylmethoxy)iodobeιιzene
Figure imgf000051_0001
A solution of 4-iodophenol (l l.Og, 50.0 mmol) in tetrahydrofuran (30 mL + 10 mL rinse) was added to a cooled (0 °C) and stirred suspension of sodium hydride (1.44 g, 60.0 mmol) in tetrahydrofuran (30 mL). The cold bath was removed and the reaction was stirred for 1 h. A solution of (bromomethyl)cyclopropane (16.2 g, 120.0 mmol) in tetrahydrofuran (20 mL) and then HMPA (5 mL) were added successively and the reaction was heated (55 °C) for 18 h. After cooling, the reaction was quenched with cold water (500 mL) and then extracted with ethyl acetate (3x200 mL). The combined organic extracts were washed with brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo. Flash chromatography of the residue over silica gel using 10% dichloromethane/hexane afforded 12.6 g (92%) of the desired Example 1. The product had: 1H NMR (300 MHz, CDC13) δ 7.54 (d, 2 H), 6.68 (d, 2 H), 3.76 (d, 2 H), 1.20-1.35 (m, 1 H), 0.60-0.70 (m, 2 H), 0.31-0.39 (m, 2 H); mass spectroscopy gave M+ of 274.0 (calc'd exact mass for C10HπIO = 273.99).
Example 2 3-(Cyclopropylmethoxy)iodobenzene
Figure imgf000051_0002
3-Iodophenol (ll.Og, 50.0 mmol) was converted to 12.4 g (90%) of the desired product using the method described for Example 1. The product had: 1H NMR (300 MHz, CDC13) δ 7.23-7.31 (m, 2 H), 6.99 (dd, 1 H), 6.84-6.90 (m, 1 H), 3.77 (d, 2 H), 1.25-1.35 (m, 1 H), 0.60-0.70 (m, 2 H), 0.32-0.39 (m, 2 H); mass spectroscopy gave MH+ of 275.0 (calc'd exact mass for oHπlO = 273.99). Example 3 4-Bromo-l-cyclopropylthiobenezene
Figure imgf000052_0001
To a solution of cyclopropylphenyl sulfide (5 g, 34.2 mmol) in 342 mL chloroform, a solution of bromine (1.94 g, 37.6 mmol) in 113 mL chloroform was added dropwise. The reaction mixture was stirred at rt overnight and then quenched with aq. NaHCO3 and sat. Na2S2O5. The reaction was extracted with dichloromethane and the organic phase was washed with water and brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. An oil (6J9 g, 79% yield) was given after distillation. 1H NMR (DMSO, δ = 2.48): 7.45 - 7.49 (m, 2H), 7.25 - 7.30 (m, 2H), 2.22 - 2.28 (m, IH), 1.04 - 1J0 (m, 2H), and 0.53 - 0.58 (m, 2H). MS [M+H] = 229 (HPLC/MS).
Example 4 2,5-Dibromo-l,3-thiozole
Figure imgf000052_0002
(Caution: Blast shield recommended). Nitric acid (65%, 11.6 mL) was added slowly to a 0°C solution of commercially available 2-amino-5-bromothiazole monohydrobromide (10 g, 38.4 mmol) in phosphoric acid (85%, 30 mL). The mixture was cooled to — 5°C and an aq. solution of sodium nitrite (3.44 g, 50 mmol) was added slowly, while maintaining the bath temperature below 0°C. The mixture was stirred for 2 h. A solution of copper sulfate (8.0 gm) and sodium bromide (10.3 g) in water (30 mL) was added slowly at 0°C and the resulting mixture was stirred for 4 h. The mixture was adjusted to pH 7 and extracted with ether. The combined extracts were dried and concentrated under reduced pressure. Purification of the remaining oil by flash chromatography (silica gel, 10:1 hexane:ethyl acetate) afforded 4.3 g (46%) of Example 4. Rf = 0.91 (10/1 hexane/ethyl acetate); GCMS (CI) obs'd: 242, 244, 246; calc'd 241. Example 5 4-(Cvclopropylmethoxy)phenylboronic acid
Figure imgf000053_0001
Butyl lithium (2.5 M in hexane, 14.4 mL, 36 mmol) was added dropwise (5 min) to a cooled (-78 °C) and stirred solution of 4-(cyclopropylmethoxy)iodobenzene 1 (9.00 g, 32.8 mmol) in tetrahydrofuran (100 mL). After 20 min, trimethyl borate (11.3 mL, 10.4 g, 100 mmol) was added dropwise (10 mL). The reaction was stirred for an additional 20 min, and was then allowed to warm to rt. The reaction was quenched with 1 M hydrochloric acid (300 mL) and stirring was continued for 30 min. The product was extracted with diethyl ether (4x100 mL) and then the combined organic extracts were dried over anhydrous magnesium sulfate and concentrated in vacuo. The residue was dissolved in toluene and then concentrated. This operation was repeated (5x) until the distillate was colorless and left 5.67 g (90%) of crude product. This material was used without purification or analysis.
The following compounds were prepared according to the method of Example 5:
Figure imgf000053_0002
Figure imgf000054_0002
Example 9 l-(BromomethyI)-3-(cvclopropylmethoxy)benzene
Figure imgf000054_0001
Pyridine (3.20 mL, 3J3 g, 39.6 mmol) and a solution of dibromophenylphosphorane (13.9 g, 32.9 mmol) in acetonitrile (50 mL) were added successively to a cooled (0 °C) and stirred solution of l-(hydroxymethyl)-3- (cyclopropylmethoxy)benzene, (Example 10, 4.40 g, 24.7 mmol) in acetonitrile (100 mL). The mixture was allowed to warm to rt and stirring was continued for 16 h. The reaction was quenched with saturated aqueous sodium thiosulfate (300 mL) and extracted with ethyl acetate (3x200 mL). The combined organic extracts were washed with 1 M hydrochloric acid and brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo. Flash chromatography of the residue over silica gel using 20% ethyl acetate/hexane gave 3.80 g (64%) of the Example 9. The product had: 1H NMR (300 MHz, acetone-D6) d 7.22 (t, 1 H), 7.01 (m, 2 H), 6.82-6.88 (m, 1 H), 4.56 (s, 2 H), 3.83 (d, 2 H), 1.16- 1.29 (m, 1 H), 0.52-0.62 (m, 2 H), 0.31-0.41 (m, 2 H). Example 10 l- HydroxymethylV3-(cyclopropylmethoxy)benzene
Figure imgf000055_0001
Sodium borohydride (0.75 g, 20 mmol) was added in portions to a stirred solution of 3-(cyclopropylmethoxy)benzaldehyde (Lit: Chem. Pharm. Bull. 1975, 23, 2878) (3.5g, 20 mmol) in methanol (80 mL). The mixture was stirred for 2 h and then quenched with water (300 mL). The product was extracted with ethyl acetate (3x150 mL) and then the combined organic extracts were dried over magnesium sulfate, filtered, and concentrated in vacuo to leave 3.2 g (89%) of crude product. This material was used in the next reaction without further purification or analysis.
Example 11 Ethyl 5-fert-butyldimethylsiloxy)-lH-indole-2-carboxylate
Figure imgf000055_0002
Imidazole (2.30 g, 33.2 mmol) and tert-butyldimethylsilyl chloride (2.50 g, 16.6 mmol) were added successively to a stirred solution of ethyl 5-hydroxy-lH-indole-2- carboxylate (1.70 g, 8.29 mmol) in dichloromethane (100 mL). The reaction was stirred for 16 h and then diluted with dichloromethane (300 L). The solution was washed with water and brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo to leave 2.65 g (100%) of Example 11. The product had: 1H NMR (300 MHz, acetone-D6) d 10.73-10.88 (br s, 1 H), 7.39 (d, 1 H), 7.11 (d, 1 H), 7.05 (s, 1 H), 6.86 (dd, 1 H), 4.34 (q, 2 H), 1.36 (t, 3 H), 1.09 (s, 9 H), 0.20 (s, 6 H). Example 12 Ethyl 3-[(4-methoxyphenyl)methyllindole-2-carboxylate
Figure imgf000056_0001
To a solution of ethyl l-[(4-methoxyphenyl)methyl]indole-2-carboxylate (Example 38) (950 mg, 3.07 mmol) in dichloromethane (15 mL) was added trifluoroacetic acid (1.2 mL). The resulting pink solution was stirred for 18 h at RT. The reaction was quenched with 1.0 N aqueous sodium hydroxide and the organic layer was collected. The aqueous layer was extracted with ethyl acetate, and the combined organic layers were dried over anhydrous magnesium sulfate, concentrated to an oil, and purified by flash chromatography on silica in 8:1 hexane: ethyl acetate (v/v) to yield 468 mg (49%) of Example 12 of a white solid. 1H NMR (300 MHz, DMSO-^) δ 11.56 (s, IH), 7.64-7.58 (m, IH), 7.42-7.38 (m, IH), 7.26-7J4 (m, 3H), 7.02-6.97 (m, IH), 6.80-6.74 (m, 2H), 4.35 (s, 2H), 4.34 (q, J= 7J Hz, 2H), 3.65 (s, 3H), 1.33 (t, j= 7J Hz, 3H); TLF Rf- 0.44 (4:1 Hexane: ethyl acetate (v/v)).
Example 13
Ethyl 5-(benzyloxy)-3-bromo-lH-indole-2-carboxylate
Figure imgf000056_0002
A solution of N-bromosuccinimide (7.83 g, 44.0 mmol) in N,N- dimethylformamide (30 mL) was added dropwise (40 min) to a cooled (0 °C) and stirred solution of ethyl 5-(benzyloxy)-lH-indole-2-carboxylate (10.0 g, 39.2 mmol) in N,N- dimethylfor amide (20 mL). The cold bath was removed and stirring was continued for an additional 1.5 h. The reaction was poured over ice water (600 mL) and the resulting precipitate was collected by vacuum filtration. The precipitate was washed with water and dried to give 12.9 g (98%) of crude product. This material was used in the next reaction without further purification or analysis.
Example 14 tert-Butyl 3-Bromoindole-2-carboxylate
Figure imgf000057_0001
Indole-2-carboxylic acid was converted to 3-bromoindole-2-carboxylic acid using the method described for Example 13. N,N-dimethylformamide di-tert-butyl acetal (35 mL) was added dropwise to a stirring mixture of indole-3-bromo-2-carboxylic acid (14.9 g, 62 mmol) suspended in toluene (100 mL). After the addition was complete, the reaction was heated at 90 °C for 8 h. The reaction mixture was then cooled to room temperature and washed with cold water (2 100 mL). The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to yield the crude tert-butyl 3-bromoindole-2-carboxylate, assume quantitative yield. The crude product was used in the next step without purification.
The following compounds were prepared according to the methods of Examples
13 and 14:
Figure imgf000057_0002
Figure imgf000058_0001
Figure imgf000059_0002
Example 22 Ethyl 5- benzyloxyV3-bromo-l-(3-methoxybenzyl)-lH-indole-2-carboxylate
Figure imgf000059_0001
Powdered potassium carbonate (2.79 g, 20.2 mmol) and 3-methoxybenzyl bromide
(2.03 g, 10J mmol) were added successively to a stirred solution of ethyl 5-(benzyloxy)- 3-bromo-lH-mdole-2-carboxylate, Lit. WO96/18393 (3.63 g, 9.70 mmol) in N,N- dimethylformamide (20 mL). The reaction was stirred for 23 h and then diluted with water (250 mL). The product was extracted with ethyl acetate (3x100 mL) and then the combined organic extracts were washed with brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo. Recrystalization of the residue using methanol afforded 4.03 g (84%) of the desired product. The product had: 1H ΝMR (300 MHz, CDC13) δ 7.05-7.91 (m, 9 H), 6.74 (dd, 1 H), 6.53-6.63 (m, 2 H), 5.37 (s, 2 H), 5J2 (s, 2 H), 4.37 (q, 2 H), 3.71 (s, 3 H), 1.39 (t, 3 H); mass spectroscopy gave MH+ = 494J (calc'd exact mass for C26H2 BrΝO4 = 493.09). Example 23 Ethyl 5-(benzyloxy)-3-bromo-l-(4-fluorobenzyl)-lH-indole-2-carboxylate
Figure imgf000060_0001
A solution of ethyl 5-(benzyloxy)-3-bromo-lH-indole-2-carboxylate, Ref. WO96/18393 (6.77 g, 20.3 mmol, Ref. 96/18393) in N,N-dimethylformamide (10 + 5 mL rinse) was added slowly (10 min) to a cooled (0 °C) and stirred suspension of sodium hydride (0.72 g, 30 mmol) in N,N-dimethylformamide (30 mL). The reaction was stirred for 1 h and then 4-fluorobenzylbromide (3.7 mL, 5.7 g, 30 mmol) was added. The cold bath was removed and the mixture was stirred for 18 h. The reaction was quenched by pouring over ice water (400 mL) and then the product was extracted with ethyl acetate (3x100 mL). The combined organic extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated in vacuo. Flash chromatography of the residue over silica gel using 50% dichloromethane/hexane gave 6.80 g (75%) of the desired product containing trace impurities. The product had: Η ΝMR (300 MHz, CDC13) δ 6.84-7.53 (m, 12 H), 5.72 (s, 2 H), 5J3 (s, 2 H), 4.38 (q, 2 H), 1.40 (t, 3 H).
Example 24
Ethyl 5-r2-(5-methyl-2-phenyl-l,3-thiazol-4-ynethoxyl-l-(tetrahvdro-2- furanylmethyl)-lH-indole-2-carboxylate
Figure imgf000060_0002
A solution of ethyl 5-[2-(5-methyl-2-phenyl-l,3-thiazol-4-yl)ethoxy]-lH-indole-2- carboxylate 220 (40.7 mg, 0J00 mmol) in N,N-dimethylformamide (0.9 mL) was added to a stirred mixture of cesium carbonate (325 mg, 1.00 mmol) and 2- (bromomethyl)tetrahydrofuran (19.8 mg, 0J20 mmol) in N,N-dimethylformamide (2.4 mL). The reaction was stirred for 16 h and then the mixture was filtered though a plug (500 mg) of silica gel using ethyl acetate to rinse. The filtrate was concentrated in vacuo and then reverse phase preparative ΗPLC chromatography gave 19.8 mg of product (retention time = 2.4 min.). This material was taken to the next reaction without further purification or analysis.
Example 25
Ethyl 3-formyl-l-(3-methoxybenzyl)-lΗ-indole-2-carboxylate
Figure imgf000061_0001
Sodium hydride (60% dispersion in mineral oil, 2.40 g, 60.0 mmol) was cooled to 0 °C, and anhydrous methyl sulfoxide (75.0 mL, 1.06 mol) was added. The mixture was stirred at 0 °C for 15 minutes before a solution of ethyl 3-formyl-lH-indole-2-carboxylate (10.9 g, 50.2 mmol, Lit. J. Heterocyclic Chem. 1997, 34, 1431.) in 75 mL of methyl sulfoxide was added over a 20 minute period. The resulting solution was wanned to room temperature and stirred for 1 hour. 3-Methoxybenzylbromide (9.8 mL, 70.0 mmol) was added, and the solution was heated at 60 °C for 16 hours. The solution was cooled and poured into water (500 mL). The aqueous solution was extracted with ethyl acetate (3x), and the combined organic extracts were washed with 1 Ν hydrochloric acid (2x), water, and brine. The solution was dried over anhydrous magnesium sulfate and concentrated in vacuo. Trituration of the residue with 33% hexane/Et2O provided the title compound as a solid (13.8 g, 81%). The product had: 1H ΝMR (300 MHz, acetone-^) δ 10.61 (s, 1 H), 8.43 (d, 1 H), 7.61 (d, 1 H), 7.30-7.45 (m, 2 H), 7J9 (dd, 1 H), 6.80 (dd, 1 H), 6.63-6.74 (m, 2 H), 5.88 (s, 2 H), 4.48 (dq, 2 H), 3.70 (s, 3 H), 1.37 (t, 3 H); mass spectroscopy gave MH+ = 338J (calc'd exact mass for C20HI9ΝO4 = 337.13). Example 26 Ethyl 3-(4-methoxybenzoylVl-(3-methoxybenzyl)-lH-indole-2-carboxylate
Figure imgf000062_0001
Indole 203 (244 mg, 0.76 mmol) was added to a suspension of sodium hydride (36 mg, 0.91 mmol) in N,N-dimethylformamide (3 mL). After 10 min., sodium iodide (20 mg, 0J33 mmol) and 3-methoxybenzyl chloride (0J3 mL, 0.91 mmol) was added and the resulting mixture was stirred at rt. for ~15 h. Purification (silica gel chromatography 25:75 ethyl acetate:hexane) afforded 236 mg (70%) of Example 26. Rf = 0.33 (75/25 hexane/ethyl acetate); LRMS (+esi) obs'd: 444J; calc'd 443.17.
Example 27 tert-Butyl 3-(4-Methoxyphenyl)-l-{[3-(trifluoromethyl)phenvnsulfonyl}indole-2- carboxylate
Figure imgf000062_0002
To a stirring solution of tert-butyl-3-(4-methoxyphenyl)indole-2-carboxylate (Example 105, 75 mg, 0.23 mmol) in tetrahydrofuran (0.4 mL) was added potassium tert- butoxide (1 M in tetrahydrofuran, 0.4 mL) in one aliquot. After 10 minutes chloro[3- (trifluoromethyl)phenyl]sulfone (113 mg, 0.46 mmol) was added. The reaction mixture was stirred at room temperature overnight. The resulting mixture was diluted with ethyl acetate (4 mL) and quenched with water (2 L). The organic phase was extracted with ethyl acetate (3 x 4mL). The combined organic layers were dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The crude product was filtered through a plug of silica gel (30% ethyl acetate/hexane) to provide tert-butyl 3-(4- methoxyphenyl)- 1 - { [3 -(trifluoromethyl)phenyl] sulfonyl } indole-2-carboxylate (45 mg, 37%), which was used in the next step without further purification.
The following compounds were prepared according to the methods of Examples 22 - 27:
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001
Figure imgf000069_0001
Figure imgf000070_0002
Example 61 Ethyl 5-(benzyloxy)-3-r4-(cvclopropylmethoxy)phenyll-l-(3-methoxybenzyl)-lH- indole-2-carboxylate
Figure imgf000070_0001
Example 5 (2.30 g, 12.0 mmol) and 2 M aqueous sodium carbonate (20 mL) were added to a stirred solution of ethyl 5-(benzyloxy)-3-bromo-l-(3-methoxybenzyl)-lH- indole-2-carboxylate (4.03 g, 8J5 mmol) in EtOH (30 mL) and toluene (30 mL). Argon was bubbled through the mixture for 15 min and then tetrakis(triphenylphosphine)palladium(0) (1J5 g, 1.00 mmol) was added. The reaction was heated (85 °C) for 16 h and then cooled. The mixture was diluted with 1 M hydrochloric acid (200 mL) and then extracted with ethyl acetate (3x100 mL). The combined organic extracts were washed with water and brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo. Flash chromatography of the residue over silica gel using 60% dichloromethane/hexane gave 3.41 g (75%) of Example 61. The product had: 1H NMR (300 MHz, CDC13) δ 6.95-7.48 (m, 13 H), 6.65-6.77 (m, 3 H), 5.76 (m, 2 H), 5.01 (s, 2 H), 4J3 (q, 2 H), 3.90 (d, 2 H), 3.74 (s, 3 H), 1.30-1.41 (s, 1 H), 1.05 (t, 3 H), 0.65-0.75 (m, 2 H), 0.38-0.45 (m, 2 H); mass spectroscopy gave MH - 562.2 (calc'd exact mass for C36H35NO5 = 561.25).
Example 62 Ethyl 3-(benzothiozole)-l-(3-trifluoromethylbenzyl)-mdole-2-carboxylate
Figure imgf000071_0001
A mixture of Example 33 (300 mg, 0.70 mmol), benzothiophene-2-boronic acid (195 mg, IJ mmol), 2N Na2CO3 (0.7 mL) and N,N-dimethylformamide (7 mL) was flushed with argon. Pd(OAc)2 (16 mg, 0.07 mmol) and P(o-tolyl)3 (43 mg, 0J4 mmol) were added and the mixture was heated at 100°C for ~15 h. The mixture was cooled and filtered through a short column of silica gel and sodium bicarbonate (elution with ethyl acetate). The filtrate was concentrated and the remaining oil was purified by flash chromatography (silica gel, 7:1 hexane:ethyl acetate) to afford 178 mg (53%) of Example 62 as a white solid. Rf = 0.51 (7/1 hexane/ethyl acetate); LRMS (+esi) obs'd: 480.0; calc'd 479.1.
Example 63
Ethyl 3-(2-furyl)-l-(3-trifluoromethylbenzyl)-mdole-2-carboxylate
Figure imgf000071_0002
A mixture of Example 33 (300 mg, 0.70 mmol), 2-(tributylstannyl)furan (0.22 mL, 0.7 mmol), lithium chloride (30 mg, 0.7 mmol) and N,N-dimethylformamide (7 mL) was flushed with argon. Tetrakis(triphenylphosphine) palladium (80 mg, 0.07 mmol) was added and the mixture was heated at 100°C for -15 h. The mixture was cooled and filtered through a short column of silica gel (elution with ethyl acetate). The filtrate was washed with water and brine, concentrated and the remaining oil was purified by flash chromatography (silica gel, 7:1 hexane:ethyl acetate) to afford 160 mg (55%) of Example 63 as a white solid. Rf = 0.45 (7/1 hexane/ethyl acetate); LRMS (+esi) obs'd: 414J; calc'd 413J.
Example 64 Ethyl 3-(2-phenylethvnyl)-l-(3-trifluoromethylbenzyl)-lH-indole-2-carboxylate
Figure imgf000072_0001
A suspension/solution of Example 33 (500 mg, 1J7 mmol), phenyl acetylene (600 mg, 5.86mmol), triethyl amine (5.5 mL) in dry N,N-dimethylformamide (12 mL) was flushed with argon. Copper iodide (73 mg, 0.38 mmol) and Pd(dppf) Cl2- dichloromethane (96 mg, 0J2 mmol) was added and again the system was flushed with Ar. The mixture was then heated at 79°C for 70 min. The suspension was filtered through Celite® (elution with ether) and the filtrate was washed water (3x 20 mL) and brine (20 mL). The ether layer was again filtered through silica to remove precipitates (elution with ether). The filtrate was concentrated and the remaining oil was purified by radial chromatography (4 mm silica gel plate, 95/5 hexane/ethyl acetate) to afford 23 mg (4%) of Example 64 as a brown solid. Rf = 0.23 (95/5 hexane/ethyl acetate). Example 65 Ethyl 7-(4-tert-butylphenyl)-5H-ri.31dioxolor4<51-findole-6-carboxyIate
Figure imgf000073_0001
To a dry 100 mL round bottom flask and stir bar, purged with argon gas, was charged with 0J4g of Pd2(dba) and 0J4g trifurylphosphine followed by addition of 5 ml of toluene. The contents were stirred until homogeneous at which time a of ethyl 7-bromo- 5H-[l,3]dioxolo[4,5-f]-indole-6-carboxylate (Example 19, 1.92 g, 6J3 mmol) in toluene (5 mL) was added to the catalyst solution via cannula. After approximately 10-15 minutes of stirring a 10 mL ethanol solution of 4-tert-butyl-phenyl boronic acid (1.64g, 9.2 mmol) to a stirring solution via cannula. This was followed by addition of 15mL of 2M sodium carbonate dropwise to the pot. The contents were heated to reflux overnight. The reaction was then quenched with 3 N hydrochloric acid and extracted with 3 times with 30 mL of ethyl acetate. The organic layer was then dried over anhydrous sodium sulfate and then concentrated in vacuo. The crude material was purified via column chromatography yielding 1.24 g (55%) of a white solid (Rf- 0.38 20% ethyl acetate/hexane). The product had: 1H NMR (300 MHz, acetone-D6) 7.46 Hz (d, 1 H), 7.02 Hz (d, IH) 6.97 Hz (d, 2H), 6.87 Hz (d, 2H), 5.99 Hz ( d, 2H), 4J8 Hz (q, 2H), 1.35 Hz (s, 9H), 1.32 Hz (t, 3H).
Example 66
Ethyl 3- [4-(cy clopropylmethoxy)phenyl1 -5-hy droxy-1 -
(3-methoxybenzyl)-lH-indole-2-carboxylate
Figure imgf000074_0001
l-Bromo-4-cyclopropylmethoxy)benzene (2.30 g, 12.0 mmol) and 2 M aqueous sodium carbonate (20 mL) were added to a stirred solution of ethyl 5-(TBDMSO)-3- bromo-l-(3-methoxybenzyl)-lH-indole-2-carboxylate (Example 58, 4.03 g, 8J5 mmol) in ethanol (30 mL) and toluene (30 mL). Argon was bubbled through the mixture for 15 min and then tetrakis(triphenylphosphine)palladium(0) (1J5 g, 1.00 mmol) was added. The reaction was stirred with heating (85 °C) for 16 h and then cooled. The mixture was diluted with 1 M hydrochloric acid (200 mL) and then extracted with ethyl acetate (3x100 mL). The combined organic extracts were washed with water and brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residue was dissolved in tetrahydrofuran (100 mL) and tetrabutylammonium fluoride (1.0 M in tetrahydrofuran, 20 mL, 20 mmol) was added. The reaction was stirred for 1 h and then diluted with ethyl acetate (300 mL). The solution was washed with water and brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo. Flash chromatography of the residue over silica gel using 20% ethyl acetate/hexane afforded 1J0 g (65%) of the desired product. The product had: 1H NMR (300 MHz, acetone-D6) δ 7.85 (s, 1 H), 7.28-7.37 (m, 3 H), 7J2 (dd, 1 H), 6.84-7.00 (m, 4 H), 6.61-6.74 (m, 3 H), 5.73 (s, 2 H), 4.09 (q, 2 H), 3.86 (d, 2 H), 3.67 (s, 3 H), 1.20-1.32 (m, 1 H), 0.84 (t, 3 H), 0.52-0.63 (m, 2 H), 0.31-0.41 (m, 2 H).
The following compounds were prepared according to the methods of Example 61 - 66:
Figure imgf000075_0001
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0001
Figure imgf000079_0001
Figure imgf000080_0001
Figure imgf000081_0001
Figure imgf000082_0001
Figure imgf000083_0002
Example 106 2-tert-ButoxycarbonvD l-[3-(trifluoromethyl)benzyl]-indole-3-yl boronic acid
Figure imgf000083_0001
A solution of butyllithium in hexane (7J0 mL, 1.6 M) was added to a -78°C solution of Example 35 (4.95 gm, 10.9 mmol) in tetrahydrofuran (30 mL). After 5 min., trimethyl borate (3.72 mL, 32.7 mmol) was added and the mixture was allowed to warm to rt. over 2 h. 2N hydrochloric acid (30 mL) was added and the mixture was vigorously stirred for 30 min. Ethyl acetate was added and the layers were separated. The organic 0 layer was dried and concentrated. Trituration of the remaining oil with ether followed by drying under reduced pressure afforded 2.3 g (50%) of Example 106 as a white solid. Rf = 0.29 (4/1 hexane/ethyl acetate).
The following compounds were prepared according to the methods of Example
106:
Figure imgf000084_0002
Example 109 fer -Butyl 3-(5-bromo-1.3-thiazol-2-yl)-l-f3-
(trifluoromethyl)benzyll-indole-2-carboxylate
Figure imgf000084_0001
To a solution of Example 106 (150 mg, 0.36 mmol) and Example 4 (68 mg, 0.28 mmol) in toluene (0.7 L) and ethanol (0.7 mL) was added aq. Na2CO3 (0.36 mL, 2N). The reaction vessel was flushed with Ar for 10 min. Tetrakis(triphenylphosphine)- palladium (34 mg, 0.029 mmol) was added and the mixture was heated at 85°C until the disappearance of the boronic acid. The mixture was cooled and filtered. The filtrate was concentrated and the remaining oil was purified by flash chromatography (silica gel, 7:1 hexane:ethyl acetate) to afford 100 mg (66%) of Example 109 as a yellow solid. Rf = 0.61 (7/1 hexane/ethyl acetate); LRMS (+esi) obs'd: 536.8; calc'd 536.0.
The following compounds were prepared according to the method of Example 109:
Figure imgf000085_0002
Example 111 fert-Butyl 3-(5-acetyl-l.,3-tIιiazol-2-vf)-l-r3-
(trifluoromethyl)benzyl]-indole-2-carboxylate
Figure imgf000085_0001
A mixture of Example 108 (300 mg, 0.56 mmol), Pd(PPh3)4 (70 mg, 0.06 mmol) and lithium chloride (80 mg, 1.68 mmol) in tetrahydrofuran (2 mL) and toluene (2 mL) was flushed with argon. 1-Ethoxyvinyl tri-77-butylstannane (224 mg, 0.62 mmol) was added and the mixture was heated at 90 °C for 4 h. A second portion of stannane (107 mg, 0.30 mmol) was added and heating was continued for 1 h. The mixture was cooled to rt. and 10% hydrochloric acid (2 mL) was added. The mixture was stirred for 1 h. The mixture was washed with water, dried and concentrated. The oil thus obtained was purified by flash chromatography (silica gel, 5:1 hexane:ethyl acetate) to afford 280 mg of slightly impure Example 111 which was used without further purification. LRMS (+esi) obs'd: 500.9; calc'd 500J.
The following compounds were prepared according to the method of Example
111:
Figure imgf000086_0002
Example 112 fer -Butyl 3-(5-cvclopropyl-1.3-thiazol-2-yl)-l
-(3-methoxybenzyI)-iαdole-2-carboxylate
Figure imgf000086_0001
Cyclopropyl boronic acid: A solution of t-butyllithium in hexane (17.0 mL, 25.4 mmol) was added to a -78°C solution of cyclopropyl bromide (1.51 gm, 12.4 mmol) in dry tetrahydrofuran (20 mL). After stirring for 15 min., trimethoxy borate (1.23 gm, 11.8 mmol) was added and the resulting mixture was wanned to rt. over Hi. 2N HC1 (15 mL) was added and the aq. phase was extracted with ethyl acetate. The extracts were dried over anhydrous sodium sulfate and concentrated to give the cyclopropyl boronic which was used in the coupling step without further purification.
A mixture of cyclopropyl boronic acid (75 mg, 0.84 mmol), Example 110 (200 mg, 0.42 mmol), Na2CO3 (2N, 0.9 mL), and N,N-dimethylformamide (3.5 mL) was flushed with argon. Palladium(II) acetate (18 mg, 0.08 mmol) and P(o-tolyl)3 (50 mg,
0J6 mmol) were added and the mixture was heated at 100°C for 1 h. The mixture was cooled, diluted with ethyl acetate, and washed with water. The organic layer was dried over anhydrous sodium sulfate and concentrated. Purification of the remaining oil by flash chromatography gave slightly impure Example 112 which was used without further purification. LRMS (+esi) obs'd: 461.0; calc'd 460.2.
Example 113 Ethyl 3-(4-ethoxyphenyl)-l-(4-fluorobenzyl)-5-hvdroxy-lH-indole-2-carboxylate
Figure imgf000087_0001
A solution of ethyl 5-(benzyloxy)-3-(4-ethoxyphenyl)-l-(4-fluorobenzyl)-lH- indole-2-carboxylate (Example 69, 4.7 g, 9.0 mmol) in ethyl acetate (15 mL) was added to a suspension of 10% palladium on charcoal (2.0 g) in ethyl acetate (10 mL). The mixture was placed under an atmosphere of hydrogen (1 atm) and stirred for 16 h. The reaction was filtered through a pad of Celite using ethyl acetate to rinse. Evaporation of the filtrate left 3.5 g (90%) of the desired product. The product had: 1H NMR (300 MHz, acetone- D6) δ 7.98 (s, 1 H), 6.89-7.42 (m, 11 H), 5.81 (s, 2 H), 4.03-4J9 (m, 4 H), 1.41 (t, 3 H), 1.04 (t, 3 H).
Example 114
Ethyl l-f(3-hydroxyphenyl)methyIl-3-(4-methoxyphenyl)indole-2-carboxylate
Figure imgf000087_0002
To a Parr shaker bottle purged with Argon was added palladium on carbon (Degussa type) (500 mg), ethyl acetate (10 mL), ethyl 3-(4-methoxyphenyl)-l-{[3- (phenylmethoxy)phenyl]methyl}indole-2-carboxylate (Example 45, 5 g crude material, 7.0 mmol, in 120 mL methanol and 40 mL ethyl acetate). The mixture was hydrogenated at 55 psi for 48 h. The mixture was then filtered through Celite and the filtrate was concentrated in vacuo. The residue was purified with silica gel flash chromatography using hexane/ethyl acetate (3/1 to 2/1) to give ethyl l-[(3-hydroxyphenyl)methyl]-3-(4- methoxyphenyl)indole-2-carboxylate as a light yellow oil (2.5 g, 89%): MS (M+) calcd for C25H23NO4 401J, found 401.0; 1H NMR (CDC13) δ 7.60 (dd, /= 8J Hz, IH), 7.30-7.45 (m, 4H), 7J3-7.21 (m, 2H), 6.98 (d, /= 8J Hz, 2H), 6.64-6.78 (m, 2H), 6.52 (s, IH), 5.77 (s, 2H), 4J4 (q, /== 7.0 Hz, 2H), 1.04 (t, /= 7.0 Hz, 3H).
The following compounds were prepared according to the method of Example
114:
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0002
Example 124 Ethyl 3-f3-(cvclopropylmethoxy)phenyl]-l-(3-methoxybenzyl)-5-{[(trifluoromethyl) suIfonyIloxyl-lH-indole-2-carboxylate
Figure imgf000090_0001
Triflic anhydride (0.84 mL, 1.4 g, 5.0 mmol) and dimethylaminopyridine (25 mg, 0.20 mmol) were added to a cooled (0 °C) and stirred solution of ethyl 3-[3- (cyclopropylmethoxy)phenyl]-5-hydroxy-l-(3-methoxybenzyl)-lH-indole-2-carboxylate (Example 66, 1.00 g, 2J 2 mmol) in dichloromethane (10 mL) and pyridine (2 mL). The reaction was warmed to rt and then stirred an additional 2 h. The solution was diluted with ethyl acetate (100 mL), washed with water and brine, dried over anhydrous magnesium sulfate, and concenfrated in vacuo. Flash cliromatography of the residue over silica gel using 15% ethyl acetate hexane afforded 1J4 g (89%) of desired product. The product had: 1H NMR (300 MHz, acetone-D6) δ 7.73 (d, 1 H), 7.54 (d, 1 H), 7.35-7.42 (m, 3 H), 7.20 (dd, 1 H), 7.00-7.07 (m, 2 H), 6.68-6.83 (m, 3 H), 5.88 (s, 2 H), 4J6 (q, 2 H), 3.91 (d, 2 H), 3.72 (s, 3 H), 1.25-1.35 (m, 1 H), 10.5 (t, 3 H), 0.55-0.65 (m, 2 H), 0.32- 0.42 (m, 2 H); mass spectroscopy gave M+ = 603J (exact mass calc'd for C oH 8F3NO7S - 603.15). The following compounds were prepared according to the method of Example
124:
Figure imgf000091_0001
Example 128
Ethyl 3-(4-tert-butylphenyl)-5-(2-cyclopenten-l-vf)-l-
(3-methoxybenzyl)-lH-indole-2-carboxylate
Figure imgf000092_0001
Cyclopentene (0.44 mL, 341 mg, 5.0 mmol), palladium acetate (22 mg, 0J0 mmol), tetrabutylammonium bromide (322 mg, 1.0 mmol) and potassium acetate (295 mg, 1.0 mmol) were added to a stirred solution of ethyl 3-(4-tert-butylphenyl)-l-(3- methoxybenzyl)-5-{[(trifluoromethyl)sulfonyl]oxy}-lH-indole-2-carboxylate (Example 125, 570 mg, 1.0 mmol) in N,N-dimethylformamide (5 mL). The reaction was stirred for 48 h and then diluted with ethyl acetate (100 mL). The solution was washed with brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo. Flash chromatography of the residue over silica gel using 6:1 ethyl acetate/hexane gave 230 mg, (45%) of the desired product. The product had: XΗ ΝMR (300 MHz, acetone-D6) δ 7.49- 7.56 (m, 3 H), 7.37-7.43 (m, 3 H), 7J 7-7.23 (m, 2 H), 6.68-6.92 (m, 3 H), 4.09 (q, 3 H), 3.92-4.01 (m, 1 H), 3.75 (s, 3 H), 2.31-2.50 (m, 3 H), 1.62-1.77 (m, 1 H), 1.39 (s, 9 H), 0.98 (t, 3 H).
Example 129 Ethyl 3-(4-fer^-butylphenyl)-l-(3-methoxybenzyl)-5-vmyl-lH-indoIe-2-carboxylate
Figure imgf000092_0002
Lithium chloride (297 mg, 7.0 mmol) and tributylvinyl tin (0.43 mL, 467 mg, 1.5 mmol) were added to a stirred solution of ethyl 3-(4-tert-butylphenyl)-l-(3- methoxybenzyl)-5-{[(trifluoromethyl)sulfonyl]oxy}-lH-indole-2-carboxylate (Example 125, 570 mg, 0.995 mmol) in tetrahydrofuran (10 mL). Argon was bubbled through the mixture for 10 min and then tetrakis(triphenylphospine)palladium (115 mg, 0J0 mmol) was added. The reaction was heated (67 °C for 18 h and then cooled to rt. The mixture was diluted with ethyl acetate (100 mL) and then washed successively with water, 10% aqueous ammonium hydroxide, water and brine. The organic solution was dried over anhydrous magnesium sulfate and concentrated in vacuo. Flash chromatography of the residue over silica gel using 10% ethyl acetate/hexane gave 334 mg (72%) of the desired product. The product had: 1H NMR (300 MHz, CDC13) δ 7J4-7.58 (m, 8 H), 6.64-6.82 (m, 4 H), 5.77 (s, 2 H), 5.65 (dd, 1 H), 5J3 (dd, 1 H), 4J0 (q, 2 H), 3.73 (s, 3 H), 1.40 (s, 9 H), 0.95 (t, 3 H); mass specfroscopy gave MH+ = 468.2 (calc'd exact mass for C3ιH33NO3 = 467.25).
The following compounds were prepared according to the method of Examples
128 - 129:
Figure imgf000093_0001
Figure imgf000094_0002
Example 133
Ethyl 3-(4-te/^-butylphenyl)-5-(2-hydroxyethyl)-l-
(3-methoxybenzyl)-lH-iιιdole-2-carboxylate
Acetic acid (63 μL, 66 mg, 1.1 mmol) was added slowly to a cooled (0 °C) and stirred slurry of sodium borohydride (41.6 mg, 1J0 mmol) in tetrahydrofuran (2 mL). The mixture was stirred for 1 h and then a solution of ethyl 3-(4-tert-butylphenyl)-l-(3- methoxybenzyl)-5 -vinyl- lH-indole-2-carboxylate (Example 129, 430 mg, 0.920 mmol) in tetrahydrofuran (5 + 2 mL rinse) was added. The reaction was stirred overnight and then cooled (0 °C). The reaction was quenched by successive addition of EtOΗ (6 mL), 6 M aqueous sodium acetate (5 mL) and 27% aqueous hydrogen peroxide (5 mL). The mixture was heated (50 °C) for 1 h and then cooled. The reaction was diluted with water (100 mL) and then extracted with ethyl acetate (3x50 mL). The combined organic extracts were washed with brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo. Flash chromatography of the residue over silica gel using 30% ethyl acetate/hexane afforded 325 mg (75%) of desired product. The product had: 1H NMR (300 MHz, CDC13) δ 7.28-7.48 (m, 6 H), 7J 5-7.22 (m, 2 H), 6.75 (dd, 1 H), 6.64- 6.72 (m, 2 H), 7.76(s, 2 H), 4.08 (q, 2 H), 3.78-4.00 (m, 3 H), 3.73 (s, 3 H), 2.91 (t, 2 H), 1.39 (s, 9 H), 0.95 (t, 3 H).
The following compounds were prepared according to the method of Example 133
Figure imgf000095_0002
Example 135
{f3-f4-(Cyclopropylmethoxy)phenvn-2-(ethoxycarbonyl)-l-
(3-methoxybenzyl)-lH-indol-5-yl]oxy}acetic acid
Figure imgf000095_0001
Formic acid (1 mL) was added to a stirred solution of ethyl 5-(2-tert-butoxy-2- oxoethoxy)-3-[4-(cyclopropylmethoxy)phenyl]-l-(3-methoxybenzyl)-lH-indole-2-carb- oxylate (Example 150, 20 mg, 0.035 mmol) in dichloromethane (1 mL). The reaction was stirred for 1 h and then concentrated in vacuo. Flash chromatography of the residue over silica gel using (1:1 ethyl acetate/hexane) gave 10 mg (53% of the desired product. The product had: 1H NMR (300 MHz, CD3OD) δ 7.30-7.48 (m, 3 H), 6.92-7J9 (m, 4 H), 6.77 (dd, 1 H), 6.54-6.68 (m, 3 H), 5.79 (s, 2 H), 4.61 (s, 2 H), 4J3 (q, 2 H), 3.95 (d, 2 H), 3.74 (s, 3 H), 1.29-1.41 (m, 1 H), 1.25 (t, 3 H), 0.61-0.71 (m, 2 H), 0.39-0.49 (m, 2 H); mass spectroscopy gave MH+ of 530.2 (calc'd exact mass for C31H31NO7 = 529.21). Example 136
Ethyl 3- [3-(cyclopropylmethoxy)phenyl] -l-(3-methoxybenzvD-5-
(2-oxoethoxy)-lH-indole-2-carboxylate
Figure imgf000096_0001
Sodium periodate (812 mg, 3.80 mmol) and osmium tetroxide (2.5 wt% solution in tert-butanol, 1.2 mL, 0J0 mmol) were added to a stirred solution of ethyl 3-[4- (cyclopropyl-methoxy)phenyl]- 1 -(3methoxy-benzyl)-5-allyloxy- lH-indole-2-carboxylate (Example 149, 640 mg, 1.25 mmol) in tetrahydrofuran (15 mL) and water (1.5 mL). The reaction was stirred for 16 h and then diluted with water (100 mL). The product was extracted with ethyl acetate (3x50 mL) and then the combined organic extracts were washed with water, dried over anhydrous magnesium sulfate, and concentrated in vacuo. Flash chromatography of the residue over silica gel using 8:1 hexane/ethyl acetate gave 395 mg (62%) of product containing impurities. The material was used in the next reaction without further purification or analysis.
Example 137
Ethyl 3- [3-(cy clopropylmethoxy)phenyl] -5-(2-hvdroxyethoxy)-l - (3-methoxybenzyl)-lH-indole-2-carboxylate
Figure imgf000096_0002
Sodium borohydride (38 mg, 1.0 mmol) was added to a stirred solution of ethyl 3- [3-(cyclopropylmethoxy)phenyl]-l-(3-methoxybenzyl)-5-(2-oxoethoxy)-lH-indole-2- carboxylate (Example 136, 380 mg, 0.74 mmol) in methanol (10 mL). The reaction was stirred for 2 h and then the reaction was quenched with water (100 mL). The product was extracted with ethyl acetate (3x40 mL) and then the combined organic extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated in vacuo to leave 363 mg (95%) of product containing some impurities. The material was used in the next reaction without further purification. The product had: 1H NMR (300 MHz, acetone- D6) δ 7.34-7.46 (m, 3 H), 7J6 (dd, 1 H), 6.93-7.02 (m, 4 H), 6.65-6.81 (m, 3 H), 5.78 (s, 2 H), 3.82-4.23 (m, 9 H), 3.69 (s, 3 H), 1.24-1.34 (m, 1 H), 1.02 (t, 3 H), 0.60-0.70 (m, 2 H), 0.34-0.44 (m, 2 H).
Example 138 Ethyl 3-f3-(cvclopropylmethoxymhenyll-l-(3-methoxybenzyl)
-5-(2-oxoethyl)-lH-indole-2-carboxylate
Figure imgf000097_0001
Sodium periodate (430 mg, 2.0 mmol) and osmium tetroxide (2.5 wt% solution in tert-butanol, 0.50 mL, 0.05 mmol) were added to a stirred solution of ethyl 5-allyl-3-[3- (cyclopropylmethoxy)phenyl]- 1 -(3-methoxybenzyl)- lH-indole-2-carboxylate (Example 132, 385 mg, 0.777 mmol) in tetrahydrofuran (10 mL) and water (1 mL). The reaction was stirred for 18 h and then diluted with water (100 mL). The product was extracted with ethyl acetate (3x50 mL) and then the combined organic extracts were washed with water, dried over anhydrous magnesium sulfate, and concentrated in vacuo. Flash chromatography of the residue over silica gel using 15% ethyl acetate/hexane gave 183 mg (47%) of product containing impurities. The material was used in the next reaction without further purification. Mass specfroscopy gave MΗ = 498J (exact mass calc'd for C3ιΗ3ιNO5 = 497.22). Example 139 r3-r3-(Cvclopropylmethoxy)phenvπ-2-(ethoxycarbonyl)-l-
(3-methoxybenzyl)-lH-indol-5-yll acetic acid
Figure imgf000098_0001
2-Methyl-2-butene (2 mL), sodium phosphate monobasic (307 mg, 2.6 mmol) and sodium perchlorate (307 mg, 3.4 mmol) were added to a stirred solution of ethyl 3-[3- (cyclopropylmethoxy)phenyl]-l-(3-methoxybenzyl)-5-(2-oxoethyl)-lH-indole-2-carboxy- late (Example 138, 169 mg, 0.34 mmol) in tert-butanol (8 mL) and water (3 mL). The reaction was stirred for 24 h and then diluted with ethyl acetate (100 mL). The solution was washed with brine, dried over anhydrous magnesium sulfate and concentrated in vacuo. Flash chromatography of the residue over silica gel using 60% ethyl acetate/hexane afforded 35 mg (20%) of the product. The product had: 1Η NMR (300 MHz, acetone-D6) δ 6.96-7.57 (m, 8 H), 6.58-6.80 (m, 3 H), 5.83 (s, 2 H), 4.11 (q, 2 H), 3.90 (d, 2 H), 3.70 (s, 3 H), 3.67 (s, 2 H), 1.24-1.40 (m, 1 H), 1.03 (t, 3 H), 0.55-0.65 (m, 2 H), 0.35-0.46 (m, 2 H); mass spectroscopy gave M-H+ = 512.5 (calc'd exact mass for C31H31NO6 = 513.22).
Example 140 Ethyl 3-(4-tert-butylphenyl)-5-formyl-l-(3-methoxybenzyl)-lH-indole-2-carboxylate
Figure imgf000098_0002
Ethyl 3 -(4-tert-butylphenyl)- 1 -(3-methoxybenzyl)-5-vinyl- 1 H-indole-2- carboxylate (Example 129, 2.28 g, 4.9 mmol) was dissolved in anhydrous tetrahydrofuran (25 mL), and osmium tetroxide (2.5 weight % solution in 2-methyl-2-propanol, 1.5 mL, 0J5 mmol) was added. After ten minutes, the reaction mixture was cooled with an ice bath. Sodium periodate (2J0 g, 9.8 mmol) was added followed by a minimum volume of water to dissolve the solids. The reaction was allowed to return to room temperature, and after 30 minutes, the reaction was partitioned between water and diethyl ether. The organic layer was separated, dried over anhydrous magnesium sulfate, and concenfrated. The resulting crude oil was passed through a pad of silica gel with 20%> ethyl acetate/hexane. The filtrate was concentrated in vacuo without heat to provide the title compound as a brown oil (1.70g, 75%). The product had: 1H NMR (300 MHz, acetone- dβ) 10.01 (s, 1 H), 8J5 (d, 1 H), 7.88 (d, 1 H), 7.75 (d, 1 H), 7.54 (d, 2 H), 7.44 (d, 2 H), 7.21-7J9 (m, 1 H), 6.81-6.79 (m, 1 H), 6.72-6.69 (m, 2 H), 5.92 (s, 2 H), 4J2 (q, 2 H), 3.71 (s, 3 H), 1.39 (s, 9 H), 0.78 (t, 3 H).
Example 141 Ethyl 3-(4-tert-butylphenyl 5-(hydroxymethyl)-l- (3-methoχybenzyl)-lH-mdole-2-carboxylate
Figure imgf000099_0001
Ethyl 3-(4-tert-butylphenyi)-5-formyl-l-(3-methoxybenzyl)-lH-indole-2- carboxylate (Example 140, 700 mg, 1.493 mmol) was dissolved in ethanol (15 mL) and cooled to 0 °C. Sodium borohydride (57 mg, 1.50 mmol) was added, and the solution was stirred for 1 hour. Water (27 μL, 1.5 mmol) was added, and the mixture was allowed to warm to room temperature. The mixture was concentrated via rotary evaporation, and the residue was partitioned between ethyl acetate and water. The organic layer was separated, washed with brine, dried over anhydrous magnesium sulfate, and concentrated. The resulting crude oil was purified by flash chromatography on silica gel eluted with hexane then 20% ethyl acetate/hexane. The title compound was collected as a foam (530 mg, 75%). The product had: 1H NMR (300 MHz, acetone-^) δ 7.56-7.55 (m, 1 H), 7.53-7.51 (m, 1 H), 7.50-7.47 (m, 2 H), 7.41-7.39 (m, 1 H), 7.37-7.34 (m, 2 H), 7J8-7J6 (m, 1 H), 6.77-6.75 (m, 1 H), 6.68-6.70 (m, 2 H), 5.85 (s, 2 H), 4.65 (d, 2 H), 4.09 (q, 2 H), 4.06- 4.04 (m, 1 H), 3.70 (s, 3 H), 1.38 (s, 9 H), 0.96 (t, 3 H); mass spectroscopy gave MH+ = 472.2 (calc'd exact mass for C30H33NO4 = 471.24).
The following compounds were prepared according to the method of Example
141:
Figure imgf000100_0001
Example 144
Ethyl 3-r4-(cyclopropylmethoxy)phenyl]-5-ethoxy-l-
(3-methoxybenzyl)-lH-indole-2-carboxylate
Figure imgf000100_0002
Iodoethane (468 mg, 3.0 mmol) and powdered potassium carbonate (138 mg, 1.0 mmol) was added to a solution of ethyl 3-[4-(cyclopropylmethoxy)phenyl]-5-hydroxy-l- (3-methoxybenzyl)-lH-indole-2-carboxylate (Example 66, 120 mg, 0.25 mmol) in DMF (5 mL). The mixture was heated (50 °C) for 16 h and then cooled. The resulting mixture was diluted with ethyl acetate (50 mL), washed with water and brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residue was purified by preparative TLC using 4:1 ethyl acetate/hexane as the eluant, to afford 52 mg (42%) of the desired product. The product had: 1H NMR (300 MHz, acetone-D6) δ 7.42 (d, 1 H), 7.37 (d, 2 H), 7J9 (t, 1 H), 6.92-7.01 (m 4 H), 6.74-6.77 (m, 1 H), 6.64-6.68 (m, 2 H), 5.80 (s, 2 H), 4J3 (q, 2 H), 3.88-3.98 (m, 4 H), 3.69 (s, 3 H), 1.34-1.45 ( , 4 H), 1.04 (t, 3 H), 0.56-0.66 (m, 2 H), 0.34-0.44 (m, 2 H).
Example 145
Ethyl 3-f3-(cyclopropylmethoxy)phenyl1-5-(2-ethoxyethoxy)-l-
(3-methoxybenzyl)-lH-indole-2-carboxylate
Figure imgf000101_0001
A solution of ethyl 3-[3-(cyclopropylmethoxy)phenyl]-5-(2-hydroxyethoxy)-l-(3- methoxybenzyl)-l-H-indole-2-carboxylate (Example 223, 110 mg, 0.23 mmol) was added to a cooled (0 °C) and stirred suspension of sodium hydride (12 mg, 0.50 mmol) in N,N- dimethylformamide (5 mL). The cold bath was removed and the reaction was stirred for 1 h. Ethyl iodide (80 μL, 156 mg, 1.0 mmol) was added and the reaction was stirred for an additional hour. The reaction was quenched with methanol (1 mL) and then diluted with water (50 mL). The product was extracted with ethyl acetate (3x30 mL) and then the combined organic extracts were washed with brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo. Flash chromatography of the residue over silica gel using 4:1 hexane/ethyl acetate gave 62 mg (50%) of product. The product had: 1H ΝMR (300 MHz, acetone-D6) δ 7.42 (d, 1 H), 7.29-7.36 (m, 2 H), 7J4 (dd, 1 H), 6.94-7.02 (m, 4 H), 6.63-6.79 (m, 3 H), 5.78 (s, 2 H), 3.99-4J2 (m, 4 H), 3.86 (d, 2 H), 3.64-3.71 (m, 5 H), 3.48 (q, 2 H), 1.24-1.34 (m, 1 H), IJ 1 (t, 3 H), 0.98 (t, 3 H), 0.54-0.64 (m, 2 H), 0.32- 0.42 (m, 2 H).
The following compounds were prepared according to the methods of Examples 144 - 145:
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0002
Example 156
Ethyl l-(3-methoxybenzyl)-3-(4-methoxyphenyl)-5- r2-(methylamino)ethoxy]-lH-indole-2-carboxylate
Figure imgf000104_0001
A reaction mixture of ethyl 5-(2-chloroethoxy)-l-(3-methoxybenzyl)-3-(4- methoxyphenyl)-lH-indole-2-carboxylate (Example 152, 290mg, O.588mmol) and methylamine in tetrahydrofuran (2 M, 40ml) was sealed in a stainless steel vessel (100ml, bomb) at 0°C. Then it was heated and stirred at 120°C for 3days in a oil bath. Oil bath was removed and the bomb was allowed to cooled to room temperature before opened. The reaction solution was transferred to an round-bottomed flask and solvent was concentrated in vacuo. The residue was dissolved in ethyl acetate and washed with IN NaOH. The organic phase was dried over anhydrous sodium sulfate, concentrated and purified by flash column (silica gel, hexane: ethyl acetate =1:1 to ethyl acetate:2M NH3/ methanol =9:1). 214 mg desired product was obtained as a light yellow oil in 75%. MS (M+H) = 489.2, Rf = 0.28 (ethyl acetate : 2M NH3/methanol = 4:1). The following compounds were prepared according to the method of Example
156:
Figure imgf000105_0002
Example 158
Ethyl 5-{2-fl -benzoxazol-2-yl(methyl)aminolethoxy}-l-(3-methoxybenzyl)-3-(4- methoxyphenyl)-lH-indole-2-carboxylate
Figure imgf000105_0001
To a solution of Ethyl l-(3-methoxybenzyl)-3-(4-methoxyphenyl)-5-[2- (methylamino)ethoxy]-lH-indole-2-carboxylate (Example 156, 100 mg, 0.2028 mmol) in N,N-dimethylformamide (1.5ml) was added diisopropylethylamine (0.09ml, 0.5167mmol, 2.5eq.) and 2-chlorobenzoxazole (0.03ml, 0.2636mmol, 1.3eq.). The reaction mixture was heated at 120 °C for 4hr. After cooling the reaction was diluted with saturated aqueous sodium bicarbonate and then extracted with ethyl acetate. The combined organic extracts were washed with brine, dried over anhydrous Νa2SO4, concentrated in vacuo and purified by flash column (silica gel, dichloromethane to dichloromethane:methanol 95:5). The desired product was obtained as a light yellow oil in 97% yield (119mg), MS (M+H) = 606.3, Rf = 0.69 (dichloromethane/methanol 95:5). The following compounds were prepared according to the method of Example
158:
Figure imgf000106_0002
Example 160 Ethyl 5-ammo-3-(4-ter -butylphenyl)-l-(3-methoxybenzyl)-lH-indole-2-carboxylate
Figure imgf000106_0001
Tin (II) chloride (8.5 g, 45 mmol) was added to a stirred solution of ethyl 3-(4-tert- butylphenyl)-l-(3-methoxybenzyl)-5-nifro-lH-indole-2-carboxylate (Example 28, 4.5 g, 9.3 mmol) in EtOΗ (24 mL). The mixture was heated (50 °C) until there was a homogenous solution and then concentrated hydrochloric acid (16 mL) was added. The reaction was stirred at 60 °C for 2 h and then cooled. The pΗ of the solution was adjusted to pΗ=12 using 1 M aqueous sodium hydroxide and then the product was extracted with ethyl acetate (3x100 mL). The combined organic extracts were dried over anhydrous magnesium sulfate, and concentrated in vacuo to leave 2.8 g (67%) of crude product that was taken to the next reaction without as proceeded to the next step without further purification. Mass spectroscopy gave MH+ = 457.4 (exact mass calc'd for C29H32N2O4 = 456.24). Example 161
Ethyl 7-amino-3-(4-methoxyphenyl)-l-f(3-methoxyphenyl) methyllindole-2-carboxylate
Figure imgf000107_0001
A solution of ethyl 3-(4-methoxyphenyl)-l-[(3-methoxyphenyl)methyl]-7- nitroindole-2-carboxylate (Example 96, 425 mg, 0.99 mmol) in ethyl acetate (15 mL) was added to 10% Pd/C Degussa type (70 mg) and the resulting suspension put under a H2 atmosphere and stirred for 18 h. The reaction was put back under argon, filtered through Celite, and the filtrate concentrated to a dark oil which was purified by flash chromatography on silica in 2:1 hexane:ethyl acetate to yield 401 mg, (100%) of an orange oil. 1H NMR (300 MHz, OMS -d6) δ 7.28-7.22 (m, 2H), 7J9-7J2 ( , IH), 7.00- 6.95 (m, 2H), 6.89-6.83 (m, IH), 6.80-6.70 M, 2H), 6.67-6.60 (m, IH), 6.55-6.50 (m, 2H), 5.89 (s, 2H), 4.93 (s, 2H), 4.05 (q, J= 1.1 Hz, 2H), 3.78 (s, 3H), 3.63 (s, 3H), 0.94 (t, J = 1.1 Hz, 3H); Mass spectroscopy gave MH+ = 431.2 (calc'd exact mass for C26H26N2O4 = 430.19); TLF R = 0.40 (2:1 hexane:ethyl acetate).
The following compounds were prepared according to the method of Example
161:
Figure imgf000107_0002
Figure imgf000108_0001
Example 165
Ethyl 3-(4-tert-butylphenyl)-5- Kcycloprop ylmethvD aminol -1 -
(3-methoxybenzyl)-lH-indole-2-carboxylate
Figure imgf000108_0002
Cyclopropanecarboxaldehyde (168 mg, 2.4 mmol) was added to a stirred mixture of ethyl 5-amino-3-(4-tert-butylphenyl)- 1 -(3-methoxybenzyl)- lH-indole-2-carboxylate (Example 160, 530 mg, 1.2 mmol) in toluene (12 mL) and molecular sieves (2 g). The reaction was stirred for 16 h and then filtered using toluene to rinse. The filtrate was concentrated in vacuo and the residue was dissolved in methanol (12 mL). Sodium borohydride (15 mg, 1.2 mmol) was added and the reaction was stirred for 2 h. The mixture was diluted with ethyl acetate (50 mL), washed with water and brine, dried over anhydrous magnesium sulfate, and concenfrated in vacuo. Flash chromatography of the residue over silica gel using 4:1 hexane/ethyl acetate afforded 480 mg (78%) of desired product. The product had: 1H NMR (300 MHz, acetone-D6) δ 7.45-7.48 (m, 2 H), 7.34- 7.38 (m, 2 H), 7.31 (d, 1 H), 7J8 (dd, 1 H), 6.87 (dd, IH), 6.77 (ddd, 1 H), 6.65-6.70 (m, 2 H), 6.62 (d, 1 H), 5.75 (s, 2 H), 4.68 (s, 1 H), 4.08 (q, 2 H), 3.69 (s, 3 H), 2.89 (d, 2 H), 1.37 (s, 9 H), 1.00-lJO (m, 1 H), 0.93 (t, 3 H), 0.42-0.49 (m, 2 H), 0J6-0.25 (m, 2 H).
The following compounds were prepared according to the method of Example
165:
Figure imgf000109_0002
Example 167
Methyl 3-(4-ter^-butylphenyl)-5-[(cyclopropylcarbonyl)ammol--l-(3-methoxybenzyl)- lH-indole-2-carboxyIate
Figure imgf000109_0001
Triethylamine (0J2 mL, 91 mg, 0.90 mmol), dimethylaminopyridine (20 mg, 0J6 mmol), and cyclopropanecarbonyl chloride (82 μL, 94 mg, 0.90 mmol) were added successively to a cooled (0 °C) and stirred solution of methyl 5-amino-3-(4-tert- butylphenyl)-l -(3-methoxybenzyl)- lH-indole-2-carboxylate (Example 160, 140 mg, 0.31 mmol) in dichloromethane (10 mL). The reaction was warmed to rt and stirred for 16 h. The solution was diluted with dichloromethane (50 mL), washed with water and brine, dried over anhydrous magnesium sulfate and concenfrated in vacuo. Flash chromatography of the residue over silica gel using 4:1 hexane/ethyl acetate afforded 58 mg (37%) of desired product. The product had: 1H NMR (300 MHz, acetone-D6) δ 9.38 (s, 1 H), 8.02 (d, 1 H), 7.37-7.65 ( , 6 H), 7J9 (dd, 1 H), 6.80 (dd, 1 H), 6.66-6.74 (m, 2 H), 5.81 (s, 2 H), 3.73 (s, 3 H), 3.62 (s, 3 H), 1.70-1.80 (m, 1 H), 1.40 (s, 9 H), 0.82-0.90 (m, 2 H), 0.70-0.78 (m, 2 H).
Example 168 and 168A
Ethyl 7-(cyclopropylcarbonylamino)-3-(4-methoxyphenyl)-l-r(3-methoxyphenylV methvHindole-2-carboxylate (Example 168) and
Ethyl 7-[cyclopropyl-N-(cyclopropyIcarbonyl)carbonylamino1-3-(4-methoxyphenyl")- l-f(3-methoxyphenyl)methyllindole-2-carboxylate (Example 168A)
Figure imgf000110_0001
To a solution of ethyl 7-amino-3-(4-methoxyphenyl)-l-[(3-methoxyphenyl)- methyl]indole-2-carboxylate (Example 161, 400 mg, 0.93 mmol) in tetrahydrofuran (5mL) was added triethylamine (0.278 mL, 2.00 mmol) and catalytic dimethylaminopyridine. The solution was stirred while cyclopropanecarbonyl chloride (0J0 mL, IJ mmol) was added. After 1 h stirring, the reaction was quenched with 1 M hydrogen chloride and the resulting mixture extracted with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate, adsorbed onto silica, and purified by flash chromatography on silica in a 3:1 to 1 :1 hexane: ethyl acetate gradient to yield 170 mg (32%) of the diacylated Example 168A and 190 mg (41%) of the monoacylated Example 168: 1H NMR (300 MHz, OMSO-d6) δ 10.04 (s, IH), 7.39-7.27 (m, 3H), 7J5-6.95 (m, 5H), 6.75-6.70 (m, IH), 6.40-6.35 (m, 2H), 5.75 (s, 2H), 4.06 (q, = 7J Hz, 2H), 3.80 (s, 3H), 3.62 (s, 3H), 1.80-1.70 (m, IH), 0.94 (t, /= 7J Hz, 3H), 0.80-0.66 (m, 4H); TLC Rf = 0.06 (2:1 hexane:ethyl acetate (v/v)). Example 168A: 1H NMR (300 MHz, DMSO-d*) D 7.58-7.53 (m, IH), 7.40-7.34 (m, 2H), 7.24-7J 1 (m, 3H), 7.07-7.02 (m, 2H), 6.80-6.73 (m, IH), 6.42-6.33 (m, 2H), 5.63 (s, 2H), 4.03 (q, P= 7J Hz, 2H), 3.81 (s, 3H), 3.65 (s, 3H), 1.85-1.76 (m, 2H), 0.90 (t, P= 7J Hz, 3H), 0.84-0.60 (m, 8H); TLC Rf = 0.40 (2:1 hexane:ethyl acetate (v/v)).
The following compounds were prepared according to the methods of Examples 167 - 168:
Figure imgf000111_0001
Example 172
Ethyl 3-(4-ter^-butylphenyl)-5-( (cyclopropy-lmethyl)amino1carbonyl}amino)-l-(3- methoxybenzyl)-lH-indole-2-carboxylate
Figure imgf000112_0001
Pyridine (0J8 mL, 174 mg, 2.2 mmol) and phosgene (1.9 M in toluene, 0.66 mL,
1.2 mmol) were added to a cooled (0 °C) and stirred solution of ethyl 5-amino-3-(4-tert- butylphenyl)-l -(3-methoxybenzyl)- lH-indole-2-carboxylate (Example 160, 500 mg, IJ mmol) in dichloromethane (10 mL). The reaction was warmed to rt and stirred for 3 h. The solution was concentrated in vacuo leaving crude Example 172. A portion (260 mg, 0.54 mmol) of the intermediate was dissolved in dichloromethane (10 mL) and then (cyclopropylmethyl)amine (0J3 mL, 108 mg, 1.5 mmol) was added. The reaction was stirred at rt for 16 h and then diluted with dichloromethane (100 mL). The solution was washed with water and brine, dried over anhydrous magnesium sulfate, and concenfrated in vacuo. Flash chromatography of the residue over silica gel using 3:1 hexane/ethyl acetate gave 160 mg (54%) of the desired product. The product had: 1H NMR (300 MHz, acetone-D6) δ 8.08 (d, 1 H), 7.09-7.45 (m, 7 H), 6.60-6.78 (m, 3 H), 6.33 (dd, 1 H), 5.76 (s, 2 H), 3.91 (q, 2 H), 3.68 (s, 3 H), 1.32 (s, 3 H), 0.87-0.96 (m, 1 H), 0.72 (t, 3 H), 0.31- 0.41 (m, 2 H), 0J 1-0.21 (m, 2 H).
Il l Example 173
Ethyl 3-(3-f(cyclopropylamino arbonylamino1phenyll-l-
[(3-methoxyphenyl)methyl]indole-2-carboxylate
Figure imgf000113_0001
To a 25 mL round-bottomed flask at rt was charged with ethyl 3-(3-aminophenyl)- l-[(3-methoxyphenyl)methyl]indole-2-carboxylate (Example 93, 222 mg, 0.55 mmol) and dichloromethane (1.5 mL). The resulting solution was cooled to 0 °C, to which was added pyridine (0.09 mL, IJ mmol) and phosgene (20% in toluene, 0.35 mL, 0.66 mmol). The mixture was left stirred at 0 °C for 2 hours and rt for 2 hours before it was concentrated in vacuo. The residue was dissolved in dichloromethane (2 mL) and cyclopropylamine (0J lmL, 1.65 mmol) was added. The mixture was left at rt for 15 minutes before it was mixed with hydrochloric acid (I N) and extracted with dichloromethane (10 mL). The organic layer was washed with aqueous sodium bicarbonate, brine, and dried over anhydrous magnesium sulfate. The crude mixture was purified with silica gel flash chromatography using hexane/ethyl acetate (3/1) as the eluant to give ethyl 3-{3- [(cyclopropylamino)carbonylamino]phenyl}-l-[(3-methoxyphenyl)methyl]indole-2- carboxylate (140 mg, 53%): MS (electrospray, MH+) calcd for C29H30N3O4 484.2, found 484J; 1H NMR (DMSO-d6) δ 8.36 (s, IH), 7.52-7.64 (m, 3H), 7J5-7.38 (m, 5H), 6.95 (ddd, J= 6.9 Hz, IH), 6.79 (dd, J = 8J, 1.9 Hz, IH), 6.65 (dd, IH), 6.59 (d, J= 1.6 Hz, IH), 6.38 (d, J= 2.6 Hz, IH), 5.77 (s, 2H), 4J0 (q, /= 7J Hz), 3.68 (s, 3H), 2.50-2.60 (m, IH), 0.97 (t, /= 7J Hz), 0.60-0.64 (m, 2H), 0.39-0.41 (m. 2H).
The following compounds were prepared according to the methods of Examples 172 - 173:
Figure imgf000114_0001
Example 176
Methyl 3-(4-^ert-butylphenyl)-5-[(cyclopropylcarbonyl methyl)anιino]-l-(3- methoxybenzviyiH-mdole-2-carboxylate
Figure imgf000114_0002
Sodium hydride (192 mg, 0.800 mmol) was added to a cooled (0 °C) and stirred solution of 3-(4-tert-butylphenyl)-5-[(cyclopropylcarbonyl)amino]-l -(3-methoxybenzyl)- lH-indole-2-carboxylic acid (Example 167, 94.5 mg, 0J90 mmol) in tetrahydrofuran (5 mL). The cold bath was removed and stirring was continued for 1 h. Dimethylsulfate (0.75 mL, 101 mg, 0.80 mmol) was added and the reaction was stirred for an additional 2 h. The reaction was quenched with water (50 mL) and then extracted with ethyl acetate (3x30 mL). The combined organic extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated in vacuo. Flash chromatography of the residue over silica gel using 40% ethyl acetate/hexane afforded 894 mg (90%) of the desired product. The product had: 1H NMR (300 MHz, CDC13) δ 7.38-7.50 (m, 3 H), 7.28-7.36 (m, 3 H), 7J 1-7.24 (m, 2 H), 6.59-6.76 (m, 3 H), 5.70 (s, 2 H), 3.90 (s, 3 H), 3.69 (s, 3 H), 3.21 (s, 3 H), 1.34 (s, 9 H), 1J5-1.35 (m, 1 H), 0.87-0.97 (m, 2 H), 0.48-0.58 (m, 2 H); mass spectroscopy gave MH+ = 525.3 (calc'd exact mass for C33H36N2O = 524.27).
Example 177 Methyl 3-f4-(N-cvclopentyl-N-methylcarbamoyl)phenyl]-l- r(3-methoxyphenyl)methyllindole-2-carboxylate
Figure imgf000115_0001
To a solution of 3-[4-(N-cyclopentylcarbamoyl)phenyl]-l-[(3-methoxyphenyl)- methyl]indole-2-carboxylic acid (Example 96, 260 mg, 0.53 mmol) in tetrahydrofuran (5 mL), was added a 1.0 M solution of potassium tert-butoxide in tetrahydrofuran (0.70 mL, 0.70 mmol) and the resulting orange solution was stirred for 5 minutes. lodomethane (0J0 L, 1.6 mmol) was added and the reaction was allowed to stir at RT for 18 h. The reaction was quenched with 10% aqueous citric acid and the resulting mixture was extracted with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate, adsorbed onto silica, and purified by flash chromatography on silica in 2:1 hexane:ethyl acetate to yield 113 mg (43%) of a clear oil. 1H NMR (300 MHz, DMSO-<fe) δ 7.67-7.67 (m, IH), 7.59-7.53 (m, IH), 7.51-7.40 (m, 4H), 7.40-7.33 (m, IH), 7.22-7J4 (m, 2H), 6.82-6.776 (m, IH), 6.67-6.64 (m, IH), 6.62-6.57 (m, IH), 5.78 (s, 2H), 3.67 (s, 3H), 3.61 (s, 3H), 2.86 (s, 3H), 1.83-1.32 (m, 9H); mass spectroscopy gave MH+ = 511.3 (calc'd exact mass for C32H34N2O4 = 510.25); TLF Rf = 0.40 (1:1 hexane:ethyl acetate). The following compounds were prepared according to the method of Example
177:
Figure imgf000116_0001
Example 182 Ethyl 3-(cyclopropylidenemethyl)-l-f3-(trifluoromethyl)benzyl]-lH-indole-2- carboxylate
Figure imgf000117_0001
Sodium hydride (60% dispersion in mineral oil, 128 mg, 3.20 mmol) was suspended in anhydrous tetrahydrofuran (10 mL) and cooled to 0 °C. Triphenyl- cyclopropylphosphonium bromide (1.23 g, 3.20 mmol) was added as a solid all at once, and the mixture was allowed to stir at room temperature. Once gas evolution ceased, a tetrahydrofuran solution of ethyl 3-formyl-l-[3-(trifluoromethyl)benzyl]-lH-indole-2- carboxylate (Example 40, 1.0 g, 2.7 mmol) was added, the mixture was stirred for 15 hours, and the resulting mixture was partitioned between water and ethyl acetate. Layers were separated, and the aqueous layer was extracted with ethyl acetate (2x). The combined organic layers were dried over anhydrous magnesium sulfate and concentrated. The resulting crude oil was purified by flash chromatography on silica gel eluted with 5% ethyl acetate/hexane. The title compound was collected as a bright yellow oil (403 mg, 38%). The product had: 1H NMR (300 MHz, CDC13) δ 8.04 (d, 1 H), 7.53 (s, 1 H), 7.41- 7.38 (m, 2 H), 7.29-7.20 (m, 3 H), 7J5-7J2 (m, 1 H), 7.05 (d, 1 H), 5.72 (s, 2 H), 4.27 (q, 2 H), 1.50-1.45 (m, 2 H), 1.25 (t, 3 H), 0.83-0.76 (m, 2 H); mass spectroscopy gave MH+ = 400.2 (calc'd exact mass for C23H20F3NO2 = 399.14).
The following compounds were prepared according to the method of Example
182:
Figure imgf000118_0002
Example 184 Ethyl 3-(4-tert-butylphenvD-5-cy clopentyl-1 - (3-methoxybenzvf)-lH-indole-2-carboxylate
Figure imgf000118_0001
A solution of ethyl 5-(l-cyclopenten-2-yl)-3-[3-(cyclopropylmethoxy)phenyl]-l- (3-methoxybenzyl)rlH-indole-2-carboxylate (Example 128, 225 mg, 0.44 mmol) in ethyl acetate (3 mL) and EtOΗ (3 mL) was added to a slurry of 10% palladium on charcoal (100 mg) in ethyl acetate (2 mL) and EtOΗ (2 mL). The reaction was placed under hydrogen (1 atm) and stirred for 16 h. The mixture was filtered through a pad of Celite using ethyl acetate to rinse. Evaporation of the filtrate gave 210 mg (93%) of the product. The product had: 1H NMR (300 MHz, acetone-D6) δ 7.37-7.53 (m, 6 H), 7.28 (dd, 1 H), 7.19 (dd, 1 H), 6.67-6.82 (m, 3 H), 5.83 (s, 3 H), 4.08 (q, 2 H), 3.75 (s, 3 H), 3.06 (p, 1 H), 1.99-2.06 (m, 2 H), 1.47-1.83 (m, 6 H), 1.40 (s, 9 H), 0.98 (t, 3 H). Example 185 Ethyl 3-(cyclopropylmethylVl-r3-(trifluoromethyl enzyll-lH-indole-2-carboxylate
Figure imgf000119_0001
Ethyl 3-(cyclopropylidenemethyl)-l-[3-(trifluoromethyl)benzyl]-lH-indole-2- carboxylate (Example 182, 140 mg, 0.351 mmol) was stirred over Lindlar catalyst (28 mg) in ethanol (15 mL) under 1 atmosphere of hydrogen for 1 hour. The mixture was filtered through Celite with an excess of ethanol. The filtrate was concentrated, and the resulting crude oil was purified by flash chromatography on silica gel eluted with 20% Et2O/hexane. The title compound was collected as a yellow oil (95 mg, 67%). The product had: 1H NMR (300 MHz, acetone-^) δ 7.78 (d, 1 H), 7.56-7.45 (m, 4 H), 7.34-7.32 (m, 1 H), 7.28-7.26 (m, 1 H), 7J6-7J3 (m, 1 H), 5.93 (s, 2 H), 4.32 (q, 2 H), 3.08 (d, 2 H), 1.31 (t, 3 H), 1J3-1J5 (m, 1 H), 0.42-0.38 (m, 2 H), 0.29-0.26 (m, 2 H).
The following compounds were prepared according to the methods of Examples 184 - 185:
Figure imgf000119_0002
Example 187 Ethyl-l-(3-trifluoromethylbenzyl)-lH-indole-2-carboxylate-3-carboxylate
Figure imgf000120_0001
To a solution of ethyl-l-(3-trifluoromethylbenzyl)-lH-indole-2-carboxylate-3- carboxaldehyde (Example 40, 6.0g, 15.9 mmol) in pH 3.5 phosphate buffer (48 mL) and t- butanol (90 mL) was added 2-methyl-2-butene (30 mL) and sodium chlorate (2J g, 1.5 eq.). The reaction was stirred at room temperature for 16 hours and then exfracted with dichloromethane (3x200 mL). The combined organic extracts were washed with brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo. Flash chromatography of the residue over silica afforded the desired product as a white solid. The product had: 1H NMR (300 MHz, dmso-D6) 8.03 (d, 1 H), 7.5 - 7.65 (m, 4 H), 7.2- 7.39 (m, 3 H), 5.61 (s, 2 H), 4.26 (q, 2 H), 1J5 (t, 3 H).
Example 189 Ethyl-l-(3-trifluoromethylbenzyl)-lH-indole-2-carboxylate-3-carbonyl chloride
Figure imgf000120_0002
Ethyl- 1 -(3-trifluoromethylbenzyl)- 1 H-indole-2-carboxylate-3 -carboxylic acid
(Example 187, 100 mg, 0.25 mmol) was taken up in dichloromethane (10 mL) with a catalytic amount of DMF, and the mixture was cooled (0 °C.) Oxalyl chloride (0.044 mL, 2 eq.) was added, and the reaction was stirred for 1 hour. The mixture was concentrated in vacuo and used directly with no further purification. Example 191
Ethyl-l-(3-trifluoromethylbenzyl)-lH-indole-2-carboxylate
-3-carboxylic acid, morpho-Iine amide
Figure imgf000121_0001
Ethyl- 1 -(3 -trifluoromethylbenzyl)- 1 H-indole-2-carboxylate-3 -carbonyl chloride
(Example 189, 0J6 g, 0.4 mmol) was taken up in excess morpholine (0.3 mL) at room temperature. The reaction was stirred for 72 hours, quenched with water, and extracted with diethyl ether (2 x 25 mL.) The combined organic extracts were dried over sodium sulfate and purified by flash chromatography to yield 0.268 mg (91%) of the desired product. The product had: 1H NMR (300 MHz, dmso-D6) δ 7.42 - 7.75 (m, 5 H), 7.4 (t, 1 H), 7.22 ( , 2 H), 5.95 (s, 2 H), 4.21 (q, 2 H), 3.0-3.8 (broad , 8 H), IJ (t, 3 H)
The following compounds were prepared according to the method of Example
191:
Figure imgf000121_0002
Example 193 Ethyl-3-benzoxazol-2-yl-l-(3-trifluoromethylbenzyl)-lH-indole-2-carboxylate
Figure imgf000122_0001
Ethyl-l-(3-trifluoromethylbenzyl)-lH-indole-2-carboxylate-3-carbonyl chloride (Example 189) was prepared as above from the corresponding acid (600 mg, 1.53 mmol.) The crude material was taken up in dichloromethane (50 mL) and cooled to 0 °C. Triethylamine (0.85 mL, 4 eq.) was added, followed by 2-aminophenol (0.5 g, 3 eq.), and the reaction mixture was allowed to warm to room temperature. The mixture was quenched with 1 N HC1, and the organic layers were separated and concentrated in vacuo. The crude intermediate was taken up in toluene (20 mL) with p-toluenesulfonic acid (0.73 g) and heated to reflux for 3 hours. The reaction was cooled to room temperature, quenched with water, and extracted with ethyl acetate (3 x 75 mL.) The organic layers were dried over sodium sulfate and purified by flash chromatography over silica gel to give the desired product (260 mg, 37 %.) The product had: 1H NMR (300 MHz, dmso- D6) δ 8.3 (d, 1 H), 7.35-7.9 (m, 11 H), 5.81 (s, 2 H), 4.37 (q, 2 H), 1J6 (t, 3 H) Mass spectroscopy gave MH+ = 437.2 (calc'd exact mass for C2 H15F3N2O3 = 436J).
Example 194 Ethyl-3-benzthiazol-2-yl-l-(3-cyclopropylmethoxybenzyl)-lH-indole-2-carboxylate
Figure imgf000122_0002
Ethyl-3-benzthiazol-2-yl-l-(3-cyclopropylmethoxybenzyl)-lH-indole-2- carboxaldehyde (Example 41, 0.42 g, IJ mmol) was taken up in EtOH (30 mL) at room temperature. 2-arninothiophenol (0J5 g, 1.05 eq.) was added, followed by cone. HCl (0.5 mL), and the reaction mixture was heated to reflux for 24 hours. The mixture was cooled to room temperature, quenched with water and extracted with diethyl ether (3 x 50 mL.) The organic layers were separated, dried over sodium sulfate, and concentrated in vacuo to give the desired product (0.38 g, 71 %) which was taken to the hydrolysis step without further purification.
The following compounds were prepared according to the method of Example 194:
Figure imgf000123_0002
Example 196
Ethyl 3-(r(2-hydroxy-lJ-dimethylethyl)aminolcarbonyU-l-[3-
(trifluoromethyl enzvn-lH-indole-2-carboxylate
Figure imgf000123_0001
To a 0°C solution of Example 189 (545 mg, 1.28 mmol) in dichloromethane (8 mL) was added 2-hydroxy-l,l-dimethyl-ethylamine (285 mg, 3.2 mmol). Triethyl amine (0.7 mL, 5J2 mmol) was added in one portion. The mixture was stirred for 15 min. and then allowed to warm to r.t. over 20 min. The reaction was quenched with IN HCl and the resulting mixture was washed with IN HCl (2X). The organic layer was dried over anhydrous sodium sulfate, concentrated, and filtered through a short plug of silica gel (elution with 8:92 methanol: dichloromethane). Concentration of the filtrate provide 440 mg (74 %) of Example 196. LRMS (+esi) obs'd: 463 J; calc'd 462.2.
Example 197 Ethyl 3-(4.4-dimethyl-4.5-dihydro-1.3-oxazol-2-yl)-l-
[3-(trifluoromethyl)benzyl)-lH-indole-2-carboxylate
Figure imgf000124_0001
A solution of Example 196 (440 mg, 0.95 mmol) and p-toluenesulfonic acid monohydrate (170 mg, 0.89 mmol) in toluene (6 mL) was refluxed for 1.5 h. The mixture was cooled and washed with water. The organic layer was dried over anhydrous sodium sulfate and concentrated. The remaining material was purified by flash chromatography (silica gel, 10:90 methanol: dichloromethane) to provide 100 mg (24%) of Example 197, which was used in the next step without purification. Rf = 0.95 (1/9 methanol/dichloromethane); LRMS (+esi) obs'd: 445.2; calc'd 444.2.
Example 198
Ethyl 3-({[l-hydroxymethyl yclopentyl]amino}carbonyl)-l-r3-
(trifluoromethyl)benzyl]-lH-indole-2-carboxylate
Figure imgf000125_0001
To a 0°C solution of acid chloride Example 189 (434 mg, 1.02 mmol) in dichloromethane (7 mL) was added cycloleucinol (295 mg, 2.55 mmol). Triethyl amine (0.57 mL, 4.08 mmol) was added in one portion. The mixture was stirred for lh and was then allowed to warm to r.t. over 40 min. The reaction was diluted with water and the organic layer was washed with IN HCl, dried over anhydrous sodium sulfate and concentrated to afford 498 mg of Example 198 which was used without further purification. LRMS (+esi) obs'd: 489J; calc'd 488.2.
Example 199
Ethyl 3-(3-oxa-l -azaspiro [4.4]non-l -en-2-yl)-l-
[3-(trifluoromethyl)benzyll-lH-indole-2-carboxylate
Figure imgf000125_0002
A solution of Example 198 (498 mg, 1.02 mmol) and p-toluenesulfonic acid monohydrate (210 mg, IJ mmol) in toluene (7 mL) was refluxed for 2 h. The mixture was cooled and washed with water. The organic layer was dried over anhydrous sodium sulfate and concentrated. Flash chromatography (5:95 methanol: dichloromethane) provided impure Example 199. Rf = 0.96 (6/94 methanol/dichloromethane); LRMS (+esi) obs'd: 471.2; calc'd 470.2.
Example 200 and 201 Ethyl 3-(4-t-butylphenyl)-5-(cvclopropyl)carbonyl-lH-indole-2-carboxyIate
(Example 200) and Ethyl 3-(4-t-butylphenyl)-7-(cvclopropyl)carbonyl-lH-indole-2-carboxylate
(Example 201)
Figure imgf000126_0001
Aluminum chloride (4.07 g, 1.5 eq.) was suspended in dichloromethane (70 mL) and cooled to 0 °C. Cyclopropyl carbonyl chloride (3.2 g, 1.5 eq.) was added slowly, and the mixture was stirred for 15 minutes. A solution of ethyl 3-(4-t-butylphenyl)-lH-indole-
2-carboxylate (Example 224, 5J6 g, 20.4 mmol) in dichloromethane (20 mL) was added dropwise. The reaction was allowed to waπn to room temperature, and was then heated to reflux for 24 hours, cooled to room temperature, quenched with water and diluted with diethyl ether. The organic layers were washed with water and IN HCl and dried over sodium sulfate, then purified by flash chromatography over silica to give 5.25 g of the 5- acylated Example 200, which had 1H NMR (300 MHz, CDC13) 9.35 (bs, IH), 8.4 (s, 1 H),
8.03 (d, 1 H), 7.45 (m, 5 H), 4.35 (q, 2 H), 2.72 (m, 1 H), 1.4 (s, 9 H), 0.9-1.4 (m, 9 H) and 1.27 g of the 7-acylated Example 201, which had: 1H NMR (300 MHz, CDC13) 10.9 (bs, IH), 8J7 (d, 1 H), 7.92 (d, 1 H), 7.45 (m, 5 H), 4.35 (q, 2 H), 2.86 (m, 1 H), 1.4 (s, 9
H), l.l-1.4 (m, 9 H) .
The following compounds were prepared according to the method of Example
200:
Figure imgf000127_0002
Example 203 Ethyl 3-(4-methvoxybenzoyl)-lH-indole-2-carboxylate (53354-02)
Figure imgf000127_0001
A 0°C suspension/solution of A1C1 (693 mg, 5.2 mmol) and 4-methoxybenzyl acid chloride (887 mg, 5.2 mmol) in 1,2 dichloroethane (10 mL) was stirred for 5 min. A solution of indole (0.5 gm, 2.6 mmol) in 1,2-dichloroethane (10 mL) was added dropwise and upon complete addition the mixture was warmed to reflux for lh. The mixture was cooled and poured over ice. The aq. layer was extracted with ethyl acetate. The extracts were washed with sat. aq. Na2CO , dried and concentrated. Purification of the remaining oil by flash chromatography (silica gel, elution with 5:5 ethyl acetate:hexane) afforded 481 mg (57%) of Example 203. Rf = 0.48 (1/1 hexane/ethyl acetate); LRMS (+esi) obs'd: 324.1: calc'd 323.1. Example 204 Ethyl 3-(cyclobutylcarbonyl)indole-2-carboxylate
Figure imgf000128_0001
To a 50 mL reaction vial and stir bar was charged with 0.563 g of FeCl3 (5.28 mmoles) followed by addition of 10 ml of dichloromethane. The heterogeneous solution was cooled to 0°C followed by addition of a 10 mL dichloromethane solution of ethyl indole-2-carboxylate ( 0.5 g, 2.64 mmoles). The contents were maintained at 0 c for 0.5 hours then poured into 30 mL of ice water and neutralized with NaHCO3 saturated solution. The contents were then extracted with 3 x 20 mL of dichloromethane and dried over Na SO and concenfrated in vacuo to yield 0.71 g ( 99.0 %) of a white solid (Rf- 0J0 in 10% ethyl acetate/hexane). The product had: 1H NMR (300 MHz, acetone-D6); δ 11.4 Hz (s, IH), 7.93 Hz (dd, IH), 7.54 Hz (dt, IH), 7.34 Hz (td, IH), 7.20 Hz (td, IH), 4.43 Hz (q, 2H), 2.32 Hz (m, IH), 2J7 Hz (m, 4H), 1.97 Hz (m, 2H), 1.40 Hz (t, 3H); mass spectroscopy gave M of 272.2 (calc'd mass for Cι6H NO3 of 271.31).
Example 205
Ethyl 3-(cyclobutylmethyl)indole-2-carboxylate
Figure imgf000128_0002
To a dry 50 mL round bottom flask and stir bar was charged with ethyl-3-
(cyclobutylcarbonyl)indole-2-carboxylate (Example 204, 0.81g, 3.0 mmol) followed by addition of TFA (5.6 mL). The contents were stirred and cooled to 0°C followed by dropwise addition of triethylsilane (1.56 mL, 9.8 mmol) via syringe. The contents of the reaction were maintained at 0°C for 20 minutes then heated to reflux for 3 hours. The reaction was cooled to room temperature followed by addition of water (20 mL) triturating a solid. The solid was filtered and washed 3 x 20 mL of water and air dried providing 0.76 g (99.0 % yield) of a white solid. The product had a Rf of 0.38 10% ethyl acetate/hexane; 1H NMR (300 MHz, acetone-D6); 10.5 Hz (s, IH), 7.71 Hz (dd, IH), 7.46 Hz (dt, IH) 7.26 Hz (td, IH), 7.08 Hz (td, IH) 4.37 Hz (q, 2H), 3.24 Hz (d, 2H), 2.74 Hz (m, IH), 1.93 Hz (m, 2H), 1.80 Hz (m, 4H), 1.39 Hz (t, 3H) mass spectroscopy gave M" of 256.5 (calc'd mass for C16H19NO2 of 257.33).
Example 206 Ethyl (2E)-3-(2-hydroxy-6-nitrophenyl)prop-2-enoate
Figure imgf000129_0001
To a thick-walled vessel was charged with 2-bromo-3-nitrophenol (1J6 g, 5.32 mmol), ethyl acrylate (666 mg, 0.72 mmol), tri-(σ-tolyl)phosphine (65 mg, 0.21 mmol), palladium acetate (12 mg, 0.05 mmol), and triethylamine(10 mL). The vessel was then sealed and the resulting mixture was heated to 100 °C overnight. In the morning, the vessel was cooled to rt and the mixture was poured into water. The mixture was acidified with hydrochloric acid and extracted with ethyl acetate (2 x 50 mL). The combined organic layer was washed with water, brine and dried over anhydrous sodium sulfate. The residue was purified with silica gel flash chromatography by using hexane/ethyl acetate (2/1) as the eluant to give ethyl (2E)-3-(2-hydroxy-6-nitrophenyl)prop-2-enoate (883 mg, 70%): fy 0.16 (3/1 hexane/ethyl acetate); 1H NMR (CDC13) δ 7.6(d, P = 16J Hz, IH), 7.05-7.23 (m, 3H), 6.71 (dd, J = 16J, 0.8 Hz, IH), 4J8 (q, /= 7J Hz, 2H), 1.26 (t, = 7J Hz, 2H).
Example 207 Ethyl 4-(lJ,2,2-tetramethyl-l-silapropoxy)indole-2-carboxylate
Figure imgf000129_0002
To a round-bottomed flask at rt was charged with ethyl (2E)-3-(2-hydroxy-6- nitrophenyl)prop-2-enoate (Example 206, 260 mg, 1J0 mmol), N,N-dimethylformamide (2 mL), t-butyldimethylsilyl chloride (198 mg, 1.32 mmol), and imidazole (150 mg, 2.20 mmol). The resulting mixture was left stirring at rt for 2 hours before hydrochloric acid was added and the mixture was extracted with diethyl ether (2 x 20 mL). The combined organic layer was washed with water, brine, and dried over anhydrous sodium sulfate. The concentrated residue was used without further purification. It was mixed with triethyl phosphite (920 mg, 5.50 mmol) and heated to 170 °C for 3 hours before it was cooled to rt and diluted with ethyl acetate. The mixture was washed with water, brine and dried over anhydrous sodium sulfate. The concentrated residue was purified with silica gel flash chromatography by using hexane/ethyl acetate (3/1) as the eluant to give ethyl 4-(l, 1,2,2- tetramethyl-l-silapropoxy)indole-2-carboxylate as a white solid (224 mg, 64%): R/0.57 (3/1 hexane/ethyl acetate); %): MS (MH+) calcd for C17H26ΝO3Si 320.2, found 320.2; 1H NMR (DMSO-d6) δ 11.87 (br s, IH), 6.99-7J5 (m, 3H), 6.47 (dd, J = 13, 0.6 Hz, IH), 4.33 (q, J= 7.0 Hz, 2H), 1.33 (t, J= 7.0 Hz, 3H), 1.01 (s, 9H), 0.22 (s, 6H).
Example 208
Ethyl 3-bromo-4-(cyclopropylmethoxy)-l - f(3-methoxyphenyl)methyl]indole-2-carboxylate
Figure imgf000130_0001
To a round-bottomed flask at rt was charged with ethyl 4-(l,l,2,2-tetramethyl-l- silapropoxy)indole-2-carboxylate (Example 18, 100 mg, 0J9 mmol), tetrabutyl- ammonium fluoride (1M in tetrahydrofuran, 0.29 mL, 0.29 mmol), molecule sieves (3A, 30 mg), and tetrahydrofuran (1 mL). After 0.5 hours at rt, cyclopropylmethyl bromide (52 mg, 0.04 mL, 0.38 mol) was added to the reaction mixture. After 2 hours at rt, the mixture was diluted with water and extracted with ethyl acetate (2 x 20 mL). The combined organic layer was washed with water, brine and dried over anhydrous sodium sulfate. The concentrated residue was purified with silica gel flash chromatography by using hexane/ethyl acetate (3/1) as the eluant to give ethyl 3-bromo-4-(cyclopropylmethoxy)-l- [(3-methoxyphenyl)methyl]indole-2-carboxylate (90 mg, 100%). The product was used without further purification: MS (MH+) calcd for C23H25BrNO4 458J, found 458.5; 1H NMR (DMSO-d6) δ 7J7-7.30 (m, 3H), 6.82 (dd, J= 8.2, 1.7 Hz, IH), 6.66 (d, J=6.9 Hz, IH), 6.59-6.61 (m, IH), 6.51 (d, /= 7.6 Hz, IH), 5.72 (s, 2H), 4.33 (q, J= 7.0 Hz, 2H), 4.02 (d, J = 6.4 Hz, 2H), 3.71 (s, 3H), 1.30 (t, J = 7.0 Hz, 3H), 0.85-0.95 (m, IH), 0.59- 0.66 (m, 2H), 0.45-0.50 (m, 2H).
Example 209 Ethyl 6-(benzyloxy)-l-(phenylsulfonyl)indole-2-carboxylate
Figure imgf000131_0001
To a dry 100 ml round bottom flask and stir bar attached with a septa and purged with argon was charged with 7.5 mL of tetrahydrofuran and 0.33g (3.25 mmol) of diisopropylamine then cooled to -78°C. To the cooled solution of the amine n-BuLi (2.6M hexane, 1.20 mL, 3J mmol) was added dropwise via syringe and allowed to stir for 20 minutes at -78°C. At this time a 7.5 mL tetrahydrofuran solution of 6-(phenylmethoxy)-l- (phenylsulfonyl)indole (Example 57, 1.06g, 2.95 mmol) was added to the LDA solution via cannula over a 10-15 minute period. The yellow solution was maintained at -78°C for 1 hour then warmed to 0°C for Vi hour followed by cooling to -78°C. Once cooled to - 78°C 0.96g of ethyl chloroformate (8.85mmol) was rapidly added via syringe. Upon complete addition the contents were warmed to room temperature and stirred for Vi hour then quenched with 20 mL of water then extracted with 3x20mL of ethyl acetate. The organics were dried over Na2SO4 then concentrated in vacuo. The crude material was purified via SiO2 column chromatography to yield 0.85g (67% yield) of a white solid. The product had a Rf of 0J5 10% ethyl acetate/hexane; 1H NMR (300 MHz, Acetone-D6); 7.90 Hz, (d, 2H), 7.66 Hz, (m, 2H), 7.54 Hz, (m, 4H), 7.40 Hz, (m, 2H), 7.21 Hz, (s, IH), 7.03 Hz, (dd, IH), 5.27 Hz, (s, 2H), 4.32 Hz, (q, 2H), 1.32 Hz, (t, 3H). Example 210 Ethyl 6-(benzoyloxy)-l-(phenylsulfonyl)indole carboxylate (dpd-53586-97)
Figure imgf000132_0001
To a dry 100 mL round-bottom flask, stir bar and purged with argon was charged with 5J0g of ethyl 6-hydroxy-l-(phenylsulfonyl)indole-2-carboxylate (Example 123, 15 mmol) followed by addition of 30 mL of anhydrous tetrahydrofuran and cooled to 0°C . To the rapidly stirring solution was added via syringe 15.2g of triethylamine (150 mmol) followed by slow addition of 3J5g of benzoyl chloride (22.4 mmol) via syringe while maintaining the solution at 0°C. The reaction was warmed to rt and stirred for an additional hour. The reaction was then quenched with 15mL of 3N HCl then extracted with 3x50 mL of ethyl acetate and dried over Na2SO4 then concenfrated in vacuo. The crude material was purified via column chromatography to yield 4.7g (70.1% yield) of a white solid. The product had a Rf of 0.33 20% ethyl acetate/hexane; 1H NMR (300 MHz, Acetone-D6); 8.22 Hz, (d, 2H), 8.11 Hz, (m, 3H), 7.73 Hz, (m, 3H), 7.62 Hz, (t, 4H), 7.34 Hz, (s, IH), 7.29 Hz, (dd, IH).
Example 211 Ethyl 6-(benzoyloxy)indole-2-carboxylate
Figure imgf000132_0002
To a dry 100 mL and stir bar was charged with 4.70 g ethyl 6-(benzoyloxy)-l- (phenylsulfonyl)indole carboxylate (Example 210) and dissolved in 12.5 mL of anhydrous tetrahydrofuran then cooled to 0°C. To this rapidly stirring solution was added 35.0 mL 1.0 M tetrahydrofuran solution of potassium tert-butoxide dropwise via syringe. Upon complete addition the contents were warmed to room temperature and stirred an additional V2 hour then quenched with 10 mL of 3N HCl solution followed by addition of 30 mL of water. The reaction was extracted with 3x50 mL of ethyl acetate then dried over Na2SO4 and concenfrated in vacuo. The crude material was purified via column chromatography to yield 3.28g (99.0% yield) of an off white solid. The product had a Rf of 0.42 20% ethyl acetate/hexane; 1H NMR (300 MHz, Acetone-D6); 8.80 Hz, (s, IH), 8.02 Hz, (dd, IH), 7.95 Hz, (dd, IH), 7.68 Hz, (dd, IH), 7.58 Hz, (m, 2H), 7.46 Hz, (d, 2H), 7.21 Hz, (d, IH), 6.87 Hz, (dd, IH), 4.31 Hz (q, 2H), 1.31 Hz (t, 3H).
The following compounds were prepared according to the method of Example
211:
Figure imgf000133_0002
Example 213 Ethyl 3-bromo-6-hydroxy-l-(4-methoxybenzyl)indole-2-carboxylate
Figure imgf000133_0001
A 0.5 mL ethanol/ 0.5 mL HF solution of 44 mg ethyl 6-(benzoyloxy)-l-(4- methoxybenzyl)indole-2-carboxylate (Example 20, 0J mmol) was cooled to 0°C in a 10 mL round-bottom flask and stir bar. To this stirring solution was added 0.3 mL of NaOEt 1.0 M in ethanol dropwise. The contents were then brought to reflux and maintained for 2 hours. The content were then cooled to room temperature and quenched with water then acidified with 1 N HCl. The reaction contents were then exfracted with 3x5 mL of ethyl acetate, dried with Na2SO4 to yield 0.42 mg (95%> yield) of an off white solid. The product had a Rf of 0J7 20% ethyl acetate/hexane; 1H NMR (300 MHz, Acetone-D6); 8.68 Hz (s, IH), 7.47 Hz (d, IH), 7J9 Hz (t, IH), 6.87 Hz (m, 2H), 6.79 Hz (dd, IH), 6.67 Hz (s, IH), 6.62 Hz (dt, IH), 5.76 Hz (s, 2H), 4.35 Hz (q, 2H), 3.40 Hz (s, 3H), 1.37 Hz (t, 3H).
Example 214 Ethyl 3-bromo-6-(cyclopropylmethoxy)-l-(3-methoxybenzyl)indole-2-carboxylate
Figure imgf000134_0001
To a dry 5 mL round-bottom flask and stir bar was charged with 3.0 mg of NaH (0J2 mmol) followed by addition of 0.2 mL of DMF and cooled to 0 C. To the heterogeneous solution was added a 0.3 ml 42 mg DMF solution of ethyl 3-bromo-6- hydroxy- l-(4-methoxybenzyl)indole-2-carboxylate (Example 213, 0J mmol). The solution was maintained at 0°C for 20 minutes after which bromomethyl cyclopropane was added via syringe and the reaction contents were warmed to rt. and stirred overnight. The reaction was quenched with water then acidified followed by extraction with ethyl acetate and concentration in vacuo to yield 30.0 mg (61.05 yield) of an off white solid. The product had a Rf of 0.58 20% ethyl acetate/hexane ; mass specfroscopy gave M+ of 459.6 (calc'd exact mass for C23H24BrNO4 = 458.34)
Example 215
Ethyl-3-(4-t-butylphenyl)-7-cyclopropylmethyl-l-
(3-methoxybenzyl)-lH-indole-2-carboxylate
Figure imgf000134_0002
Aluminum chloride (0.24 g, 2 eq.) was suspended in dichloromethane (20 mL) and cooled to 0 °C. Borane-t-butylamine complex (0J4 g, 1.8 eq.) was added slowly, and the mixture was stirred for 30 minutes. A solution of ethyl-3-(4-t-butylphenyl)-7- (cyclopropyl)carbonyl-l-(3-methoxybenzyl)-lH-indole-2-carboxylate (Example 201, 0.405 g, 0.9 mmol.) in dichloromethane (5 mL) was added, and the reaction was stirred for two hours. The mixture was quenched with water and diluted with dichloromethane. The organic layer was washed with IN HCl and saturated sodium bicarbonate, dried over sodium sulfate, then purified by flash chromatography over silica to give 0.26 g (62%.) The desired product had: 1H NMR (300 MHz, CDC13) 7.21-7.4 (m, 5 H), 7.11 (d, 1 H), 7.02 (t, 1 H), 6.95 (t, 1 H), 6.59 (d, IH), 6.35 (m, 2 H), 5.9 (s, 2 H), 3.9 (q, 2 H), 3.58 (s, 3 H), 2.75 (d, 2 H), 1.26 (s, 9 H), 0.85 (t, 3 H), 0.4 (m, 2 H), 0.02 (m, 2H).
The following compounds were prepared according to the method of Example
215:
Figure imgf000135_0001
Example 217 (3-(4-Methoxyphenyl)-l-{r3-(trifluoromethyl)phenynmethyl)indol-2-yl)methan-l-ol
Figure imgf000136_0001
To a stirred solution of ethyl 3-(4-methoxyphenyl)-l-{[3-(trifluoromethyl)phenyl]- methyl }indole-2-carboxylate, prepared by the method described in WO94/14434 (1.20 g, 2.65 mmol), in tetrahydrofuran was added a 2.0 M solution of LiBH4 in tetrahydrofuran (2.65 mL, 5.29 mmol). The resulting mixture was heated to reflux for 18 h. The reaction was cooled to RT and then to 0°C. A 1.0 M solution of LiAlH4 in tetrahydrofuran (4 mL, 4 mmol) was added and the reaction stirred another 2 h. The reaction was quenched by the addition of water then 1.0 M HCl in water. The resulting mixture was extracted with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate and concentrated to a residue. Flash chromatography of the residue on silica in a 2.J to 1:2 hexane:ethyl acetate gradient yielded 650 mg (60%) of a white solid. 1H NMR (300 MHz, OMSO-dg) δ 7.65-7.46 (m, 6H), 7.39-7.34 (m, IH), 7.32-7.25 (m, IH), 7.17-7.02 (m, 4H), 5.68 (s, 2H), 5.40 (s, 2H), 4.59 (s, 2H), 3.81 (s, 3H) ppm; Rf = 0.41 (2:1 hexane:ethyl acetate (v/v)).
Example 218 3-(4-Methoxyphenyl)-l- 3-(trifluoromethyl)phenvnmethyl}indole-2-carbaldehyde
Figure imgf000137_0001
To a solution of (3-(4-methoxyphenyl)-l-{[3- (trifluoromethyl)phenyl]methyl}indol-2-yl)methan-l-ol (Example 217, 600 mg, 1.45 mmol) in dichloromethane (20 mL) was added Dess-Martin Periodinane (1.2 g, 2.9 mmol) and the resulting yellow solution was stirred for 30 min at RT. The reaction was quenched by the addition of saturated aqueous sodium bicarbonate (10 mL) and saturated aqueous sodium thiosulfate (10 L). The resulting mixture was extracted with ethyl acetate and the combined organic layers were dried over anhydrous magnesium sulfate and concentrated to an orange solid. The solid was washed with Et2O and collected by filtration to yield 257 mg (45%) of a pale yellow solid. Rf = 0.66 (4:1 hexane:ethyl acetate (v/v)).
Example 219 2,2.2-Trifluoro-l-(3-(4-methoxyphenyl)-l- 3-(trifluoromethyl)phenyl1methyl}indol-2-yl)ethan-l-ol
Figure imgf000137_0002
To a solution of 3-(4-methoxyphenyl)-l-{[3-
(trifluoromethyl)phenyl]methyl}indole-2-carbaldehyde (Example 218, 200 mg, 0.49 mmol) in tetrahydrofuran (5 mL) was added a 0.5 M solution of TMSCF3 in tetrahydrofuran (4.9 mL, 2.4 mmol). The resulting solution was cooled to 0°C and a 1.0 M solution of TBAF in tetrahydrofuran (0J0 mL, 0J0 mmol) was added. The mixture was stirred for 10 min at 0°C and then let warm to RT and quenched by the addition of water. The resulting mixture was extracted with tetrahydrofuran, adsorbed onto silica, and purified by flash chromatography on silica in 4:1 hexane: ethyl acetate (v/v) to yield 49 mg (21%) of an orange solid. 1H NMR (300 MHz, OMSO-dg) δ 7.60-7.26 (m, 6H), 7.22-7.01 (m, 6H), 5.81 (s, 2H), 3.83 (s, 3H); mass spectroscopy gave MH+ = 480.2 (calc'd exact mass for C25H19F3NO2 = 479.13).
Example 220 Ethyl 5-f2-(5-methyl-2-phenyl-l,3-thiazol-4-yl)ethoxy1-lH-indole-2-carboxylate
Figure imgf000138_0001
A solution of ethyl 5(hydroxy)-lH-indole-2-carboxylate (991 mg, 4.83 mmol) and
2-(5-methyl-2 -phenyl- l,3-thiazol-4-yl)ethanol (1.06 g, 4.83 mmol) in tetrahydrofuran (30 + 5 mL rinse) was added to a stirred mixture of triphenylphosphine (1.3 g, 4.9 mmol) and l,l '-(azodicarbonyl)dipiperidine (1.2 g, 4.9 mmol) in tetrahydrofuran (10 mL). The reaction was stirred for 48 h and then diluted with ethyl acetate (200 mL). This solution was washed successively with water, 10% hydrochloric acid, and brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo. Flash chromatography of the residue over silica gel using 25% ethyl acetate/hexane gave 1.04 g (53%) of the desired product. The product had: !Η NMR (300 MHz, acetone-D6) D 10.40-10.55 (br s, 1 H), 7.89-7.95 (m, 2 H), 7.38-7.49 (m, 4 H), 7J9 (d, 1 H), 7.06-7.09 (m, 1 H), 6.95 (dd, 1 H), 4.30-4.40 (m, 4 H), 3.20 (t, 2 H), 2.51 (s, 3 H), 1.35 (t, 3 H); mass spectromefry gave MH+ = 407J (calc'd exact mass for C23H22N2O3S = 406.14).
The following compounds were prepared according to the method of Example 220:
Figure imgf000139_0002
Example 222
Ethyl 19-aza-19-f(3-methoxyphenyl)methyn-7J4-dioxatetracyclo- ri3.5.2.1<2,6>.0<18.21>1tricosa-l(20).2.4.6(23)J5(22)J6J8(21)-heptaene-20- carboxylate
Figure imgf000139_0001
To a solution of ethyl 5-hydroxy-3-(3-hydroxyphenyl)-l-[(3-methoxyphenyl)- methyl]indole-2-carboxylate (Example 118, 237 mg, 0.57 mmol) in acetone (20 mL) was added potassium carbonate (200 mg, 1.45 mmol) and 1,6-dibromohexane (0.079 mL, 0.52 mmol). The resulting mixture was heated to reflux for 48 h, cooled to RT, concentrated and partitioned between ethyl acetate and water. The organic layer was collected and the aqueous layer was extracted with ethyl acetate. The combined organics were dried over anhydrous magnesium sulfate and concentrated to 25 mg (9%) of an oil. Mass spectroscopy gave MH+ = 500.2 (calc'd exact mass for C31H33NO5 = 499.24); TLF Rf = 0.22 (hexane/ethyl acetate 2: 1). Example 229
5-(Benzyloxy)-3- f4-(cy clopr opylmethoxyiphenyl] -1-
(3-methoxybenzyl)-lH-indole-2-carboxylic acid
Figure imgf000140_0001
1 M Aqueous sodium hydroxide (1 mL) was added to a stirred solution of ethyl 5-
(benzyloxy)-3-[4-(cyclopropylmethoxy)phenyl]-l-(3-methoxybenzyl)-lH-indole-2-carb- oxylate (Example 61, 100 mg, 0J78 mmol) in methanol (1 mL). The reaction was warmed (50 °C) and stirring was continued for 18 h. After cooling the reaction was diluted with water (20 mL) and then the solution was adjusted to pH = 2 using 1 M hydrochloric acid. The product was extracted with ethyl acetate (3x20 mL) and then the combined organic extracts were washed with brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo. Flash chromatography of the residue over silica gel using 50% ethyl acetate hexane gave 38.4 mg (40%) of the desired product as a pure white solid (mp = 185-187 °C). The product had: 1H NMR (300 MHz, CDC13) δ 7.25-7.48 (m, 8 H), 6.89-7J7 (m, 3 H), 6.65-6.78 (m, 2 H), 5.83 (s, 2 H), 5.05 (s, 2 H), 3.84 (d, 2 H), 3.68 (s, 3 H), 1.25-1.35 (m, 1 H), 0.57-0.67 (m, 2 H), 0.31-0.41 (m, 2 H); mass spectroscopy gave MH+ = 534J (calcd exact mass for C3 H31NO5 = 533.22).
Example 230 l-(Cyclopropylmethyl)-3-f(4-methoxyphenyl)methyllindole-2-carboxylic acid
Figure imgf000140_0002
1.0 M Aqueous sodium hydroxide (4 mL), methanol (2 mL), and potassium hydroxide (5 pellets) were added to a stirred solution of Example 42 (181 mg, 0.499 mmol) in tetrahydrofuran (4 mL). The resulting mixture was heated to reflux for 18 h, cooled to RT, and acidified with 1.0 M hydrochloric aced. The resulting mixture was extracted with ethyl acetate and the combined organic extracts were dried over anhydrous magnesium sulfate and concentrated in vacuo to give 122 mg (72%) of a white solid. 1H NMR (300 MHz, OMSO-d6) δ 7.65-7.53 (m, 2H), 7.30-7.23 (m, IH), 7J6-7J 1 (m, 2H), 7.07-7.00 (m, IH), 6.79-6.74 (m, 2H), 4.44 (d, P= 7.0 Hz, 2H), 4.35 (s, 2H), 3.66 (s, 3H), 1.25-1J5 (m, IH), 0.40-0.30 (m, 4H); mass spectroscopy gave MH+ = 336.0 (calcd exact mass for C21H2ιNO3 = 335.15), mp = 162-163°C.
Example 231
3-(Cyclopropylidenemethyl)-l-r3-(trifluoromethyl)benzyl]
-lH-indole-2-carboxyIic acid
Figure imgf000141_0001
The compound was prepared from ethyl 3-(cyclopropylidenemethyl)-l-[3-
(trifluoromethyl)benzyl]-lH-indole-2-carboxylate (Example 182) using the method described in Example 229, except 6N aqueous sodium hydroxide solution was used with tetrahydrofuran as a co-solvent. Flash chromatography of the residue over silica gel using 50% ethyl acetate/hexane gave the title compound (57%) as a pale yellow solid (mp = 148-150 °C). The product had: 1H NMR (300 MHz, acetone-^) δ 11.70 (s, 1 H), 8J6 (d, 1 H), 7.70 (s, 1 H), 7.56-7.46 (m, 4 H), 7.35-7.27 (m, 2 H), 7J9-7J5 (m, 1 H), 5.98 (s, 2 H), 1.58-1.53 (m, 2 H), 1.33-1.28 (m, 2 H); mass spectroscopy gave MH+ = 372J (calcd exact mass for C21H16F3NO2 = 371.11). Example 232 3-(Benzothien-2-yl)-l-f3-(trifluoromethyl)benzyl)-indole-2-carboxylic cid
Figure imgf000142_0001
A mixture of 3 N aq. potassium hydroxide (0.85 mL), Example 62 (100 mg, 0.210 mmol), tefrahydrofuran (0.75 mL) and ethanol (0.75 mL) was refluxed for 2 h. The resulting mixture was diluted with ethyl acetate and acidified with 2 N hydrochloric acid. The organic layer was separated, dried over anhydrous sodium sulfate and concentrated to afford 67 mg (71%) of product as a white solid. Rf = 0.40 (9/1 dichloromethane/methanol); LRMS (+esi) obs'd: 452.0; calcd 451 J, m.p. 243-246°C.
The following compounds were prepared according to the methods of Examples
229, 230, 232 or 232:
Figure imgf000142_0002
Figure imgf000143_0001
Figure imgf000144_0001
Figure imgf000145_0001
Figure imgf000146_0001
Figure imgf000147_0001
Figure imgf000148_0001
Figure imgf000149_0001
Figure imgf000150_0001
Figure imgf000151_0001
Figure imgf000152_0001
Figure imgf000153_0001
Figure imgf000154_0001
Figure imgf000155_0001
Figure imgf000156_0001
Example 305 3-f4-(Cyclopropylmethoxy)phenyl]-l-(3-methoxybenzvI)-lH-indole-2-carboxyIic acid
Figure imgf000157_0001
Ethyl 3-[4-hydroxyphenyl]-l-(3-methoxybenzyl)-lH-indole-2-carboxylate
(Example 121, 21 mg, 0.05 mmol), bromomethylcyclopropane (14 mg, 0J0 mmol), potassium carbonate (21 mg, 0J5 mmol), and potassium iodide (catalytic amount) were heated (90 °C) in DMF (0.8 mL) for 15 hrs. The solvent was then removed under reduced pressure and the residue was dissolved in dichloromethane (2 mL). The mixture was filtered and then preparative thin layer chromatography of the filfrate (ethyl acetate:hexane = 1:3) afforded the desired intermediate (31%).
Ethanol (300 μL) was added to the intermediate (7 mg). A 2 N solution of potassium hydroxide in ethanol/water (1:1, 200 μL) was added and the mixture was heated (60 °C) for 2 hrs. The mixture was cooled to rt and put into an ice bath. 2 N hydrochloric acid (210 μL) was added and a white precipitate formed. The solvent was removed under reduced pressure and the residue was dissolved in 2 L of dichloromethane. The mixture was filtered and then preparative thin layer chromatography of the filtrate (ethyl acetate:methanol = 95:5) gave 4 mg (61%) of desired product. !H NMR (300 MHz, CDC13) δ 6.65-7.60 (m, 12 H), 5.75 (s, 2 H), 3.84 (d, 2 H), 3.68 (s, 3 H), 1.25 (m, 1 H), 0.65 (m, 2 H), 0.40 (m, 2 H); mass spectroscopy (negative ion mode) gave [M-H]" = 426.2 (RT = 4.73, calcd exact mass for C27H25NO4 = 427.18).
The following compounds were prepared according to the method of Example
305:
Figure imgf000158_0001
Figure imgf000159_0001
Figure imgf000160_0001
Figure imgf000161_0001
Example 323
3- [4-(N-cyclopropylcarbamoyl)phenyll -1- f (3-methoxyphenyl) methyllindole-2-carboxyIic acid
Figure imgf000161_0002
To a 25 mL round-bottomed flask at rt was charged with 4-{2-(ethoxycarbonyl)-l- [(3-methoxyphenyl)methyl]indol-3-yl}benzoic acid (Example 98, 270 mg, 0.63 mmol), tetrahydrofuran (2 mL) and one drop of N,N-dimethylformamide. Oxalyl chloride (240 mg, 0J6 mL, 1.89 mmol) was added to the above mixture dropwise. After 1 hour, the reaction mixture was concentrated and re-dissolved in tetrahydrofuran (2 mL) and cyclopropylamine (359 mg, 6.3 mmol) was added. After 10 minutes at rt, aqueous sodium hydroxide (3 Ν) was added to the reaction mixture and enough methanol was added to make the mixture one phase. The resulting solution was refluxed for 1 hour before it was cooled to rt and acidified with hydrochloric acid (IN) and extracted with ethyl acetate (25 mL). The organic layer was washed with water, brine and dried over anydrous sodium sulfate. The solution was concentrated in vacuo to give a white solid which was triturated with diethyl ether to provide 3-[4-(Ν-cyclopropylcarbamoyl)phenyl]-l-[(3- methoxyphenyl)methyl]indole-2-carboxylic acid as a white solid (142 mg, 51%): mp 237 °C; MS (electrospray, MH+) calcd for C27H25N2O4 441, found 441; 1H NMR (DMSO-d6) δ 13J (br s, IH), 8.48 (d, /= 4.0 Hz, IH), 7.88 (d, J = 8.3 Hz, 2H), 7.62 (d, P= 8.4 Hz, IH), 7.50 (d, J= 8.6 Hz, 2H), 7.46 (d, J= 8J Hz, IH), 7.30-7.37 (m, IH), 7J2-7.22 (m, 2H), 6.79 (dd, J= 8.2, 2.5 Hz, IH), 6.69 (dd, IH), 6.62 (d, P= 7.6 Hz, IH), 5.83 (s, 2H), 3.68 (s, 3H), 2.85-2.89 (m, IH), 0.56 - 0.64 (m, 2H), 0.65-0.75 (m, 2H).
The following compounds were prepared according to the method of Example 323.
Figure imgf000162_0001
Figure imgf000163_0001
Example 330 3-f4-(Cvclopropylmethoxy)phenyn-5-ethoxy-l- (3-methoxybenzyl)-lH-indole-2-carboxyIic acid
Figure imgf000164_0001
Water (5 ύL) was added to a cooled (0 °C ) and stirred suspension of potassium t- butoxide (90 mg, 0.80 mmol) in ethyl ether (5 mL). The slurry was stirred for 5 min and then a solution of ethyl 3-[4-(cyclopropylmethoxy)phenyl]-5-ethoxy-l-(3- methoxybenzyl)-lH-indole-2-carboxylate (Example 144, 52 mg, 0J0 mmoL) in ethyl ether (2 + 1 mL rinse) was added. The mixture was warmed to rt and stirred for 16 h. The solution was adjusted to pΗ = 7 with 1 M hydrochloric acid and diluted with ethyl acetate (50 mL). This mixture was washed with water and brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residue was purified by preparative TLC, using 1:1 ethyl acetate/hexane as the eluent, to afford 7.0 mg (14%) of desired product. The product had: 1H NMR (300 MHz, acetone-D6) δ 7.45-7.37 (m, 3 H), 7J8 (t, 1 H), 6.99-6.91 (m, 4 H), 6.77 (dd, 1 H), 6.70 (m, 2 H), 5.85 (d, 2 H), 3.99-3.86 (m, 4 H), 3.69 (s, 3 H), 1.36-1.28 (m, 4 H), 0.63-0.59 (m, 2 H), 0.39-0.37 (m, 2 H); mass spectroscopy gave MH+ = 472.2 (calcd exact mass for C29H29NO5 = 471.20).
The following compounds were prepared according to the method of Example 330:
Figure imgf000165_0001
Figure imgf000166_0002
Example 337 3-(4-Methoxyphenyl)-l-{ f 3-(trifluoromethyl)phenyn sulfonyl! mdole-2-carboxylic acid
Figure imgf000166_0001
tert-Butyl 3 -(4-methoxyphenyl)- 1 - { [3 -(trifluoromethyl)phenyl] sulfonyl } indole-2- carboxylate (Example 27, 45 mg, 0.085 mmol) was dissolved in trifluoroacetic acid (0.4 mL). The resulting mixture was allowed to stir for 5 minutes. The reaction mixture was freated with a saturated aqueous sodium bicarbonate solution and then exfracted with ethyl acetate (3x4 mL). The combined organic extracts were dried over anhydrous magnesium sulfate and concentrated in vacuo to afford 3-(4-methoxyphenyl)-l-{[3- (trifluoromethyl)phenyl] sulfonyl} indole-2-carboxylic acid as an oil (17 mg, 42%): !H (acetone-d6) δ 3.70 (s, 3 H), 6.85-6.89 (m, 2 H), 7.20-7.34 (m, 2 H), 7.47 (dd, .7=0.6, 8J Hz, 1 H), 7.60-7.68 (m, 3 H), 7.83 (br d, 1 H), 8.06 (d, .7=8.2 Hz, 1 H), 8.63 ( , 2 H); mass spectroscopy HPLC ES MS mlz (rel abundance) 476 ((M+H)+, 48%). Example 338
3-(4-Methoχyphenyl)-l- 3-(trifluoromethyl)phenvIlcarbonyl} indole-2-carboxylic Acid
Figure imgf000167_0001
tert-Butyl 3 -(4-methoxyphenyl)- 1 - { [3-(trifluoromethyl)phenyl] carbonyl} indole-2- carboxylate (Example 226, 32 mg, 0.065 mmol) was converted using the method described above for Example 230 afford 3-(4-methoxyphenyl)-l-{[3-(trifluoromethyl)- phenyl]carbonyl}indole-2-carboxylic acid as an oil (2 mg, 7%): 1H NMR (acetone-d6) 3.84 (s, 1 H), 7.04-7.05 (m, 2 H), 7.32-7.33 (m, 1 H), 7.50-7.52 (m, 4 H), 7.84-7.87 (m, 1 H), 7.99-8.06 (m, 1 H), 8J4-8J9 (m, 1 H), 8.42-8.47 (m, 2 H).
Example 339
3-f3-(Cyclopropylmethoxy)phenyl]-l-[(4-fluorophenyl) methyIlindole-2-carboxylic Acid
Figure imgf000167_0002
Formic acid (4 mL) was added dropwise to a stirred solution of tert-Butyl 3-[3-
(cyclopropylmethoxy)phenyl]-l-[(4-fluorophenyl)methyl]indole-2-carboxylate (Example 72, 431 mg, 0.91 mmol) in dichloromethane (1.0 mL). The reaction was stirred at room temperature for 8 h, then concentrated in vacuo. The resulting solids were placed on a pad of silica gel and purified by chromatography (gradient from 30% ethyl acetate/hexane to 100%) ethyl acetate) to afford 3-[3-(cyclopropylmethoxy)phenyl]-l-[(4- fluorophenyl)methyl]indole-2-carboxylic acid (324 mg, 85%): mp = 200-202 °C, 1H NMR (acetone-d6) 0.32-0.37 (m, 2 H), 0.55-0.61 (m, 2 H), 1.21-1.31 (m, 1 H), 3.86 (d, =7.0 Hz, 2 H), 5.90 (s, 2 H), 6.89-6.93 (m, 1 H), 7.00-7.08 (m, 4 H), 7J 1-7J6 (m, 1 H), 7J8- 7.24 (m, 2 H), 7.30-7.36 (m, 2 H), 7.52-7.58 (m, 2 H), 11.28 (br s, 1 H); mass spectroscopy gave MH+ = 416 (60%).
The following compounds were prepared in according to the method of Example
339:
Figure imgf000168_0001
Figure imgf000169_0001
Example 347
5-[(Cvclopropylmethoxy)methyll-3-(4-ethoxyphenyl)-l-
(4-fluorobenzyl)-lH-indole-2-carboxylic acid
Figure imgf000170_0001
Sodium hydride (60% dispersion in mineral oil, 64 mg, 1.60 mmol) was added in portions to a cooled (0 °C) and stirred solution of ethyl 3-(4-ethoxyphenyl)-l-(4- fluorobenzyl)-5-(hydroxymethyl)-lH-indole-2-carboxylate (Example 141, 480 mg, 1.073 mmol) in tetrahydrofuran (10 mL). The mixture was allowed to warm to room temperature over a period of 1 hour. Cyclopropylmethylbromide (216 mg, 1.60 mmol) was added, and the mixture was stirred for 18 hours. The reaction was partitioned between water and ethyl acetate. The aqueous layer was extracted with ethyl acetate (2x). The combined organic extracts were washed with brine, dried over anhydrous magnesium sulfate, and concenfrated in vacuo. The resulting crude oil was purified by flash chromatography on silica gel eluted on a gradient from 100% hexane to 50% ethyl acetate/hexane. The title compound was obtained as a white solid (50 mg, 10%) with a mp = 171-173 °C. The product had: 1H NMR (300 MHz, acetone- tf) δ 7.52 (d, 1 H), 7.48-7.47 (m, 1 H), 7.42-7.38 (m, 2 H), 7.34-7.33 ( , 1 H), 7.22-7J8 (m, 2 H), 7.06-6.98 (m, 4 H), 5.89 (s, 2 H), 4.53 (s, 2 H), 4J0 (q, 2 H), 3.27 (d, 2 H), 1.40 (t, 3 H), 1.13-1.01 (m, 1 H), 0.47-0.42 (m, 2 H), 0.25-0.22 (m, 2 H); mass spectroscopy gave MH+ = 474.2 (calcd exact mass for C29H28FNO4 = 473.20). Example 348
5-r2-(Cyclopropylmethoxy)ethyll-3-(4-ethoxyphenyl)-l-
(4-fluorobenzyl)-lH-indole-2-carboxylic acid
Figure imgf000171_0001
A solution of ethyl 3-(4-ethoxyphenyl)-l-(4-fluorobenzyl)-5-(2-hydroxyethyl)-lH- indole-2-carboxylate (Example 133, 275 mg, 0.596 mmol) in tetrahydrofuran (8 + 2 mL rinse) was added slowly (5 min) to a cooled suspension of sodium hydride (72 mg, 3.0 mmol) in tetrahydrofuran (2 mL). The reaction was stirred for 1 h and then (bromomethyl)cyclopropane (0.29 mmol, 400 mg, 3.0 mmol) was added. The cold bath was removed and the solution was stirred for 18 h. The reaction was quenched by pouring onto ice water (100 mL) and then the solution was adjusted to pΗ = 7 using 1 M hydrochloric acid. The product was extracted with ethyl acetate (3x70 mL) and then the combined organic extracts were washed with brine, dried over anhydrous magnesium sulfate and concenfrated in vacuo. Flash chromatography of the residue over silica gel using 50% ethyl acetate/hexane gave 154 mg (53%) of product. The product had: 1H NMR (300 MHz, acetone-D6) δ 7.32-7.50 (m, 4 H), 7.18-7.30 (m, 3 H), 6.97-7J0 (m, 4 H), 5.87 (s, 2 H), 4.09 (q, 2 H), 3.59 (t, 2 H), 3.22 (d, 2 H), 2.88 (t, 2 H), 1.40 (t, 3 H), 0.85-0J0 (m, 1 H), 0.38-0.48 (m, 2 H), 0J 3-0.23 (m, 2 H); mass spectroscopy gave MH+ = 488.0 (exact mass calcd for C30H30FNO4 = 487.22).
Example 349 l-((lE)-2-Phenylvinyl)-3-(4-methoxyphenyl)indole-2-carboxylate
Figure imgf000172_0001
A 60% suspension of sodium hydride in mineral oil (75 mg, 1.85 mmol) was stirred in DMF (5 mL). To this suspension was added ethyl 3-(4-methoxyphenyl)indole- 2-carboxylate (Example 105, 500 mg, 1.65 mmol). The resulting mixture was stirred for 30 min at RT before (R)-styrene oxide was added. The resulting mixture was then heated to 120°C for 18 h. The reaction was cooled to RT, diluted with water, and washed with ethyl acetate. The aqueous layer was collected, acidified with hydrochloric acid, and the resulting suspended solid collected by filtration to yield 311 mg (51%) of a solid. 1H NMR (300 MHz, DMSO-^) δ 13.00 (s, IH), 8.02 (d, </ = 14.9 Hz, IH), 7.87-7.82 (m, IH), 7.63-7.56 (m, 2H), 1.52-1.36 (m, 6H), 7.36-7.25 (m, 2H), 7.07-7.00 (m, 2H), 6.91 (d, J= 14.9 Hz, IH), 3.8 l (s, 3H).
Example 350 Sodium 3-f4-(cyclopropylsulf anyl)phenyll-l- f 3-(trifluoromethyl)benzyl] -1 H-indole-2-carboxylate
Figure imgf000172_0002
To a slurry of sodium hydride (10.8 mg, 0.428 mmol) in 5 ml tetrahydrofuran, was added a solution of 3-(4-Cyclopropylthiophenyl)-l-{[3-
(trifluoromethyl)phenyl]methyl}indole-2-carb-oxylic acid (Example 77, 100 mg, 0.214 mmol) in tefrahydrofuran (5 mL). The reaction mixture was stirred at rt for 30 min and filtered to give a 210 mg (100%) of product. 1H NMR (DMSO-D6, δ = 2.48): 7.78 (s, IH), 7.46 - 7.61 (m, 6 H), 7.29 - 7.35 (m, 3H), 6.95 - 7.05 (m, 2H), 5.71(s, 2H), 2.47 - 2.49 (m, IH), 1.04 - 1J5 (m, 2H), and 0.58 - 0.63 (m, 2H).
Example 351 Sodium 3-(4-tert-butylphenyl)-5-f2-(cyclopropy-lmethoxy)ethyl1 -l-(3-methoxybenzyl)-lH-indole-2-carboxylate
Figure imgf000173_0001
Sodium hydride (6.8 mg, 0.28 mmol) was added to a cooled (0 °C) and stirred solution of 3-(4-tert-butylphenyl)-5-[2-(cyclopropylmethoxy)ethyl]-l-(3-methoxybenzyl)- lH-indole-2-carboxylic acid (Example 275, 145 mg, 0.283 mmol) in tetrahydrofuran (10 mL). The cold bath was removed and the mixture was stirred 2 h. Concentration in vacuo left 148 mg (98%) of the desired product. The product had: 1H NMR (300 MHz, acetone- D6) δ 7.63 (d, 2 H), 7.47 (s, 1 H), 7.34 (d, 2 H), 7J8 (d, 1 H), 7.09(dd, 1 H), 6.96 (dd, 1 H), 6.91 (s, 1 H), 6.85 (d, 1 H), 6.69 (dd, 1 H), 5.75 (s, 2 H), 3.66 (s, 3 H), 3.56 (t, 2 H), 3.22 (d, 2 H), 2.84 (t, 2 H), 1.32 (s, 9 H), 0.89-1.05 (m, 1 H), 0.35-0.45 (m, 2 H), 0.07- 0J7 (m, 2 H); mass specfroscopy gave M+2HpNa = 512.2 (calcd exact mass for C33H36NNaO4 = 533.25). Example 352
Potassium 3-(4-cyclopropylthiophenyl)-l-{ r3-(trifluoromethyl)- phenyll methyl} indole-2-carboxylate
Figure imgf000174_0001
A solution of 10% potassium hydroxide in methanoLwater (1:9, 30 mL) was added to a stirred solution of ethyl 3-(4-cyclopropylthiophenyl)-l-{[3-(trifluoromethyl)- phenyl]methyl}indole-2-carboxylate (Example 262.5 g, 3 mmol) in tetrahydrofuran (3 mL). The reaction was warmed to 50 °C and stirred 18 h. After cooling, the reaction mixture was filtered to leave 50 mg of potassium 3-(4-cyclopropylthiophenyl)-l-{[3- (trifluoromethyl)-phenyl]-methyl}indole-2-carboxylate. 1H NMR (DMSO-D6) δ 7.80 (s, 1 H), 7.69 - 7.60 (m, 11 H), 5.69 (s, 2 H), 2.27 - 2.31 (m, 1 H), 1.04 - 1J0 (m, 2 H), and 0.58 - 0.63 (m, 2 H).
Example 353
3-r4-(Cyclopropylsulfonyl)phenyl]-l-{r3-(trifluoromethyl)phenyll methyllindole-2-carb-oxylic acid
Figure imgf000174_0002
To a solution of 3-(4-Cyclopropylthiophenyl)-l-{[3-(trifluoro- methyl)phenyl]methyl}indole-2-carb-oxylic acid (Example 262) 100 mg, 0.214 mmol) in 10 mL CHC13, m-CPBA (162 mg, 0.47 mmol) was added at -10 °C. The reaction was stirred for 2 h and then warmed to rt. The reaction was diluted with dichloromethane and washed with water and brine. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo. Flash chromatography of the residue over silica gel using ethyl acetate/hexane gave 70 mg (65%) of product. 1H NMR (DMSO-D6) δ 13.22 (br s, IH), 7.93 (d, J= 8.7 Hz, 2H), 7.14 -7J2 (m, 10 H), 5.94 (s, 2H), 2.89 - 2.93 (m, IH), and 1.06 - 1J6 (m, 4H). MS [M-H] = 498 (HPLC/MS).
Example 354
3-(4-tert-Butylphenyl)-5-f(cyclopropylmethyl)amino]-l-(3-methoxybenzyl)-lH- indole-2-carboxylic acid hydrochloride
Figure imgf000175_0001
Ethyl 3-(4-tert-butylphenyl)-5-[(cyclopropylmethyl)amino]- 1 -(3-methoxybenzyl)- lH-indole-2-carboxylate (Example 165, 420 mg, 0.84 mmol) was reacted using the method described for Example 237. After hydrolysis the solution was adjusted to pΗ=l using 1 M hydrochloric acid. The resulting precipitate was collected by filtration, using ethyl ether to wash, to afford 250 mg, (59%) of product. The product had: !H NMR (300 MHz, CD3OD) δ 7.71 (d, 1 H), 7.39-7.59 (m, 6 H), 7J6 (dd, 1 H), 6.72-6.80 (m, 1 H), 6.61-6.69 (m, 2 H), 5.84 (s, 2 H), 4.36 (s, 2 H), 3.71 (s, 3 H), 2.68-2.80 (m, 1 H), 1.41 (s, 9 H), 1.15- 1.25 (m, 1 H), 0.80-0.96 (m, 4 H); mass spectroscopy gave ME^-HCl = 483.3 (calcd exact mass for C3ιH3 N2O3 = 482.26). Example 355
5-[(Cvclopropylmethyl)amino1-3-(4-ethoxyphenyl)-l-
(4-fluorobenzyl)-lH-indole-2-carboxylic acid hydrochloride
Figure imgf000176_0001
Ethyl 5-[(cyclopropylmethyl)amino]-3-(4-ethoxyphenyl)-l-(4-fluorobenzyl)-lH- indole-2-carboxylate (Example 166, 470 mg, 0.97 mmol) was converted to 430 mg (90%) of product using the method described for Example 238. The product had: 1H NMR (300 MHz, CD3OD) δ 7.70 (d, 1 H), 0.87 (d, 1 H), 7.34-7.44 (m, 3 H), 7.07-7J6 (m, 2 H), 6.92-7.03 (m, 4 H), 5.82 (s, 2 H), 4.35 (s, 2 H), 4.08 (q, 2 H), 2.68-2.77 (m, 1 H), 1.41 (t, 3 H), 1.34-1.43 (m, 1 H), 0.83-0.94 (m, 4 H).
Example 356
(3-(4-Methoxyphenyl)-l-{r3-(trifluoromethyl)phenyllmethyl}indol
-2-yl)-N-(phenylsulfonyl)carboxamide
Figure imgf000176_0002
Benzenesulfonamide (155 mg, 1.0 mmol), l-(3-dimethylaminopropyl)-3-ethyl- carbodiimide hydrochloride (96 mg, 0.50 mmol), and 4-(dimethylamino)pyridine (20 mg, 0J6 mmol) were added to a stirred solution of 3 -(4-methoxyphenyl)- 1- {[3- (trifluoromethyl)phenyl]methyl}indole-2-carboxylic acid (Lit: WO94/14434, 213 mg, 0.50 mmol in dichloromethane (5 mL). The resulting mixture was stirred for 18 h and then quenched with hydrochloric acid ( IN). The mixture was extracted with ethyl acetate (2 x 20 mL) and the combined organic exfracts was washed with brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The residue was purified with silica gel flash chromatography using hexane/ethyl acetate (2/1) as the eluant to give a white solid. It was further purified by trituration with diethyl ether to afford (3-(4- methoxyphenyl)-l-{[3-(trifluoromethyl)phenyl]methyl}indol-2-yl)-N-(phenylsulfonyl) carboxamide as a white solid (220 mg, 78%): mp > 250 °C; MS (electrospray, MH+) calcd for C30H24F3N2O4S 565J, found 565.0; 1H NMR (DMSO-d6) δ 7.51-8.31 (m, 17 H), 7.03 (br s, IH), 6J7 (s, 2H), 4.36 (s, 3H).
The following compounds were prepared according to the method of Example
356:
Figure imgf000177_0001
Example 360 2.2.2-Trifluoro-l-(3-(4-methoχyphenyl)-l-r3-(trifluoromethyl)benzyl]
-lH-indol-2-yl}ethanone
Figure imgf000178_0001
Dess-Martin reagent (39 mg, 0.09 mmol) was added to a stirred solution of 2,2,2- trifluoro-l-(3-(4-methoxyphenyl)-l-{[3-(trifluoromethyl)phenyl]methyl}indol-2-yl)ethan- l-ol (Example 219, 40 mg, 0.08 mmol) in dichloromethane (2 mL). The resulting solution was stirred for 2 hours, more oxidant was added, and then the mixture was left stirring for 18 h. The reaction was quenched with a mixed aqueous solution of saturated sodium bicarbonate and saturated sodium thiosulfate (l.J, 10 mL), and the mixture was extracted with ethyl acetate (2 x 10 mL). The combined organic exfracts were washed with water, and brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo. Silica gel flash chromatography using hexane/ethyl acetate (4/1) as the eluant gave 2,2,2-trifluoro-l- (3-(4-methoxyphenyl)-l-{[3-(trifluoromethyl)phenyl]methyl}indol-2-yl)ethan-l-one as an orange oil (27 mg, 70%): 1H NMR (300 MHz, OMSO-d6) δ 7.76 (d, IH), 7.47-7.62 (m, 4H), 7.20-7.45 (m, 5H), 7.05 (d, 2H), 5.76 (s, 2H); MS (MH+) calcd for C25H18F6NO2: 478., found: 478.
Biological Protocol
The activity of a given compound in binding to PPAR-γ can be assayed routinely according to procedures known in the art. See, e.g., Nichols, et al, Anal. Biochem., 257 (2), (1998), 112-119, 114; Brown, et al, Chem. & Bio.. 4 (12), (1997) 909-918. The PPAR-γ binding assay described below was used to determine the PPAR-γ binding activities of the compounds of the invention. Compounds were tested for their ability to bind to PPARγ using a spin plate assay (gel filtration binding assay). The PPARγ ligand binding domain (LBD) (amino acids 195-475) was expressed in Escherichia coli as polyHis-tagged fusion proteins and purified by means of an epitope tag. The LBD (210 ng per well) was then incubated in 96-well microtiter plates for two hours at room temperature with a constant concentration of radioligand (8nM per well) ([3H]BRL 49653) and four concentrations (1 nM, 10 nM, lOOnM and 1 μM) of test compound. Each compound was tested in triplicate. Fifty- micloliter aliquots of each well were loaded into each well of an equilibrated 96-well gel filtration plate (Edge Biosystems 31909) and placed on top of a pre-labeled Wallac plate (1450-515). The plates were centrifuged (Beckman GS-6R) at 2500 rpm for 5 minutes, 170 μl Scitisafe® scintillation fluid (Fisher) was added to each well, the plates were sealed, and after 1 hour, were counted in a Wallac MicroBeta counter. The amount of nonspecific binding, as assessed by control wells containing 10 μM of the corresponding unlabeled ligand, was subtracted from each data point. For each compound tested, the data was averaged and plots of ligand concentration versus CPM of radioligand bound were constructed. Apparent IC50 values were estimated from nonlinear least-squares fit of the data assuming simple competitive binding.
The compounds of the invention were found to inhibit [3H]BRL 49653 binding at PPAR-γ with an IC50 of 10 μM or less. IC50 ranges of compounds of the present invention in the PPAR-γ Binding Assay are given in the table below.
Activity of Exemplified Compounds
Figure imgf000179_0001
Figure imgf000180_0001
Figure imgf000181_0001
The entire disclosures of all applications, patents and publications cited above are hereby incorporated by reference.
The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing examples are included by way of illustration only. Accordingly, the scope of the invention is limited only by the scope of the appended claims.

Claims

Claims
What is claimed is:
A compound according to the general formula (I)
Figure imgf000183_0001
wherein
R'
is R8-Ry
Rδ is selected from alkyl of 1-7 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, (CH2)tS(=O)2, and (CH2)nC(=O);
is 1-7; n is 0-8;
R is selected from phenyl, cycloalkyl of 3-8 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O,
wherein R may be substituted with alkoxy of 1-8 carbon atoms, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, halogen, alkyl of 1-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or Q-(CH2)nR 110.
is selected from NR33, NH, S and O;
R 10
is selected from cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O;
R 33
is selected from alkyl of 1-8 carbon atoms, alkenyl of 1-8 carbon atoms and alkynyl of 1-8 carbon atoms;
X
is selected from NR33, NH, O, and S;
Rz
is selected from hydrogen, alkyl of 1-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, and (CH2)nS(=O)2RU;
R11 is selected from aryl of 5-14 carbon atoms and heteroaryl of 3-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, with the proviso that
R is not isoxazole, wherein R may be substituted with alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, alkoxy of
1-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or halogen;
R
is selected from:
(a) R -R > wherein
R12 is selected from alkyl of 1-7 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, and C(=O), and
R 13
is selected from cycloalkyl of 3-7 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O,
13 wherein R may be substituted with alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, alkoxy of 1-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or halogen; or
(b) cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, all of which may be substituted with alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, heterocycloalkenyl of 3-8 carbon atoms and 1- 2 heteroatoms selected from N, S and O, aryl of 5-14 carbon atoms and heteroaryl of 4-8 carbon atoms and 1- 2 heteroatoms selected from N, S and O, or may be spiro fused with cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, heterocycloalkenyl of 3-8 carbon atoms and 1- 2 heteroatoms selected from N, S and O, aryl of 5-14 carbon atoms and heteroaryl of 4-8 carbon atoms and 1- 2 heteroatoms selected from N, S and O; or (c) aryl of 5-14 carbon atoms or heteroaryl of 3-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, which are substituted with 1-3 of the following: (i) Si(CH3)3;
(ii) cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, with the proviso that said heterocycloalkenyl is not imidazole; (iii) S(=O)2R14 wherein R14 is selected from cycloalkyl of 3-7 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, aryl of 5- 14 carbon atoms and heteroaryl of4-ll carbon atoms and 1-2 heteroatoms selected from N, S and O; (iv) R 5, which combines with R to form a radical of the formula -Y-(CH2)t-Y-,
33 wherein Y is selected from NR > NH, S and O; (v) C(=O)R16 3
- wherein R is selected from alkyl of 1-8 carbon atoms, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and Z-R17>
- wherein Z is selected from (CH2)n, NH, NR33, O and S,
- wherein R is selected from cycloalkyl of 3- 9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, aryl of 5-14 carbon atoms and heteroaryl of 3-11 carbon atoms and 1-2 heteroatoms selected from N, S and O;
(vi) Z-R18-R19, wherein:
ι o
R is selected from alkyl of 1-8 carbon atoms, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, aryl of 5-14 carbon atoms, heteroaryl of 3-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, and (CH2)nC(=O), and R is selected from hydrogen, halogen, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, R20-R21 and Z-R21, and - Z is as defined above, and
20
- R is selected from aryl of 5-14 carbon atoms and heteroaryl of 3-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, and
21
- R is selected from hydrogen, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, aryl of 5-14 carbon atoms and heteroaryl of 3-11 carbon atoms and 1-2 heteroatoms selected from N, S and O; with the proviso that when R is furyl, benzofuranyl, benzothienyl, benzoxazolidinyl, benzoxazolyl, benzothiazolydinyl, benzothiazolyl, benzoisothiazolyl, benzopyrazolyl, benzoimidazolyl, benzoimidazolidinyl, benzoisooxazolyl, or benzoxadiazolyl R may be unsubstituted, and
with the further proviso that, (1) when R is aryl or heteroaryl, Z is O or (CH2)n, R18 is (CH2)nC(=O), alkyl, aryl or heteroaryl,
19 3 and R is hydrogen, halogen, haloalkyl or alkyl, or (2) when R is phenyl or napthyl and R is alkyl, one of the following applies:
5 23
R is other than hydrogen and R is other than alkyl or alkenyl, X is NH and R2 is (CH2)nS(=O)2 RU>
R8 is (CH2)nC(=O), (CH2)tS(=O)2, alkenyl or alkynyl,
Q 10
R is substituted with Q(CH2)nR » η
R is other than hydrogen, or R is other than hydrogen; and
(d) furyl, benzofuranyl, benzothienyl, benzoxazolidinyl, benzoxazolyl, benzothiazolydinyl, benzothiazolyl, benzoisothiazolyl, benzopyrazolyl, benzoimidazolyl, benzoimidazolidinyl, benzoisooxazolyl, or benzoxadiazolyl, which may be substituted with alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, alkoxy of 1-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or halogen; or
R*
is selected from hydrogen and E-R -R , wherein
E is selected from NR33' NH, S and O;
R34 is selected from alkyl of 1-8 carbon atoms, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O;
R35 is selected from hydrogen, halogen, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O; and
33
R has the meanings given above;
R5
(1) is selected from:
(a) hydrogen;
( ) (CH2)qCOOH where q is 1-4
(c) C(=O)R22>
00 wherein R is selected from alkyl of 1-8 carbon atoms, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, aryl of 5-14 carbon atoms and heteroaryl of 3-11 carbon atoms and 1-2 heteroatoms selected from N, S and O;
(d) cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, and heterocycloalkenyl of 3- 8 carbon atoms and 1-2 heteroatoms selected fromN, S and O;
(e) -(CH2)n-D-R23> wherein:
(i) D is selected from NR33> NH, S and O, and
(ii) R is selected from alkyl of 1-8 carbon atoms, alkenyl of 2- 8 carbon atoms, alkynyl of 2-8 carbon atoms, C(=O)R24, and
(CH2)mR , 244, wherein - m is 0-4, with the proviso that when R3 is phenyl or napthyl, Z is O, R18 is alkyl and R19 is hydrogen, halogen, haloalkyl or alkyl, m is 1-4,
- R24 is selected from cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, C(=O)OH, NHR27"R28, NR27"R28, (CH2)nOR27'R28, NH- R29"R30and R29-R30,
- R27 is alkyl of 1-8 carbon atoms,
- R is selected from hydrogen, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, aryl of 5-14 carbon atoms and heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O,
R29 is selected from cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, aryl of 5-14 carbon atoms, and heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, and
- R30 is selected from hydrogen, halogen, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, alkoxy of 1- 8 carbon atoms, aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, and C(=O)OH, or
(2) R combines with R to form a radical of formula -Y-(CH2)t-Y-,
wherein Y is as defined above;
Rυ
is selected from hydrogen, OH, and T-R18-R19'
wherein T is selected from NR33, NH, S and O and R18> R19 and R33 are as defined above;
R7
is selected from hydrogen, C( =O)R22> (CH2)n-D-R23> and R -R32>
22 23 wherein D, R and R are as defined above, and
R 31
is selected from alkyl of 1-7 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, and C(=O), and
R32
is selected from aryl of 5-14 carbon atoms, heteroaryl of 3-1 1 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O,
wherein R may be substituted with alkyl of 1-7 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, alkoxy of 1-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or halogen;
and pharmaceutically acceptable salts thereof.
2. The compound of claim 1, wherein one of R > R > R and R7 is hydrogen, and pharmaceutically acceptable salts thereof.
4 7
3. The compound of claim 2, wherein R and R are hydrogen, and pharmaceutically acceptable salts thereof.
4. The compound of claim 3, wherein
R .5J
is selected from (CH2)qCOOH, C(=O)R22, (CH2)nD-R23, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloakenyl of 3-9 carbon atoms and 1-2 heteroatoms selected from N, S and O, or R combines with R or R to form a radical of the formula -Y- (CH2)rY-;
R6
is selected from OH, T-R -R or combines with R to form a radical of the formula -Y-(CH2)t-Y-;
and pharmaceutically acceptable salts thereof.
5. The compound of claim 4, wherein R combines with R to form a radical of the formula -Y-(CH2)t-Y-; and pharmaceutically acceptable salts thereof.
6. The compound of claim 5:
Figure imgf000195_0001
and pharmaceutically acceptable salts thereof.
The compound of claim 4, wherein R combines with R to form a radical of the formula -Y-(CH2)t-Y-; and pharmaceutically acceptable salts thereof.
The compound of claim 7:
Figure imgf000195_0002
and pharmaceutically acceptable salts thereof.
The compound of claim 4, wherein
R>
is selected from (CH2)qCOOH, C(=O)R22, (CH2)nD-R23, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, and heterocycloakenyl of 3-9 carbon atoms and 1-2 heteroatoms selected from N, S and O; and 6
R
is selected from OH and T-R18-R19;
and pharmaceutically acceptable salts thereof.
10. The compound of claim 3, wherein R is hydrogen; and pharmaceutically acceptable salts thereof.
11. The compound of claim 10, wherein R is selected from OH and T-R -R .
12. The compound of claim 11 :
Figure imgf000196_0001
and pharmaceutically acceptable salts thereof.
13. The compound of claim 3, wherein R is hydrogen; and pharmaceutically
acceptable salts thereof.
14. The compound of claim 13 , wherein
R5
ii - 23 is selected from (CH2)qCOOH, C(=0)R , (CH2)„D-R , cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, and heterocycloakenyl of 3-9 carbon atoms and 1-2 heteroatoms selected from N, S and O; and pharmaceutically acceptable salts thereof.
15. The compound of claim 14, wherein R is selected from (CH2)nD-R , cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, and heterocycloakenyl of 3-9 carbon atoms and 1-2 heteroatoms selected from N, S and O; and pharmaceutically acceptable salts thereof.
16. The compound of claim 15, wherein
D is selected from O, NR 3"3 and NH;
n is 0-2;
R ,2"3 i •s selected from alkyl, alkenyl, C(=O)R 2^4 and (CH2)mR .24.
R is selected from cycloalkyl of 3-9 carbon atoms, COOH, NR /-R28, NH-R27-
R28, C(=O)R29-R30 and O-R2PR28;
and pharmaceutically acceptable salts thereof.
17. The compound of claim 16 selected from:
Figure imgf000197_0001
Figure imgf000198_0001
Figure imgf000199_0001
Figure imgf000199_0002
Figure imgf000200_0001
Figure imgf000200_0002
199
Figure imgf000201_0001
Figure imgf000202_0001
and pharmaceutically acceptable salts thereof.
18. The compound of claim 2, wherein R > R and R are hydrogen; and pharmaceutically acceptable salts thereof.
19. The compound of claim 18, wherein R is E-R -R ; and pharmaceutically acceptable salts thereof.
20. The compound of claim 19, wherein E is O, R is alkyl and R is cylcoalkyl; and pharmaceutically acceptable salts thereof.
21. The compound of claim 20 :
Figure imgf000203_0001
and pharmaceutically acceptable salts thereof.
22. The compound of claim 2, wherein
Figure imgf000203_0002
are hydrogen; and pharmaceutically acceptable salts thereof.
1 1 3
23. The compound of claim 22, wherein R is selected from C(=O)R "» (CH2)nD-R >
31 32 and R "R and pharmaceutically acceptable salts thereof.
24. The compound of claim 23, wherein
D is selected from O, NH and NR33;
n is 0-2;
R23 is selected from alkyl of 1-8 carbon atoms, C(=O)R24> and (CH2)mR24; R24 is selected from C(=O)R29-R30> NHR29-R30 and NR27-R28;
and pharmaceutically acceptable salts thereof.
25. The compound of claim 24 selected from:
Figure imgf000204_0001
and pharmaceutically acceptable salts thereof.
26. The compound of claim 2, wherein all of R > R > R and R are hydrogen; and pharmaceutically acceptable salts thereof.
27. The compound of claim 26, wherein
R8
is selected from alkyl, alkenyl and (CH2)nC(=O);
Ry
is selected from phenyl and cylcoalkyl;
X
is selected from O, NH and NR 33.
R
is selected from H and (CH2)nS(=O)2Rπ;
R>
is selected from
(a) R12-R13,
(b) heterocycloalkyl or heterocycloalkenyl,
(c) aryl or heteroaryl, and
(d) furyl, benzofuranyl, benzothienyl, benzoxazolidinyl, benzoxazolyl, benzothiazolydinyl, benzothiazolyl, benzoisothiazolyl, benzopyrazolyl, benzoimidazolyl, benzoimidazolidinyl, benzoisooxazolyl, or benzoxadiazolyl, which may be substituted with alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2- 8 carbon atoms, alkoxy of 1-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or halogen;
and pharmaceutically acceptable salts thereof.
28. The compound of claim 27, wherein
R12
is selected from alkyl, alkenyl and C(=O);
R13
is selected from cycloalkyl, heterocylcoalkyl and heterocycloakenyl;
R3
is selected from:
(a) phenyl and furyl, benzofuranyl, benzothienyl, benzoxazolidinyl, benzoxazolyl, benzothiazolydinyl, benzothiazolyl, benzoisothiazolyl, benzopyrazolyl, benzoimidazolyl, benzoimidazolidinyl, benzoisooxazolyl, or benzoxadiazolyl, which may be substituted with:
(i) C(=O)R16, wherein R16 is selected from alkyl and QR17, Q is selected from O, NH and NR33, and R17 is cycloalkyl,
(ii) Z-R18-R19, wherein Z is selected from O, NH, NR33, S and
(CH2)n, R is selected from C(=O), alkyl, cycloalkyl and heterocycloalkyl, R is selected from hydrogen, cycloalkyl,
91 90 91 heterocycloalkyl, Q-R and R -R , Q is selected from O,
33 20
NH and NR , R is selected from aryl and heteroaryl, and
21
R is selected from hydrogen, heterocycloalkyl and cycloalkyl;
(iii) cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl;
(b) furyl, benzofuranyl, benzothienyl, benzoxazolidinyl, benzoxazolyl, benzothiazolydinyl, benzothiazolyl, benzoisothiazolyl, benzopyrazolyl, benzoimidazolyl, benzoimidazolidinyl, benzoisooxazolyl, or benzoxadiazolyl, which may be substituted with alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, alkoxy of 1-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or halogen; and
(c) cycloalkyl and heterocycloalkenyl;
and pharmaceutically acceptable salts thereof.
29. The compound of claim 28, wherein R , 112Z is C(=O); and pharmaceutically acceptable salts thereof.
30. The compound of claim 29, selected from:
Figure imgf000207_0001
and pharmaceutically acceptable salts thereof.
31. The compound of claim 28, wherein R , 12 i •s selected from alkyl and alkenyl; and pharmaceutically acceptable salts thereof.
32. The compound of claim 31 , selected from:
Figure imgf000208_0001
and pharmaceutically acceptable salts thereof.
33. The compound of claim 28, wherein R is selected from furyl, benzofuranyl, benzothienyl, benzoxazolidinyl, benzoxazolyl, benzothiazolydinyl, benzothiazolyl, benzoisothiazolyl, benzopyrazolyl, benzoimidazolyl, benzoimidazolidinyl, benzoisooxazolyl, or benzoxadiazolyl, which may be substituted with alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, alkoxy of 1-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or halogen; and pharmaceutically acceptable salts thereof.
34. The compound of claim 33, selected from:
Figure imgf000209_0001
Figure imgf000210_0001
and pharmaceutically acceptable salts thereof.
35. The compound of claim 28, wherein R is phenyl; and pharmaceutically acceptable salts thereof.
36. The compound of claim 35, wherein R is (CH2)nC(=O); and pharmaceutically acceptable salts thereof.
37. The compound of claim 36, selected from:
Figure imgf000210_0002
and pharmaceutically acceptable salts thereof
38. The compound of claim 35, wherein
R is selected from alkyl and alkenyl;
X is selected NH and NR 3J3.
R2 is (CH2)nS(=O)2RU; and
pharmaceutically acceptable salts thereof.
39. The compound of claim 38 selected from:
Figure imgf000211_0001
and pharmaceutically acceptable salts thereof.
40. The compound of claim 35, wherein R is selected from alkyl or alkenyl;
X is O;
R is hydrogen;
R3 is phenyl substituted with C(=O)R16;
and pharmaceutically acceptable salts thereof.
41. The compound of claim 40, selected from:
Figure imgf000212_0001
Figure imgf000213_0001
and pharmaceutically acceptable salts thereof.
42. The compound of claim 35, wherein
R is selected from alkyl and alkenyl;
X is O;
R is hydrogen;
R ,3 is phenyl substituted with cycloalkyl, heterocycloalkyl, cycloalkenyl or heterocycloakenyl;
and pharmaceutically acceptable salts thereof.
43. The compound of claim 42, selected from:
Figure imgf000214_0001
and pharmaceutically acceptable salts thereof.
44. The compound of claim 35, wherein
R is selected from alkyl and alkenyl;
X is O;
R is hydrogen;
R3 is phenyl substituted with Z-R18-R19;
and pharmaceutically acceptable salts thereof.
45. The compound of claim 44, selected from:
Figure imgf000215_0001
214
Figure imgf000216_0001
215
Figure imgf000217_0001
216
Figure imgf000218_0001
and pharmaceutically acceptable salts thereof.
46. Pharmaceutical compositions comprising a compound according to claim 1, 2, 3, 4, 9, 10, 11, 13, 14, 18, 19, 22, 23, 26, 27, 28, 29, 31, 33, 35, 38, 40, 42, or 44 and a pharmaceutically acceptable carrier.
47. A method of treating or preventing a PPAR-γ mediated disease or condition, comprising administering to a mammal a compound according to formula Ila
Figure imgf000219_0001
wherein
R1
(1) is selected from hydrogen and R8-R9, or n
(2) combines with R to form a radical of the formula
Figure imgf000219_0002
R* is selected from alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, (CH2)nS(=O)2 and (CH2)nC(=O);
Ry is selected from aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O; wherein R9 may be substitituted with alkoxy of 1-8 carbon atoms, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, halogen, alkyl of 1-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or X- (CH2)nCH3R10, Rιo
is selected from cycloalkyl of 3-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkenyl of 5-9 carbon atoms, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O;
X and X' are each independently selected from NH, NR33, (CH2)n, O and S; n is a number from 0-8;
R33
is selected from alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms and alkynyl of 2-8 carbon atoms;
R 2
is selected from hydrogen, alkyl of 1-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, NHS(=O)2Rπ, and (CH2)nS(=O)2Rπ;
R 11
is selected from aryl of 5-14 carbon atoms and heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, wherein R11 may be substituted with alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, alkoxy of 1-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, alkoxy of 1-8 carbon atoms, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or halogen;
R3 is selected from:
(a) hydrogen,
(b) R12-R13, wherein
R12
is selected from alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, and (CH2)nC(=O),
R13
is selected from aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, wherein R may be substituted with alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, alkoxy of 1-8 carbon atoms, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or halogen;
(c) cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, all of which maybe:
(i) substituted with aryl of 5-14 carbon atoms, heteroaryl of 4- 11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and C(=O)(CH2)nCH3, or
(ii) fused with a spiro ring of 1 -6 carbon atoms, or
(iii) fused with an aryl of 5-14 carbon atoms or a heteroaryl of 4- 11 carbon atoms and 1-2 heteroatoms selected from N, S and O, either of which may be substituted with alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, alkoxy of 1-8 carbon atoms, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, or halogen;
(d) aryl of 5-14 carbon atoms or heteroaryl of 4-11 carbon atoms and 1- 2 heteroatoms selected from N, S and O, either of which may be substituted with:
(i) -Si(CH3)3;
(ii) S(=O)2R14, wherein R14 is selected from aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O,
(iii) R15, which combines with R5 to form a radical of the formula -Y-(CH2)n-Y-, wherein Y and n are as defined above;
(iv) C(=O)R16,
- wherein R16 is selected from alkyl of 1-8 carbon atoms and X-R17 wherein R17 is selected from aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and
- wherein X is as defined above; (v) X-R18-R19
- R18 is selected from alkyl of 1-8 carbon atoms, aryl of 5- 14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1- 2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O,
- R19 is selected from hydrogen, halogen, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, R20-R21 and X- R21,
- X is as defined above, - R20 is aryl of 5-14 carbon atoms or heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, and
R21 is selected from aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O,
R4 is selected from hydrogen and X-R18-R19, wherein X, R18 and R19 have the meanings given above;
RD
(1) is selected from:
(a) hydrogen;
(b) R12-R13, wherein R12 and R13 are as defined above,
(c) C(=O)R22, wherein
99
R is selected from alkyl of 1-8 carbon atoms, aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O,
(d) alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected
Figure imgf000225_0001
(e) -(CH2)n-Y-R23, wherein:
(i) Y and n are as defined above,
(ii) R23 is selected from alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, C(=O)R24, (CH2)nR24, and R25-R26, wherein
- R25 is alkyl of 1-8 carbon atoms,
R26 is selected from aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O,
R24 is selected from cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3- 8 carbon atoms and 1-2 heteroatoms selected from N, S and O, heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, . S and O, C(=O)OH, NHR27-R28, NR27-R28, NR33R27-R28, (CH2)nR27-R28, and R29-R30,
- R27 is alkyl of 1 -8 carbon atoms,
- R28 is selected from hydrogen, aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, all of which, with the exception of hydrogen, may be fused with aryl of 5- 14 carbon atoms or heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected N, S and O,
R29 is selected from aryl of 5-14 carbon atoms, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, cycloalkyl of 3-9 carbon atoms, cycloalkenyl of 5-9 carbon atoms, heterocycloalkyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and heterocycloalkenyl of 3-8 carbon atoms and 1-2 heteroatoms selected from N, S and O, and
R30 is selected from hydrogen, halogen, haloalkyl of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, alkoxy of 1- 8 carbon atoms, haloalkoxy of 1-8 carbon atoms and a number of halogen atoms up to the perhalo level, aryl of 5-14 carbon atoms and heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O;
(2) combines with R6 to form a radical of the formula -Y-(CH2)n-Y-, wherein Y and n have the meanings given above;
R° is selected from hydrogen, OH and X-R18-R19, wherein X, R18 and R19 have the meanings give above R7 is selected from hydrogen, C(=O)R22, (CH2)„-Y-R23, and R12-R13, wherein R22, R23, R12, R13, Y and n have the meanings give above; and pharmaceutically acceptable salts thereof.
48. A method of treating or preventing a PPAR-γ mediated disease or condition, comprising administering to a mammal a compound according to claim 1, 2, 3, 4, 9, 10, 11, 13, 14, 18, 19, 22, 23, 26, 27, 28, 29, 31, 33, 35, 38, 40, 42, or 44.
49. The method of claim 47 or 48, wherein said PPAR-γ mediated disease or condition is osteoporosis or osteopenia.
50. The method of claim 47 or 48, wherein said PPAR-γ mediated disease or condition is a PPAR-γ mediated cancer.
51. The method of claim 50, wherein said PPAR-γ mediated cancer is selected from breast, prostate, lung, liposacrcoma and colon cancer.
52. The method of claim 47 or 48, wherein said PPAR-γ mediated disease or condition is selected from hyperglycemia, type 1 diabetes, type 2 diabetes, syndrome X and insulin resistance.
53. The method of claim 47 or 48, wherein said PPAR-γ mediated disease or condition is selected from dyslipidemia, hypertriglyceridemia, diabetic dyslipidemia, hyperhpidemia, and hypercholesteremia.
54. The method of claim 47 or 48, wherein said PPAR-γ mediated disease or condition is an inflammatory condition.
55. The method of claim 54, wherein said inflammatory condition is selected from atherosclerosis, inflammatory bowel disease, Alzheimer's disease and rheumatoid arthritis.
56. The method of claim 47 or 48, wherein said PPAR-γ mediated disease or condition is hypertension.
57. The method of claim 47 or 48, wherein said PPAR-γ mediated disease or condition is obesity.
58. The method of claim 47 or 48, wherein said PPAR-γ mediated disease or condition is a skin disorder.
59. The method of claim 58, wherein said skin disorder is selected from acne, psoriasis, dermatitis, eczema, and keratosis.
60. The method of claim 47 or 48, wherein said PPAR-γ mediated disease or condition is lupus erythematosus.
PCT/US2001/042644 2000-10-10 2001-10-09 SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-η BINDING AGENTS WO2002030895A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2002211901A AU2002211901A1 (en) 2000-10-10 2001-10-09 Substituted indoles, pharmaceutical compositions containing such indoles and their use as PPAR-gamma binding agents
KR10-2003-7005093A KR20030036917A (en) 2000-10-10 2001-10-09 SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-γBINDING AGENTS
HU0302477A HUP0302477A2 (en) 2000-10-10 2001-10-09 Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-gamma binding agents
CA002427499A CA2427499A1 (en) 2000-10-10 2001-10-09 Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-.gamma. binding agents
IL15498101A IL154981A0 (en) 2000-10-10 2001-10-09 Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppay-y-binding agents
EP01979996A EP1341761A1 (en) 2000-10-10 2001-10-09 SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-$g(g) BINDING AGENTS
JP2002534281A JP2004529855A (en) 2000-10-10 2001-10-09 Substituted indoles, pharmaceutical compositions containing such substituted indoles and their use as PPAR-γ binders
MXPA03003174A MXPA03003174A (en) 2000-10-10 2001-10-09 SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-ggr; BINDING AGENTS.
NO20031619A NO20031619L (en) 2000-10-10 2003-04-09 Substituted indoles, pharmaceutical compositions containing such indoles and their use as PPAR gamma binding agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23919500P 2000-10-10 2000-10-10
US60/239,195 2000-10-10
US24366500P 2000-10-27 2000-10-27
US60/243,665 2000-10-27

Publications (1)

Publication Number Publication Date
WO2002030895A1 true WO2002030895A1 (en) 2002-04-18

Family

ID=26932362

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/042644 WO2002030895A1 (en) 2000-10-10 2001-10-09 SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-η BINDING AGENTS

Country Status (14)

Country Link
US (1) US6787651B2 (en)
EP (1) EP1341761A1 (en)
JP (1) JP2004529855A (en)
KR (1) KR20030036917A (en)
CN (1) CN1505613A (en)
AR (1) AR035348A1 (en)
AU (1) AU2002211901A1 (en)
CA (1) CA2427499A1 (en)
HU (1) HUP0302477A2 (en)
IL (1) IL154981A0 (en)
MX (1) MXPA03003174A (en)
NO (1) NO20031619L (en)
PL (1) PL366068A1 (en)
WO (1) WO2002030895A1 (en)

Cited By (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1284728A1 (en) * 1999-10-22 2003-02-26 Merck & Co., Inc. Pharmaceuticals for treating obesity
WO2004063190A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Fused heterocyclic derivates as ppar modulators
WO2004075891A1 (en) * 2003-02-27 2004-09-10 Aventis Pharma Deutschland Gmbh 1,3-substituted cycloalkyl derivatives containing acidic, mainly heterocyclic groups, corresponding production method and use of said derivatives as medicaments
WO2004092130A2 (en) * 2003-04-07 2004-10-28 Kalypsys, Inc. N-containing heteroaromatic compounds as modulators of ppars and methods of treating metabolic disorders
WO2005005423A1 (en) * 2003-07-02 2005-01-20 F. Hoffmann-La Roche Ag Indolyl derivatives substituted with a thiazole ring and their use as ppar modulators
EP1546142A2 (en) * 2002-08-29 2005-06-29 Merck & Co., Inc. Indoles having anti-diabetic activity
US7056943B2 (en) 2002-12-10 2006-06-06 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
FR2879194A1 (en) * 2004-12-14 2006-06-16 Galderma Res & Dev New biaromatic compounds are peroxisome proliferator-activated receptor modulators, useful as medication to control and/or restore metabolism of cutaneous lipids and in the treatment e.g. dermatological affections
US7074817B2 (en) 2001-06-20 2006-07-11 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7078429B2 (en) 2002-12-10 2006-07-18 Wyeth Substituted 3-carbonyl-1H-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
WO2006074789A1 (en) * 2005-01-14 2006-07-20 Merck Patent Gmbh 1h-indole-3-carboxylic acid derivatives and their use as ppar agonists
US7101903B2 (en) 2002-12-10 2006-09-05 Wyeth Substituted dihydropyrano indole-3,4-dione derivatives as inhibitiors of plasminogen activator inhibitor-1 (PAI-1)
EP1740531A1 (en) * 2004-04-13 2007-01-10 Korea Research Institute of Chemical Technology Indene derivatives and process for the preparation thereof
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7186746B2 (en) 2002-08-29 2007-03-06 Merck & Co., Inc. Indoles having anti-diabetic activity
JP2007506783A (en) * 2003-09-25 2007-03-22 ワイス Substituted indoleic acid derivatives and their use as PAI-1 inhibitors
JP2007511530A (en) * 2003-11-13 2007-05-10 アボット・ラボラトリーズ N-acylsulfonamide-based apoptosis promoter
WO2007068621A1 (en) 2005-12-15 2007-06-21 F. Hoffmann-La Roche Ag Novel fused pyrrole derivatives
US7259182B2 (en) 2002-12-10 2007-08-21 Wyeth Aryl, aryloxy, and aklyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
WO2008028118A1 (en) * 2006-08-31 2008-03-06 Smithkline Beecham Corporaiton 1h-indole-2-carboxylic acid derivatives useful as ppar modulators
US7348351B2 (en) 2002-12-10 2008-03-25 Wyeth Substituted 3-alkyl and 3-arylalkyl 1H-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7351730B2 (en) 2001-06-20 2008-04-01 Wyeth Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
WO2008131000A2 (en) * 2007-04-16 2008-10-30 Abbott Laboratories 7-substituted indole mcl-1 inhibitors
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7449478B2 (en) 2003-12-04 2008-11-11 National Health Research Institutes Indole compounds
WO2008136815A2 (en) * 2006-12-22 2008-11-13 Schering Corporation 5, 6-ring annulated indole derivatives and use thereof
WO2009047240A1 (en) * 2007-10-09 2009-04-16 Smithkline Beecham Corporation Indole derivatives useful as ppar activators
WO2009147121A1 (en) * 2008-06-02 2009-12-10 Smithkline Beecham Corporation Carboxyl substituted indoles for use as ppar alpha modulators
US7683091B2 (en) 2005-08-17 2010-03-23 Wyeth Substituted indoles and methods of their use
US20100098661A1 (en) * 2006-12-22 2010-04-22 Schering Corporation 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
US7705023B2 (en) 2004-06-18 2010-04-27 Biolipox Ab Indoles useful in the treatment of inflammation
US7754747B2 (en) 2004-08-23 2010-07-13 Wyeth Llc Oxazolo-naphthyl acids
US7803835B2 (en) 2003-09-25 2010-09-28 Wyeth Llc Substituted acetic acid derivatives
US7855225B2 (en) 2006-03-02 2010-12-21 Astellas Pharma Inc. 17βHSD type 5 inhibitor
US20110263599A1 (en) * 2007-04-16 2011-10-27 Abbott Laboratories 7-nonsubstituted indole mcl-1 inhibitors
US8097623B2 (en) 2005-01-19 2012-01-17 Biolipox Ab Indoles useful in the treatment of inflammation
US8143305B2 (en) 2007-08-29 2012-03-27 Schering Corporation 2,3-substituted indole derivatives for treating viral infections
US8377928B2 (en) 2007-11-16 2013-02-19 Merck Sharp & Dohme Corp. 3-aminosulfonyl substituted indole derivatives and methods of use thereof
US8404845B2 (en) 2007-08-29 2013-03-26 Merck Sharp & Dohme Corp. 2,3-substituted azaindole derivatives for treating viral infections
US8546420B2 (en) 2006-12-22 2013-10-01 Merck Sharp & Dohme Corp. 4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
US8614229B2 (en) 2007-08-29 2013-12-24 Merck Sharp & Dohme Corp. Substituted indole derivatives and methods of use thereof
EP2730558A1 (en) 2012-11-08 2014-05-14 Ikerchem, S.L. Indole derivatives, pharmaceutical compositions containing such indoles and their use as DNA methylation modulators
US8765757B2 (en) 2007-11-16 2014-07-01 Merck Sharp & Dohme Corp. 3-heterocyclic substituted indole derivatives and methods of use thereof
US8901139B2 (en) 2008-06-13 2014-12-02 Merck Sharp & Dohme Corp. Tricyclic indole derivatives and methods of use thereof
WO2014198844A1 (en) * 2013-06-12 2014-12-18 Lytix Biopharma As Protein kinase inhibitors
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
WO2014198848A3 (en) * 2013-06-12 2015-06-04 Lytix Biopharma As Compounds
US9579335B2 (en) 2010-10-19 2017-02-28 Indiana University Research And Technology Corporation Treatment of cystic diseases
WO2018021762A1 (en) * 2016-07-26 2018-02-01 현대약품 주식회사 Novel compound, preparation method therefor, and pharmaceutical composition containing same
EP3203840A4 (en) * 2014-10-06 2018-08-15 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US10570115B2 (en) 2016-09-30 2020-02-25 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
US10738030B2 (en) 2016-03-31 2020-08-11 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US10793547B2 (en) 2016-12-09 2020-10-06 Vertex Pharmaceuticals Incorporated Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US10927106B2 (en) 2016-10-12 2021-02-23 Pharmasum Therapeutics As Benzothiazole derivatives as DYRK1 inhibitors
US11179367B2 (en) 2018-02-05 2021-11-23 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for treating cystic fibrosis
US11253509B2 (en) 2017-06-08 2022-02-22 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
JP2022062093A (en) * 2017-09-14 2022-04-19 アッヴィ・グローバル・エンタープライザズ・リミテッド Modulator of cystic fibrosis transmembrane conductance controlling factor protein and its usage
US11339144B2 (en) * 2017-04-10 2022-05-24 Navitor Pharmaceuticals, Inc. Heteroaryl Rheb inhibitors and uses thereof
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US11434201B2 (en) 2017-08-02 2022-09-06 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
US11465985B2 (en) 2017-12-08 2022-10-11 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
US11517564B2 (en) 2017-07-17 2022-12-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
RU2734876C9 (en) * 2014-10-06 2024-02-28 Вертекс Фармасьютикалз Инкорпорейтед Modulators of transmembrane conductance regulator in cystic fibrosis

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632955B2 (en) * 2001-12-13 2009-12-15 National Health Research Institutes Indole compounds
US7528165B2 (en) * 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
SE0302035D0 (en) * 2003-07-09 2003-07-09 Biolipox Ab New compound
ES2321422T3 (en) * 2004-06-18 2009-06-05 Biolipox Ab USEFUL INDOLES FOR THE TREATMENT OF INFLAMMATION.
CA2570365A1 (en) * 2004-06-18 2005-12-29 Biolipox Ab Indoles useful in the treatment of inflammation
US7456289B2 (en) * 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
JP2008527030A (en) * 2005-01-19 2008-07-24 バイオリポックス エービー Indoles useful for the treatment of inflammation
EP1838669A1 (en) * 2005-01-19 2007-10-03 Biolipox AB Indoles useful in the treatment of inflammation
EP1844013A1 (en) * 2005-01-19 2007-10-17 Biolipox AB Indoles useful in the treatment of inflammation
CA2594665A1 (en) * 2005-01-19 2006-07-27 Biolipox Ab Thienopyrroles useful in the treatment of inflammation
US20090048285A1 (en) * 2005-01-19 2009-02-19 Benjamin Pelcman Pyrrolopyridines Useful in the Treatment of Inflammation
FR2890071B1 (en) * 2005-08-30 2007-11-09 Fournier Sa Sa Lab NEW INDOLE COMPOUNDS
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
RU2448703C2 (en) 2005-11-23 2012-04-27 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Oncogenic ras-specific cytotoxic compound and methods for using it
CN100361973C (en) * 2006-03-06 2008-01-16 复旦大学 Benzyloxy-substituted tryptophan derivative, its analogs, production and use thereof
JP2009543805A (en) * 2006-07-13 2009-12-10 スミスクライン ビーチャム コーポレーション Indoline derivatives and GPR119 agonists
US9308198B2 (en) 2006-09-08 2016-04-12 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
EP2079466B1 (en) * 2006-09-29 2014-01-15 GlaxoSmithKline LLC Substituted indole compounds
ES2392120T3 (en) * 2007-08-31 2012-12-04 Astellas Pharma Inc. Piperidine derivative
JP2013100235A (en) * 2010-03-08 2013-05-23 Dainippon Sumitomo Pharma Co Ltd Novel indole derivative
US10093640B2 (en) 2012-09-21 2018-10-09 Vanderbilt University Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors
WO2015031608A1 (en) 2013-08-28 2015-03-05 Vanderbilt University Substituted indole mcl-1 inhibitors
US10533010B2 (en) 2014-03-27 2020-01-14 Vanderbilt University Substituted indole Mcl-1 inhibitors
US9572794B2 (en) * 2014-08-06 2017-02-21 Vanderbilt University Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists
US9949965B2 (en) 2014-10-17 2018-04-24 Vanderbilt University Tricyclic indole Mcl-1 inhibitors and uses thereof
CN107098846B (en) * 2016-02-26 2020-10-09 中国医学科学院药物研究所 N-acyl sulfonamide FBPase inhibitor, preparation method thereof, pharmaceutical composition and application thereof
AU2017228385B2 (en) 2016-03-04 2021-11-04 Vanderbilt University Substituted indole Mcl-1 inhibitors
WO2019199979A1 (en) 2018-04-10 2019-10-17 The General Hospital Corporation Antibacterial compounds
CN111269167A (en) * 2018-12-05 2020-06-12 中国医学科学院药物研究所 N-acyl sulfonamide salt FBPase inhibitor, preparation method, pharmaceutical composition and application thereof
WO2023279280A1 (en) * 2021-07-07 2023-01-12 中国医学科学院药物研究所 N-(arylsulfonyl)-indole-2-carboxamide fbpase inhibitor and use thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0449196A2 (en) * 1990-03-26 1991-10-02 Takeda Chemical Industries, Ltd. Indole derivatives, their production and use
JPH06145150A (en) * 1992-11-09 1994-05-24 Kyowa Hakko Kogyo Co Ltd Imidazole derivative
WO1994014434A1 (en) * 1992-12-22 1994-07-07 Smithkline Beecham Corporation Endothelin receptor antagonists
WO1997019077A1 (en) * 1995-11-23 1997-05-29 MERCK Patent Gesellschaft mit beschränkter Haftung Endothelin receptor antagonists
EP0782989A1 (en) * 1995-07-18 1997-07-09 Kyowa Hakko Kogyo Co., Ltd. Indole derivatives
WO2000023425A1 (en) * 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
US6090839A (en) * 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1210568A (en) 1967-09-22 1970-10-28 Sumitomo Chemical Co 2-aminomethylindole derivatives and a process for preparing 1,4-benzodiazepine derivatives
US3922264A (en) 1967-12-07 1975-11-25 Sumitomo Chemical Co Production of benzodiazepine derivatives
US3634402A (en) 1968-04-26 1972-01-11 Sumitomo Chemical Co Process for producing 1 4-benzodiazepine derivatives and their salts
US3723464A (en) 1968-10-25 1973-03-27 Sumitomo Chemical Co Process for manufacturing nitrobenzodiazepine derivatives
CH561702A5 (en) 1969-03-11 1975-05-15 Hoffmann La Roche
US4697018A (en) 1981-08-06 1987-09-29 The Hilton-Davis Chemical Co. 9-julolidinyl derivatives and process of preparing them
FR2648459B1 (en) 1989-04-25 1994-05-27 Rhone Poulenc Agrochimie FUNGICIDAL DIPHENYLAMIDES
JP3223193B2 (en) 1991-08-09 2001-10-29 株式会社日清製粉グループ本社 Indole derivatives and anticancer drug resistance overcoming substances containing them as active ingredients
NZ250916A (en) 1993-02-27 1995-08-28 Nihon Nohyaku Co Ltd N-heteroaryl-n'-phenylureas, their use as acat inhibitors
DE4338770A1 (en) 1993-11-12 1995-05-18 Matthias Dr Lehr Indole-2-alkanoic acids and their derivatives as inhibitors of phospholipase A¶2¶
US5686481A (en) 1993-12-21 1997-11-11 Smithkline Beecham Corporation Endothelin receptor antagonists
US5891902A (en) 1994-01-18 1999-04-06 Kyowa Hakko Kogyo Co., Ltd. Indole derivatives
US5563157B1 (en) 1994-10-31 1999-02-02 Hoecst Marion Roussel Inc Heterocycle substituted propenoic acid derivatives and pharmaceutical compositions thereof
AU4514496A (en) 1994-12-13 1996-07-03 Smithkline Beecham Corporation Novel compounds
US5684032A (en) 1994-12-13 1997-11-04 Smithkline Beecham Corporation Compounds
US5902726A (en) 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
JPH09100278A (en) 1995-10-03 1997-04-15 Kyowa Hakko Kogyo Co Ltd Production of indole derivative
US5869519A (en) 1996-12-16 1999-02-09 Idun Pharmaceuticals, Inc. C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US5877197A (en) 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
JPH10195048A (en) 1997-01-17 1998-07-28 Sumitomo Chem Co Ltd Production of 3-(nitrobenzoyl) indole derivative
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
GB9805716D0 (en) 1998-03-17 1998-05-13 Merck Sharp & Dohme Therapeutic agents
US6121271A (en) 1998-05-12 2000-09-19 American Home Products Corporation Naphtho[2,3-B]heteroar-4-yl derivatives
GB9824614D0 (en) 1998-11-11 1999-01-06 Glaxo Group Ltd Chemical compounds
WO2000044743A1 (en) 1999-01-28 2000-08-03 Nippon Shinyaku Co., Ltd. Amide derivatives and drug compositions
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902461D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902459D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0449196A2 (en) * 1990-03-26 1991-10-02 Takeda Chemical Industries, Ltd. Indole derivatives, their production and use
JPH06145150A (en) * 1992-11-09 1994-05-24 Kyowa Hakko Kogyo Co Ltd Imidazole derivative
WO1994014434A1 (en) * 1992-12-22 1994-07-07 Smithkline Beecham Corporation Endothelin receptor antagonists
EP0782989A1 (en) * 1995-07-18 1997-07-09 Kyowa Hakko Kogyo Co., Ltd. Indole derivatives
WO1997019077A1 (en) * 1995-11-23 1997-05-29 MERCK Patent Gesellschaft mit beschränkter Haftung Endothelin receptor antagonists
US6090839A (en) * 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
WO2000023425A1 (en) * 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ACHAB, SAIED ET AL: "An expeditious synthesis of structural analogs of the marine cytotoxic agents grossularines-1 and -2", TETRAHEDRON LETT. (1995), 36(15), 2615-18, XP001057893 *
GABRIELYAN, G. E. ET AL: "Indole derivatives. XXXVII. Synthesis of indole compounds containing a furan ring", ARM. KHIM. ZH. (1973), 26(9), 768-74, XP001061897 *
MEDERSKI W W K R ET AL: "2, ENDOTHELIN ANTAGONISTS: EVALUATION OF 2,1,3-BENZOTHIADIAZOLE AS A METHYLENDIOXYPHENYL BIOISOSTER", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 8, no. 1, 1998, pages 17 - 22, XP001057891, ISSN: 0960-894X *

Cited By (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1284728A4 (en) * 1999-10-22 2004-05-19 Merck & Co Inc Pharmaceuticals for treating obesity
EP1284728A1 (en) * 1999-10-22 2003-02-26 Merck & Co., Inc. Pharmaceuticals for treating obesity
US7074817B2 (en) 2001-06-20 2006-07-11 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7629377B2 (en) 2001-06-20 2009-12-08 Wyeth Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US7368471B2 (en) 2001-06-20 2008-05-06 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7351730B2 (en) 2001-06-20 2008-04-01 Wyeth Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US7345085B2 (en) 2002-08-29 2008-03-18 Merck & Co., Inc. Indoles having anti-diabetic activity
US7186746B2 (en) 2002-08-29 2007-03-06 Merck & Co., Inc. Indoles having anti-diabetic activity
EP1546142A2 (en) * 2002-08-29 2005-06-29 Merck & Co., Inc. Indoles having anti-diabetic activity
US7393960B2 (en) 2002-08-29 2008-07-01 Merck & Co., Inc. Indoles having anti-diabetic activity
EP1546142A4 (en) * 2002-08-29 2007-10-17 Merck & Co Inc Indoles having anti-diabetic activity
US7101903B2 (en) 2002-12-10 2006-09-05 Wyeth Substituted dihydropyrano indole-3,4-dione derivatives as inhibitiors of plasminogen activator inhibitor-1 (PAI-1)
US7674818B2 (en) 2002-12-10 2010-03-09 Wyeth Llc Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7078429B2 (en) 2002-12-10 2006-07-18 Wyeth Substituted 3-carbonyl-1H-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7056943B2 (en) 2002-12-10 2006-06-06 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7566791B2 (en) 2002-12-10 2009-07-28 Wyeth Substituted 3-carbonyl-1h-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7348351B2 (en) 2002-12-10 2008-03-25 Wyeth Substituted 3-alkyl and 3-arylalkyl 1H-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7160918B2 (en) 2002-12-10 2007-01-09 Hassan Mahmoud Elokdah Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor (PAI-1)
US7459478B2 (en) 2002-12-10 2008-12-02 Wyeth Substituted dihydropyrano indole-3,4-dione derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7259182B2 (en) 2002-12-10 2007-08-21 Wyeth Aryl, aryloxy, and aklyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
WO2004063190A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Fused heterocyclic derivates as ppar modulators
WO2004092131A1 (en) * 2003-01-06 2004-10-28 Eli Lilly And Company Indole derivatives as ppar modulators
US7528160B2 (en) 2003-01-06 2009-05-05 Eli Lilly And Company Fused heterocyclic derivatives as PPAR modulators
CN100398105C (en) * 2003-02-27 2008-07-02 塞诺菲-安万特德国有限公司 1,3-substitued cycloalkyl derivatives having acidic, mostly heterocyclic groups, processes for their preparation and their use as pharmaceuticals
US8048901B2 (en) 2003-02-27 2011-11-01 Aventis Pharma Deutschland Gmbh 1,3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups, processes for their preparation and their use as pharmaceuticals
WO2004075891A1 (en) * 2003-02-27 2004-09-10 Aventis Pharma Deutschland Gmbh 1,3-substituted cycloalkyl derivatives containing acidic, mainly heterocyclic groups, corresponding production method and use of said derivatives as medicaments
WO2004092130A2 (en) * 2003-04-07 2004-10-28 Kalypsys, Inc. N-containing heteroaromatic compounds as modulators of ppars and methods of treating metabolic disorders
WO2004092130A3 (en) * 2003-04-07 2005-01-13 Kalypsys Inc N-containing heteroaromatic compounds as modulators of ppars and methods of treating metabolic disorders
WO2005005423A1 (en) * 2003-07-02 2005-01-20 F. Hoffmann-La Roche Ag Indolyl derivatives substituted with a thiazole ring and their use as ppar modulators
KR100796093B1 (en) * 2003-07-02 2008-01-21 에프. 호프만-라 로슈 아게 Indolyl derivatives substituted with a thiazole ring and their use as ppar modulators
US7235572B2 (en) 2003-07-02 2007-06-26 Hoffman-La Roche Inc. Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
JP2007506783A (en) * 2003-09-25 2007-03-22 ワイス Substituted indoleic acid derivatives and their use as PAI-1 inhibitors
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7803835B2 (en) 2003-09-25 2010-09-28 Wyeth Llc Substituted acetic acid derivatives
JP2007511530A (en) * 2003-11-13 2007-05-10 アボット・ラボラトリーズ N-acylsulfonamide-based apoptosis promoter
JP4870570B2 (en) * 2003-11-13 2012-02-08 アボット・ラボラトリーズ N-acylsulfonamide-based apoptosis promoter
US7449478B2 (en) 2003-12-04 2008-11-11 National Health Research Institutes Indole compounds
EP1740531A4 (en) * 2004-04-13 2012-02-29 Korea Res Inst Chem Tech Indene derivatives and process for the preparation thereof
EP1740531A1 (en) * 2004-04-13 2007-01-10 Korea Research Institute of Chemical Technology Indene derivatives and process for the preparation thereof
US7705023B2 (en) 2004-06-18 2010-04-27 Biolipox Ab Indoles useful in the treatment of inflammation
US7754747B2 (en) 2004-08-23 2010-07-13 Wyeth Llc Oxazolo-naphthyl acids
FR2879194A1 (en) * 2004-12-14 2006-06-16 Galderma Res & Dev New biaromatic compounds are peroxisome proliferator-activated receptor modulators, useful as medication to control and/or restore metabolism of cutaneous lipids and in the treatment e.g. dermatological affections
WO2006063863A1 (en) * 2004-12-14 2006-06-22 Galderma Research & Development Biaromatic compounds that modulate ppar type receptors, process for preparing them and use thereof in cosmetic or pharmaceutical compositions
AU2005324895B2 (en) * 2005-01-14 2011-08-04 Merck Patent Gmbh 1H-indole-3-carboxylic acid derivatives and their use as PPAR agonists
WO2006074789A1 (en) * 2005-01-14 2006-07-20 Merck Patent Gmbh 1h-indole-3-carboxylic acid derivatives and their use as ppar agonists
FR2880889A1 (en) * 2005-01-14 2006-07-21 Merck Sante Soc Par Actions Si 1H-INDOLE-3-CARBOXYLIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THERAPEUTIC APPLICATIONS
US7754740B2 (en) 2005-01-14 2010-07-13 Merck Patent Gmbh 1H-indole-3-carboxylic acid derivatives and their use as PPAR agonists
US8097623B2 (en) 2005-01-19 2012-01-17 Biolipox Ab Indoles useful in the treatment of inflammation
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
US7683091B2 (en) 2005-08-17 2010-03-23 Wyeth Substituted indoles and methods of their use
WO2007068621A1 (en) 2005-12-15 2007-06-21 F. Hoffmann-La Roche Ag Novel fused pyrrole derivatives
US7696240B2 (en) 2005-12-15 2010-04-13 Hoffmann-La Roche Inc. Fused pyrrole derivatives
US7855225B2 (en) 2006-03-02 2010-12-21 Astellas Pharma Inc. 17βHSD type 5 inhibitor
WO2008028118A1 (en) * 2006-08-31 2008-03-06 Smithkline Beecham Corporaiton 1h-indole-2-carboxylic acid derivatives useful as ppar modulators
US20100098661A1 (en) * 2006-12-22 2010-04-22 Schering Corporation 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
US8546420B2 (en) 2006-12-22 2013-10-01 Merck Sharp & Dohme Corp. 4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
WO2008136815A3 (en) * 2006-12-22 2009-05-22 Schering Corp 5, 6-ring annulated indole derivatives and use thereof
US8557848B2 (en) 2006-12-22 2013-10-15 Merck Sharp & Dohme Corp. 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
US8268803B2 (en) 2006-12-22 2012-09-18 Merck Sharp & Dohme Corp. 5, 6-ring annulated indole derivatives and use thereof
WO2008136815A2 (en) * 2006-12-22 2008-11-13 Schering Corporation 5, 6-ring annulated indole derivatives and use thereof
AU2008242983B2 (en) * 2007-04-16 2013-07-11 Abbvie Inc. 7-substituted indole Mcl-1 inhibitors
EP3243814A1 (en) * 2007-04-16 2017-11-15 AbbVie Inc. 7-substituted indole as mcl-1 inhibitors
US9359296B2 (en) 2007-04-16 2016-06-07 Abbvie Inc. 7-substituted indole Mcl-1 inhibitors
US8445679B2 (en) 2007-04-16 2013-05-21 Abbvie Inc. 7-substituted indole MCL-1 inhibitors
WO2008131000A3 (en) * 2007-04-16 2008-12-18 Abbott Lab 7-substituted indole mcl-1 inhibitors
US8853209B2 (en) 2007-04-16 2014-10-07 Abbvie Inc. 1-oxyalkyl-2-carboxy-7-nonsubstituted indole derivatives
WO2008131000A2 (en) * 2007-04-16 2008-10-30 Abbott Laboratories 7-substituted indole mcl-1 inhibitors
US9035047B2 (en) 2007-04-16 2015-05-19 Abbvie Inc. 7-substituted indole Mcl-1 inhibitors
US20110263599A1 (en) * 2007-04-16 2011-10-27 Abbott Laboratories 7-nonsubstituted indole mcl-1 inhibitors
US8143305B2 (en) 2007-08-29 2012-03-27 Schering Corporation 2,3-substituted indole derivatives for treating viral infections
US8404845B2 (en) 2007-08-29 2013-03-26 Merck Sharp & Dohme Corp. 2,3-substituted azaindole derivatives for treating viral infections
US8614229B2 (en) 2007-08-29 2013-12-24 Merck Sharp & Dohme Corp. Substituted indole derivatives and methods of use thereof
WO2009047240A1 (en) * 2007-10-09 2009-04-16 Smithkline Beecham Corporation Indole derivatives useful as ppar activators
US8765757B2 (en) 2007-11-16 2014-07-01 Merck Sharp & Dohme Corp. 3-heterocyclic substituted indole derivatives and methods of use thereof
US8377928B2 (en) 2007-11-16 2013-02-19 Merck Sharp & Dohme Corp. 3-aminosulfonyl substituted indole derivatives and methods of use thereof
WO2009147121A1 (en) * 2008-06-02 2009-12-10 Smithkline Beecham Corporation Carboxyl substituted indoles for use as ppar alpha modulators
US8901139B2 (en) 2008-06-13 2014-12-02 Merck Sharp & Dohme Corp. Tricyclic indole derivatives and methods of use thereof
US9579335B2 (en) 2010-10-19 2017-02-28 Indiana University Research And Technology Corporation Treatment of cystic diseases
WO2014072371A1 (en) 2012-11-08 2014-05-15 Ikerchem, S.L. Indole derivatives, pharmaceutical compositions containing such indoles and their use as dna methylation modulators
EP2730558A1 (en) 2012-11-08 2014-05-14 Ikerchem, S.L. Indole derivatives, pharmaceutical compositions containing such indoles and their use as DNA methylation modulators
WO2014198848A3 (en) * 2013-06-12 2015-06-04 Lytix Biopharma As Compounds
WO2014198844A1 (en) * 2013-06-12 2014-12-18 Lytix Biopharma As Protein kinase inhibitors
US11426407B2 (en) 2014-10-06 2022-08-30 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP3203840A4 (en) * 2014-10-06 2018-08-15 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US10258624B2 (en) 2014-10-06 2019-04-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
RU2734876C9 (en) * 2014-10-06 2024-02-28 Вертекс Фармасьютикалз Инкорпорейтед Modulators of transmembrane conductance regulator in cystic fibrosis
EP4159717A1 (en) * 2014-10-06 2023-04-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US10758534B2 (en) 2014-10-06 2020-09-01 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
AU2020220185B2 (en) * 2014-10-06 2022-12-08 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
RU2734876C2 (en) * 2014-10-06 2020-10-23 Вертекс Фармасьютикалз Инкорпорейтед Modulators of transmembrane conductance regulator in cystic fibrosis
US10738030B2 (en) 2016-03-31 2020-08-11 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2018021762A1 (en) * 2016-07-26 2018-02-01 현대약품 주식회사 Novel compound, preparation method therefor, and pharmaceutical composition containing same
US10570115B2 (en) 2016-09-30 2020-02-25 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US11186566B2 (en) 2016-09-30 2021-11-30 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US10927106B2 (en) 2016-10-12 2021-02-23 Pharmasum Therapeutics As Benzothiazole derivatives as DYRK1 inhibitors
US10793547B2 (en) 2016-12-09 2020-10-06 Vertex Pharmaceuticals Incorporated Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US11453655B2 (en) 2016-12-09 2022-09-27 Vertex Pharmaceuticals Incorporated Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US11339144B2 (en) * 2017-04-10 2022-05-24 Navitor Pharmaceuticals, Inc. Heteroaryl Rheb inhibitors and uses thereof
US11253509B2 (en) 2017-06-08 2022-02-22 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US11517564B2 (en) 2017-07-17 2022-12-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US11434201B2 (en) 2017-08-02 2022-09-06 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
JP2022062093A (en) * 2017-09-14 2022-04-19 アッヴィ・グローバル・エンタープライザズ・リミテッド Modulator of cystic fibrosis transmembrane conductance controlling factor protein and its usage
US11155533B2 (en) 2017-10-19 2021-10-26 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
US11465985B2 (en) 2017-12-08 2022-10-11 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
US11179367B2 (en) 2018-02-05 2021-11-23 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for treating cystic fibrosis
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

Also Published As

Publication number Publication date
AU2002211901A1 (en) 2002-04-22
CA2427499A1 (en) 2002-04-18
EP1341761A1 (en) 2003-09-10
CN1505613A (en) 2004-06-16
MXPA03003174A (en) 2003-07-14
JP2004529855A (en) 2004-09-30
KR20030036917A (en) 2003-05-09
PL366068A1 (en) 2005-01-24
NO20031619D0 (en) 2003-04-09
AR035348A1 (en) 2004-05-12
US20030087902A1 (en) 2003-05-08
US6787651B2 (en) 2004-09-07
IL154981A0 (en) 2003-10-31
HUP0302477A2 (en) 2003-12-29
NO20031619L (en) 2003-06-02

Similar Documents

Publication Publication Date Title
WO2002030895A1 (en) SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-η BINDING AGENTS
RU2288914C2 (en) Novel substituted indoles
TWI714527B (en) Amide derivatives and salts thereof, preparation process and pharmaceutical use thereof
EP1614683B1 (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
JP5275236B2 (en) Substituted indole compounds
US6534524B1 (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
CN101141956B (en) Use of CRTH2 antagonist compounds in therapy,its preparation method and pharmaceutical uses
KR101653229B1 (en) Novel estrogen receptor ligands
RU2407736C2 (en) Peri-substituted arylsulphonamide bicyclic compounds for treating artery occlusive diseases
KR20110130388A (en) Pharmaceutical compounds
JP2007500253A (en) Indole derivative modulators of steroid hormone nuclear receptors
KR20080108478A (en) Quinolones useful as inducible nitric oxide synthase inhibitors
JP2007509173A (en) Indolinone derivatives and their use in the treatment of disease states such as cancer
JP2006510673A (en) Aryl, aryloxy and alkyloxy substituted 1H-indol-3-ylglyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor 1 (PAI-1)
JP2000503984A (en) Thiazolylbenzofuran derivatives and pharmaceutical compositions thereof
WO2001032621A1 (en) Novel indole derivatives and drugs containing the same as the active ingredient
WO2007085136A1 (en) 1,3-benzodioxolecyclopentene derivates, preparation process and medical uses thereof
CN109942505B (en) Isothiazolinone compounds and corresponding use
JP4986927B2 (en) Medicine
WO2018042377A1 (en) Novel indazole compounds
JP2728357B2 (en) Benzylidene derivative
BG60375B2 (en) 3-substituted 2-oxindol-1-carboxamides and their application as analgetic and antiinflamation agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 154981

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002211901

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 337/KOLNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 525037

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003/02529

Country of ref document: ZA

Ref document number: 200302529

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2002534281

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2427499

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020037005093

Country of ref document: KR

Ref document number: PA/a/2003/003174

Country of ref document: MX

Ref document number: PV2003-1005

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2001979996

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020037005093

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 018203140

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: PV2003-1005

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001979996

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2003-1005

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2001979996

Country of ref document: EP

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0114541

Country of ref document: BR

Free format text: PEDIDO RETIRADO FACE A IMPOSSIBILIDADE DE ACEITACAO DA ENTRADA NA FASE NACIONAL POR TER SIDO INTEMPESTIVA. O PRAZO PARA ENTRADA NA FASE NACIONAL EXPIRAVA EM 10.06.2002( 20 MESES - BR DESIGNADO APENAS) , E A PRETENSA ENTRADA NA FASE NACIONAL SO OCORREU EM 09.04.2003